

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
19 September 2002 (19.09.2002)

PCT

(10) International Publication Number
WO 02/072754 A2

(31) International Patent Classification:

C12N

(21) International Application Number: PCT/US02/06713

(22) International Filing Date: 1 March 2002 (01.03.2002)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/274,494 8 March 2001 (08.03.2001) US

(71) Applicant (for all designated States except US): THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US/US); National Institutes of Health, Office of Technology Transfer, Suite 325, 6011 Executive Boulevard, Rockville, MD 20852-3804 (US).

(72) Inventors; and

(73) Inventors/Applicants (for US only): MOSS, Bernard [US/US]; 10301 Dickens Avenue, Bethesda, MD 20814 (US), WYATT, Linda [US/US]; 11201 Hunter Drive, Rockville, MD 20852 (US), EARL, Patricia [US/US]; 3520 Woodbine Street, Chevy Chase, MD 20815 (US).

(74) Agent: ALTMAN, Daniel, E.; Knobbe, Martens, Olson And Bear, LLP, 16th floor, 620 Newport Center Drive, Newport Beach, CA 92660 (US).

(83) Designated States (national): AL, AQ, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CI, CN, CO, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EC, EH, EG (utility model), ES, FI, FI (utility model), GR, GL, GE, OH, OM, HR, MU, ID, IL, IN, IS, JP, KH, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NJ, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SR, SI, SK, SK (utility model), SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GL, GM, KR, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BH, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(h)) for US only

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/072754 A2

(34) Title: MVA EXPRESSING MODIFIED HIV ENVELOPE, GAG, AND POL GENES

(57) Abstract: The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.

WO 02/072754

PCT/US02/06713

MVA EXPRESSING MODIFIED HIV ENVELOPE, GAG, AND POL GENESField of the Invention

The invention provides modified vaccinia Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) *env*, *gag*, and *pol* genes.

Background of the Invention

Cellular immunity plays an important role in the control of immunodeficiency virus infections (P.J. Goulder *et al.* 1999 *AIDS* 13:8121). Recently, a DNA vaccine designed to enhance cellular immunity by cytokine augmentation successfully contained a highly virulent immunodeficiency virus challenge (D.H. Barouch *et al.* 2000 *Science* 290:486). Another promising approach to raising cellular immunity is DNA priming followed by recombinant poxvirus boosters (H.L. Robinson *et al.* 2000 *AIDS Rev* 2:105). This heterologous prime/boost regimen induces 10- to 100-fold higher frequencies of T cells than priming and boosting with DNA or recombinant poxvirus vaccines alone. Previously, investigators showed that boosting a DNA-primed response with a poxvirus was superior to boosting with DNA or protein for the control of a non-pathogenic immunodeficiency virus (H.L. Robinson *et al.* 1999 *Nat Med* 5:S26). There is a need for the control of a pathogenic immunodeficiency virus.

Summary of the Invention

Here we report that DNA priming followed by a recombinant modified vaccinia Ankara (rMVA) booster has controlled a highly pathogenic immunodeficiency virus challenge in a rhesus macaque model. Both the DNA and rMVA components of the vaccine expressed multiple immunodeficiency virus proteins. Two DNA inoculations at 0 and 8 weeks and a single rMVA booster at 24 weeks effectively controlled an intrarectal challenge administered seven months after the booster. These findings are envisioned as indicating that a relatively simple multiprotein DNA/MVA vaccine can help to control the acquired immune deficiency syndrome (AIDS) epidemic. We also report that inoculations of rMVA induce good immune responses even without DNA priming.

WD 02/072754

PCT/US02/06713

Brief Description of the Drawings

Figure I. Phylogenetic relationships of HIV-1 and HIV-2 based on identity of *pol* gene sequences. SIV_{cpz} and SIV_{smn} are subhuman primate lentiviruses recovered from a chimpanzee and sooty mangabey monkey, respectively.

Figure II. Phylogenetic relationships of HIV-1 groups M, N and O with four different SIV_{cpz} isolates based on full-length *pol* gene sequences. The bar indicates a genetic distance of 0.1 (10% nucleotide divergence) and the asterisk positions group N HIV-1 isolates based on *env* sequences.

Figure III. Tropic and biologic properties of HIV-1 isolates.

Figure IV. HIV-encoded proteins. The location of the HIV genes, the sizes of primary translation products (in some cases polyproteins), and the processed mature viral proteins are indicated.

Figure V. Schematic representation of a mature HIV-1 virion.

Figure VI. Linear representation of the HIV-1 Env glycoprotein. The arrow indicates the site of gp160 cleavage to gp120 and gp41. In gp120, cross-hatched areas represent variable domains (V₁ to V₅) and open boxes depict conserved sequences (C₁ to C₅). In the gp41 ectodomain, several domains are indicated: the N-terminal fusion peptide, and the two ectodomain helices (N- and C-helix). The membrane-spanning domain is represented by a black box. In the gp41 cytoplasmic domain, the Tyr-X-X-Leu (YXXL) endocytosis motif (SEQ ID NO: 9) and two predicted helical domains (helix-1 and -2) are shown. Amino acid numbers are indicated.

Figure 1. Temporal frequencies of Gag-specific T cells. (A) Gag-specific CD8 T cell responses raised by DNA priming and rMVA booster immunizations. The schematic presents mean Gag-CM9-tetramer data generated in the high-dose i.d. DNA-immunized animals. (B) Gag-specific IFN- γ ELISPOTs in A*01 (open bars) and non-A*01 (filled bars) macaques at various times before challenge and at two weeks after challenge. Three pools of 10 to 13 Gag peptides (22-mers overlapping by 12) were used for the analyses. The numbers above data bars represent the arithmetic mean \pm SD for the ELISPOTs within each group. The numbers at the top of the graphs designate individual animals. *, data not available; #, <20 ELISPOTs per 1×10^5 peripheral blood mononuclear cells (PBMC). Temporal data for Gag-CM9-Mamu-A*01 tetramer-specific T cells can be found in Figure 6.

WO 02/072754

PCT/US02/06713

Figure 2. Temporal viral loads, CD4 counts, and survival after challenge of vaccinated and control animals. (A) Geometric mean viral loads and (B) geometric mean CD4 counts. (C) Survival curve for vaccinated and control animals. The dotted line represents all 24 vaccinated animals. (D) Viral loads and (E) CD4 counts for individual animals in the vaccine and control groups. The key to animal numbers is presented in (E). Assays for the first 12 weeks after challenge had a detection level of 1000 copies of RNA per milliliter of plasma. Animals with loads below 1000 were scored with a load of 300. For weeks 16 and 20, the detection level was 300 copies of RNA per milliliter. Animals with levels of virus below 300 were scored at 300.

Figure 3. Postchallenge T cell responses in vaccine and control groups. (A) Temporal tetramer⁺ cells (dashed line) and viral loads (solid line). (B) Intracellular cytokine assays for IFN- γ production in response to stimulation with the Gag-CM9 peptide at two weeks after challenge. This *ex vivo* assay allows evaluation of the functional status of the peak postchallenge tetramer⁺ cells displayed in Figure 1A. (C) Proliferation assay at 12 weeks after challenge. Gag-Pol-Env (open bars) and Gag-Pol (hatched bars) produced by transient transfections were used for stimulation. Supernatants from mock-transfected cultures served as control antigen. Stimulation indices are the growth of cultures in the presence of viral antigens divided by the growth of cultures in the presence of mock antigen.

Figure 4. Lymph node histomorphology at 12 weeks after challenge. (A) Typical lymph node from a vaccinated macaque showing evidence of follicular hyperplasia characterized by the presence of numerous secondary follicles with expanded germinal centers and discrete dark and light zones. (B) Typical lymph node from an infected control animal showing follicular depletion and paracortical lymphocellular atrophy. (C) A representative lymph node from an age-matched, uninfected macaque displaying nonreactive germinal centers. (D) The percentage of the total lymph node area occupied by germinal centers was measured to give a non-specific indicator of follicular hyperplasia. Data for uninfected controls are for four age-matched rhesus macaques.

Figure 5. Temporal antibody responses. Micrograms of total Gag (A) or Env (B) antibody were determined with ELISAs. The titers of neutralizing antibody for SHIV-89.6 (C) and SHIV-89.6P (D) were determined with MT-2 cell killing and neutral red staining (D.C. Montefiori *et al.* 1988 *J Clin Microbiol* 26:231). Titers are the reciprocal of the

WO 02/072754

PCT/US02/06713

serum dilution giving 50% neutralization of the indicated viruses grown in human PBMC. Symbols for animals are the same as in Figure 2.

Figure 6. Gag-CM9-Mamu-A*01 tetramer-specific T cells in *Mamu-A*01* vaccinated and control macaques at various times before challenge and at two weeks after challenge. The number at the upper right corner of each plot represents the frequency of tetramer-specific CD8 T cells as a % of total CD8 T cells. The numbers above each column of FACS data designate individual animals.

Figure A. Map and sequence of plasmid transfer vector pLW-48.

Figure B. Sequences of plasmid transfer vector pLW-48, Psy II promoter (which controls ADA envelope expression), ADA envelope truncated, PmHS promoter (which controls HXB2 gag pol expression), and HXB2 gag pol (with safety mutations, Δ integrase).

Figure C. Plasmid transfer vector pLW-48 and making MVA recombinant virus MVA/HIV 48.

Figure D. A clade B gag pol.

Figure E. Sequence of new Psy II promoter.

Detailed Description of the Preferred Embodiment

Recombinant MVA Virus

Vaccinia virus, a member of the genus Orthopoxvirus in the family of Poxviridae, was used as live vaccine to immunize against the human smallpox disease. Successful worldwide vaccination with vaccinia virus culminated in the eradication of variola virus, the causative agent of the smallpox (The global eradication of smallpox. Final report of the global commission for the certification of smallpox eradication. History of Public Health, No. 4, Geneva: World Health Organization, 1980). Since that WHO declaration, vaccination has been universally discontinued except for people at high risk of poxvirus infections (e.g. laboratory workers).

More recently, vaccinia viruses have also been used to engineer viral vectors for recombinant gene expression and for the potential use as recombinant live vaccines (Mackett, M. et al. 1982 *PNAS USA* 79:7415-7419; Smith, G.L. et al. 1984 *Biotech Genet Engin Rev* 2:383-407). This entails DNA sequences (genes) which code for foreign antigens being introduced, with the aid of DNA recombination techniques, into the genome of the vaccinia viruses. If the gene is integrated at a site in the viral DNA which is non-

WO 02/072754

PCT/US02/06713

essential for the life cycle of the virus, it is possible for the newly produced recombinant vaccinia virus to be infectious, that is to say able to infect foreign cells and thus to express the integrated DNA sequence (EP Patent Applications No. 83,286 and No. 110,385). The recombinant vaccinia viruses prepared in this way can be used, on the one hand, as live vaccines for the prophylaxis of infectious diseases, on the other hand, for the preparation of heterologous proteins in eukaryotic cells.

For vector applications health risks would be lessened by the use of a highly attenuated vaccinia virus strain. Several such strains of vaccinia virus were especially developed to avoid undesired side effects of smallpox vaccination. Thus, the modified vaccinia Ankara (MVA) has been generated by long-term serial passages of the Ankara strain of vaccinia virus (CVA) on chicken embryo fibroblasts (for review see Mayr, A. *et al.* 1975 *Infection* 3:6-14; Swiss Patent No. 568,392). The MVA virus is publicly available from American Type Culture Collection as ATCC No. VR-1508. MVA is distinguished by its great attenuation, that is to say by diminished virulence and ability to replicate in primate cells while maintaining good immunogenicity. The MVA virus has been analyzed to determine alterations in the genome relative to the parental CVA strain. Six major deletions of genomic DNA (deletion I, II, III, IV, V, and VI) totaling 31,000 base pairs have been identified (Meyer, H. *et al.* 1991 *J Gen Virol* 72:1031-1038). The resulting MVA virus became severely host cell restricted to avian cells.

Furthermore, MVA is characterized by its extreme attenuation. When tested in a variety of animal models, MVA was proven to be avirulent even in immunosuppressed animals. More importantly, the excellent properties of the MVA strain have been demonstrated in extensive clinical trials (Mayr A. *et al.* 1978 *Zentralbl Bakteriol* [B] 167:375-390; Stickl *et al.* 1974 *Dtsch Med Wschr* 99:2386-2392). During these studies in over 120,000 humans, including high-risk patients, no side effects were associated with the use of MVA vaccine.

MVA replication in human cells was found to be blocked late in infection preventing the assembly to mature infectious virions. Nevertheless, MVA was able to express viral and recombinant genes at high levels even in non-permissive cells and was proposed to serve as an efficient and exceptionally safe gene expression vector (Sutter, O. and Moss, B. 1992 *PNAS USA* 89:10847-10851). Additionally, novel vaccinia vector vaccines were established on the basis of MVA having foreign DNA sequences inserted at

WO 02/072754

PCT/US02/06713

the site of deletion III within the MVA genome (Sutter, G. et al. 1994 *Vaccine* 12:1032-1040).

The recombinant MVA vaccinia viruses can be prepared as set out hereinafter. A DNA-construct which contains a DNA-sequence which codes for a foreign polypeptide flanked by MVA DNA sequences adjacent to a naturally occurring deletion, e.g. deletion III, or other non-essential sites, within the MVA genome, is introduced into cells infected with MVA, to allow homologous recombination. Once the DNA-construct has been introduced into the eukaryotic cell and the foreign DNA has recombined with the viral DNA, it is possible to isolate the desired recombinant vaccinia virus in a manner known per se, preferably with the aid of a marker. The DNA-construct to be inserted can be linear or circular. A plasmid or polymerase chain reaction product is preferred. The DNA-construct contains sequences flanking the left and the right side of a naturally occurring deletion, e.g. deletion III, within the MVA genome. The foreign DNA sequence is inserted between the sequences flanking the naturally occurring deletion. For the expression of a DNA sequence or gene, it is necessary for regulatory sequences, which are required for the transcription of the gene, to be present on the DNA. Such regulatory sequences (called promoters) are known to those skilled in the art, and include for example those of the vaccinia 11 kDa gene as are described in EP-A-198,328, and those of the 7.5 kDa gene (EP-A-110,385). The DNA-construct can be introduced into the MVA infected cells by transfection, for example by means of calcium phosphate precipitation (Graham et al. 1973 *Virology* 52:456-467; Wigler et al. 1979 *Cell* 16:777-785), by means of electroporation (Neumann et al. 1982 *EMBO J* 1:841-845), by microinjection (Grassmann et al. 1983 *Meth Enzymol* 101:482-492), by means of liposomes (Straubinger et al. 1983 *Meth Enzymol* 101:512-527), by means of spheroplasts (Schaffner 1980 *PNAS USA* 77:2163-2167) or by other methods known to those skilled in the art.

HTVs and Their Replication

The etiological agent of acquired immune deficiency syndrome (AIDS) is recognized to be a retrovirus exhibiting characteristics typical of the lentivirus genus, referred to as human immunodeficiency virus (HIV). The phylogenetic relationships of the human lentiviruses are shown in Figure 1. HIV-2 is more closely related to SIV_{sooty}, a virus isolated from sooty mangabey monkeys in the wild, than to HIV-1. It is currently believed

WO 02/072754

PCT/US02/06713

that HIV-2 represents a zoonotic transmission of SIV_{sooty} to man. A series of lentiviral isolates from captive chimpanzees, designated SIV_{cpz}, are close genetic relatives of HIV-1.

The earliest phylogenetic analyses of HIV-1 isolates focused on samples from Europe/North America and Africa; discrete clusters of viruses were identified from these two areas of the world. Distinct genetic subtypes or clades of HIV-1 were subsequently defined and classified into three groups: M (major); O (outlier); and N (non-M or O) (Fig. II). The M group of HIV-1, which includes over 95% of the global virus isolates, consists of at least eight discrete clades (A, B, C, D, F, G, H, and J), based on the sequence of complete viral genomes. Members of HIV-1 group O have been recovered from individuals living in Cameroon, Gabon, and Equatorial Guinea; their genomes share less than 50% identity in nucleotide sequence with group M viruses. The more recently discovered group N HIV-1 strains have been identified in infected Cameroonian, fail to react serologically in standard whole-virus enzyme-linked immunosorbent assay (ELISA), yet are readily detectable by conventional Western blot analysis.

Most current knowledge about HIV-1 genetic variation comes from studies of group M viruses of diverse geographic origin. Data collected during the past decade indicate that the HIV-1 population present within an infected individual can vary from 6% to 10% in nucleotide sequence. HIV-1 isolates within a clade may exhibit nucleotide distances of 15% in gag and up to 30% in gp120 coding sequences. Interclade genetic variation may range between 30% and 40% depending on the gene analyzed.

All of the HIV-1 group M subtypes can be found in Africa. Clade A viruses are genetically the most divergent and were the most common HIV-1 subtype in Africa early in the epidemic. With the rapid spread of HIV-1 to southern Africa during the mid to late 1990s, clade C viruses have become the dominant subtype and now account for 48% of HIV-1 infections worldwide. Clade B viruses, the most intensively studied HIV-1 subtype, remain the most prevalent isolates in Europe and North America.

High rates of genetic recombination are a hallmark of retroviruses. It was initially believed that simultaneous infections by genetically diverse virus strains were not likely to be established in individuals at risk for HIV-1. By 1995, however, it became apparent that a significant fraction of the HIV-1 group M global diversity included interclade viral recombinants. It is now appreciated that HIV-1 recombinants will be found in geographic areas such as Africa, South America, and Southeast Asia, where multiple HIV-1 subtypes

WO 02/072754

PCT/US02/06713

coexist and may account for more than 10% of circulating HIV-1 strains. Molecularly, the genomes of these recombinant viruses resemble patchwork mosaics, with juxtaposed diverse HIV-1 subtype segments, reflecting the multiple crossover events contributing to their generation. Most HIV-1 recombinants have arisen in Africa and a majority contain segments originally derived from clade A viruses. In Thailand, for example, the composition of the predominant circulating strain consists of a clade A *gag* plus *pol* gene segment and a clade E *env* gene. Because the clade E *env* gene in Thai HIV-1 strains is closely related to the clade E *env* present in virus isolates from the Central African Republic, it is believed that the original recombination event occurred in Africa, with the subsequent introduction of a descendent virus into Thailand. Interestingly, no full-length HIV-1 subtype E isolate (i.e., with subtype E *gag*, *pol*, and *env* genes) has been reported to date.

The discovery that α and β chemokine receptors function as coreceptors for virus fusion and entry into susceptible CD4 $^{+}$ cells has led to a revised classification scheme for HIV-1 (Fig. III). Isolates can now be grouped on the basis of chemokine receptor utilization in fusion assays in which HIV-1 gp120 and CD4 $^{+}$ coreceptor proteins are expressed in separate cells. As indicated in Figure III, HIV-1 isolates using the CXCR4 receptor (now designated X4 viruses) are usually T cell line (TCL)-tropic syncytium inducing (SI) strains, whereas those exclusively utilizing the CCR5 receptor (R5 viruses) are predominantly macrophage (M)-tropic and non-syncytium inducing (NSI). The dual-tropic R5/X4 strains, which may comprise the majority of patient isolates and exhibit a continuum of tropic phenotypes, are frequently SI.

As is the case for all replication-competent retroviruses, the three primary HIV-1 translation products, all encoding structural proteins, are initially synthesized as polyprotein precursors, which are subsequently processed by viral or cellular proteases into mature particle-associated proteins (Fig. IV). The 55-kd Gag precursor Pr55^{Gag} is cleaved into the matrix (MA), capsid (CA), nucleocapsid (NC), and p6 proteins. Autocatalysis of the 160-kd Gag-Pol polyprotein, Pr160^{Gag-Pol}, gives rise to the protease (PR), the heterodimeric reverse transcriptase (RT), and the integrase (IN) proteins, whereas proteolytic digestion by a cellular enzyme(s) converts the glycosylated 160-kd Env precursor gp160 to the gp120 surface (SU) and gp41 transmembrane (TM) cleavage products. The remaining six HIV-1

WO 02/072754

PCT/US02/06713

encoded proteins (Vif, Vpr, Tat, Rev, Vpu, and Nef) are the primary translation products of spliced mRNAs.

Gag

The Gag proteins of HIV, like those of other retroviruses, are necessary and sufficient for the formation of noninfectious, virus-like particles. Retroviral Gag proteins are generally synthesized as polyprotein precursors; the HIV-1 Gag precursor has been named, based on its apparent molecular mass, Pr55^{Gag}. As noted previously, the mRNA for Pr55^{Gag} is the unspliced 9.2-kb transcript (Fig. IV) that requires Rev for its expression in the cytoplasm. When the *pol* ORF is present, the viral protease (PR) cleaves Pr55^{Gag} during or shortly after budding from the cell to generate the mature Gag proteins p17 (MA), p24 (CA), p7 (NC), and p6 (see Fig. IV). In the virion, MA is localized immediately inside the lipid bilayer of the viral envelope, CA forms the outer portion of the cone-shaped core structure in the center of the particle, and NC is present in the core in a ribonucleoprotein complex with the viral RNA genome (Fig. V).

The HIV Pr55^{Gag} precursor oligomerizes following its translation and is targeted to the plasma membrane, where particles of sufficient size and density to be visible by EM are assembled. Formation of virus-like particles by Pr55^{Gag} is a self-assembly process, with critical Gag-Gag interactions taking place between multiple domains along the Gag precursor. The assembly of virus-like particles does not require the participation of genomic RNA (although the presence of nucleic acid appears to be essential), *pol*-encoded enzymes, or Env glycoproteins, but the production of infectious virions requires the encapsidation of the viral RNA genome and the incorporation of the Env glycoproteins and the Gag-Pol polyprotein precursor Pr160^{Gag-Pol}.

Pol

Downstream of *gag* lies the most highly conserved region of the HIV genome, the *pol* gene, which encodes three enzymes: PR, RT, and IN (see Fig. IV). RT and IN are required, respectively, for reverse transcription of the viral RNA genome to a double-stranded DNA copy, and for the integration of the viral DNA into the host cell chromosome. PR plays a critical role late in the life cycle by mediating the production of mature, infectious virions. The *pol* gene products are derived by enzymatic cleavage of a 160-kd Gag-Pol fusion protein, referred to as Pr160^{Gag-Pol}. This fusion protein is produced by ribosomal frameshifting during translation of Pr55^{Gag} (see Fig. IV). The frame-shifting

WO 02/072754

PCT/US02/06713

mechanism for Gag-Pol expression, also utilized by many other retroviruses, ensures that the *pol*-derived proteins are expressed at a low level, approximately 5% to 10% that of Gag. Like Pr55^{gag}, the N-terminus of Pr160^{gag-pol} is myristylated and targeted to the plasma membrane.

Protease

Early pulse-chase studies performed with avian retroviruses clearly indicated that retroviral Gag proteins are initially synthesized as polyprotein precursors that are cleaved to generate smaller products. Subsequent studies demonstrated that the processing function is provided by a viral rather than a cellular enzyme, and that proteolytic digestion of the Gag and Gag-Pol precursors is essential for virus infectivity. Sequence analysis of retroviral PRs indicated that they are related to cellular "aspartic" proteases such as pepsin and renin. Like these cellular enzymes, retroviral PRs use two apposed Asp residues at the active site to coordinate a water molecule that catalyzes the hydrolysis of a peptide bond in the target protein. Unlike the cellular aspartic proteases, which function as pseudodimers (using two folds within the same molecule to generate the active site), retroviral PRs function as true dimers. X-ray crystallographic data from HIV-1 PR indicate that the two monomers are held together in part by a four-stranded antiparallel β -sheet derived from both N- and C-terminal ends of each monomer. The substrate-binding site is located within a cleft formed between the two monomers. Like their cellular homologs, the HIV PR dimer contains flexible "flaps" that overhang the binding site and may stabilize the substrate within the cleft; the active-site Asp residues lie in the center of the dimer. Interestingly, although some limited amino acid homology is observed surrounding active-site residues, the primary sequences of retroviral PRs are highly divergent, yet their structures are remarkably similar.

Reverse Transcriptase

By definition, retroviruses possess the ability to convert their single-stranded RNA genomes into double-stranded DNA during the early stages of the infection process. The enzyme that catalyzes this reaction is RT, in conjunction with its associated RNaseH activity. Retroviral RTs have three enzymatic activities: (a) RNA-directed DNA polymerization (for minus-strand DNA synthesis), (b) RNaseH activity (for the degradation of the tRNA primer and genomic RNA present in DNA-RNA hybrid intermediates), and (c) DNA-directed DNA polymerization (for second- or plus-strand DNA synthesis).

WO 02/072754

PCT/US02/06713

The mature HIV-1 RT holoenzyme is a heterodimer of 66 and 51 kd subunits. The 51-kd subunit (p51) is derived from the 66-kd (p66) subunit by proteolytic removal of the C-terminal 15-kd RNaseH domain of p66 by PR (see Fig. IV). The crystal structure of HIV-1 RT reveals a highly asymmetric folding in which the orientations of the p66 and p51 subunits differ substantially. The p66 subunit can be visualized as a right hand, with the polymerase active site within the palm, and a deep template-binding cleft formed by the palm, fingers, and thumb subdomains. The polymerase domain is linked to RNaseH by the connection subdomain. The active site, located in the palm, contains three critical Asp residues (110, 185, and 186) in close proximity, and two coordinated Mg²⁺ ions. Mutation of these Asp residues abolishes RT polymerizing activity. The orientation of the three active-site Asp residues is similar to that observed in other DNA polymerases (e.g., the Klenow fragment of *E. coli* DNA polI). The p51 subunit appears to be rigid and does not form a polymerizing cleft; Asp 110, 185, and 186 of this subunit are buried within the molecule. Approximately 18 base pairs of the primer-template duplex lie in the nucleic acid binding cleft, stretching from the polymerase active site to the RNaseH domain.

In the RT-primer-template-dNTP structure, the presence of a dideoxynucleotide at the 3' end of the primer allows visualization of the catalytic complex trapped just prior to attack on the incoming dNTP. Comparison with previously obtained structures suggests a model whereby the fingers close in to trap the template and dNTP prior to nucleophilic attack of the 3'-OH of the primer on the incoming dNTP. After the addition of the incoming dNTP to the growing chain, it has been proposed that the fingers adopt a more open configuration, thereby releasing the pyrophosphate and enabling RT to bind the next dNTP. The structure of the HIV-1 RNaseH has also been determined by x-ray crystallography; this domain displays a global folding similar to that of *E. coli* RNaseH.

Integrase

A distinguishing feature of retrovirus replication is the insertion of a DNA copy of the viral genome into the host cell chromosome following reverse transcription. The integrated viral DNA (the provirus) serves as the template for the synthesis of viral RNAs and is maintained as part of the host cell genome for the lifetime of the infected cell. Retroviral mutants deficient in the ability to integrate generally fail to establish a productive infection.

WO 02/072754

PCT/US02/06713

The integration of viral DNA is catalyzed by integrase, a 32-kd protein generated by PR-mediated cleavage of the C-terminal portion of the HIV-1 Gag-Pol polyprotein (see Fig. IV).

Retroviral IN proteins are composed of three structurally and functionally distinct domains: an N-terminal, zinc-finger-containing domain, a core domain, and a relatively nonconserved C-terminal domain. Because of its low solubility, it has not yet been possible to crystallize the entire 288-amino-acid HIV-1 IN protein. However, the structure of all three domains has been solved independently by x-ray crystallography or NMR methods. The crystal structure of the core domain of the avian sarcoma virus IN has also been determined. The N-terminal domain (residues 1 to 55), whose structure was solved by NMR spectroscopy, is composed of four helices with a zinc coordinated by amino acids His-12, His-16, Cys-40, and Cys-43. The structure of the N-terminal domain is reminiscent of helical DNA binding proteins that contain a so-called helix-turn-helix motif; however, in the HIV-1 structure this motif contributes to dimer formation. Initially, poor solubility hampered efforts to solve the structure of the core domain. However, attempts at crystallography were successful when it was observed that a Phe-to-Lys change at IN residue 185 greatly increased solubility without disrupting *in vitro* catalytic activity. Each monomer of the HIV-1 IN core domain (IN residues 50 to 212) is composed of a five-stranded β -sheet flanked by helices; this structure bears striking resemblance to other polynucleotidyl transferases including RNaseH and the bacteriophage MuA transposase. Three highly conserved residues are found in analogous positions in other polynucleotidyl transferases; in HIV-1 IN these are Asp-64, Asp-116 and Glu-152, the so-called D,D-35-E motif. Mutations at these positions block HIV IN function both *in vivo* and *in vitro*. The close proximity of these three amino acids in the crystal structure of both avian sarcoma virus and HIV-1 core domains supports the hypothesis that these residues play a central role in catalysis of the polynucleotidyl transfer reaction that is at the heart of the integration process. The C-terminal domain, whose structure has been solved by NMR methods, adopts a five-stranded β -barrel folding topology reminiscent of a Src homology 3 (SH3) domain. Recently, the x-ray structures of SIV and Rous sarcoma virus IN protein fragments encompassing both the core and C-terminal domains have been solved.

WO 02/072754

PCT/US02/06713

Env

The HIV Env glycoproteins play a major role in the virus life cycle. They contain the determinants that interact with the CD4 receptor and coreceptor, and they catalyze the fusion reaction between the lipid bilayer of the viral envelope and the host cell plasma membrane. In addition, the HIV Env glycoproteins contain epitopes that elicit immune responses that are important from both diagnostic and vaccine development perspectives.

The HIV Env glycoprotein is synthesized from the singly spliced 4.3-kb $\text{V}\mu\text{V}\text{e}$ Env bicistronic mRNA (see Fig. IV); translation occurs on ribosomes associated with the rough endoplasmic reticulum (ER). The 160-kd polyprotein precursor (gp160) is an integral membrane protein that is anchored to cell membranes by a hydrophobic stop-transfer signal in the domain destined to be the mature TM Env glycoprotein, gp41 (Fig. VI). The gp160 is cotranslationally glycosylated, forms disulfide bonds, and undergoes oligomerization in the ER. The predominant oligomeric form appears to be a trimer, although dimers and tetramers are also observed. The gp160 is transported to the Golgi, where, like other retroviral envelope precursor proteins, it is proteolytically cleaved by cellular enzymes to the mature SU glycoprotein gp120 and TM glycoprotein gp41 (see Fig. VI). The cellular enzyme responsible for cleavage of retroviral Env precursors following a highly conserved Lys/Arg-X-Lys/Arg-Arg motif is furin or a furin-like protease, although other enzymes may also catalyze gp160 processing. Cleavage of gp160 is required for Env-induced fusion activity and virus infectivity. Subsequent to gp160 cleavage, gp120 and gp41 form a noncovalent association that is critical for transport of the Env complex from the Golgi to the cell surface. The gp120-gp41 interaction is fairly weak, and a substantial amount of gp120 is shed from the surface of Env-expressing cells.

The HIV Env glycoprotein complex, in particular the SU (gp120) domain, is very heavily glycosylated; approximately half the molecular mass of gp160 is composed of oligosaccharide side chains. During transport of Env from its site of synthesis in the ER to the plasma membrane, many of the side chains are modified by the addition of complex sugars. The numerous oligosaccharide side chains form what could be imagined as a sugar cloud obscuring much of gp120 from host immune recognition. As shown in Figure VI, gp120 contains interspersed conserved (C₁ to C₅) and variable (V₁ to V₅) domains. The Cys residues present in the gp120s of different isolates are highly conserved and form disulfide bonds that link the first four variable regions in large loops.

WO 07/077794

PCT/US02/06713

A primary function of viral Env glycoproteins is to promote a membrane fusion reaction between the lipid bilayers of the viral envelope and host cell membranes. This membrane fusion event enables the viral core to gain entry into the host cell cytoplasm. A number of regions in both gp120 and gp41 have been implicated, directly or indirectly, in Env-mediated membrane fusion. Studies of the HA, hemagglutinin protein of the orthomyxoviruses and the F protein of the paramyxoviruses indicated that a highly hydrophobic domain at the N-terminus of these proteins, referred to as the fusion peptide, plays a critical role in membrane fusion. Mutational analyses demonstrated that an analogous domain was located at the N-terminus of the HIV-1, HIV-2, and SIV TM glycoproteins (see Fig. VI). Nonhydrophobic substitutions within this region of gp41 greatly reduced or blocked syncytium formation and resulted in the production of noninfectious progeny virions.

C-terminal to the gp41 fusion peptide are two amphipathic helical domains (see Fig. VI) which play a central role in membrane fusion. Mutations in the N-terminal helix (referred to as the N-helix), which contains a Leu zipper-like heptad repeat motif, impair infectivity and membrane fusion activity, and peptides derived from these sequences exhibit potent antiviral activity in culture. The structure of the ectodomain of HIV-1 and SIV gp41, the two helical motifs in particular, has been the focus of structural analyses in recent years. Structures were determined by x-ray crystallography or NMR spectroscopy either for fusion proteins containing the helical domains, a mixture of peptides derived from the N- and C-helices, or in the case of the SIV structure, the intact gp41 ectodomain sequence from residue 27 to 149. These studies obtained fundamentally similar trimeric structures, in which the two helical domains pack in an antiparallel fashion to generate a six-helix bundle. The N-helices form a coiled-coil in the center of the bundle, with the C-helices packing into hydrophobic grooves on the outside.

In the steps leading to membrane fusion CD4 binding induces conformation changes in Env that facilitate coreceptor binding. Following the formation of a ternary gp120/CD4/coreceptor complex, gp41 adopts a hypothetical conformation that allows the fusion peptide to insert into the target lipid bilayer. The formation of the gp41 six-helix bundle (which involves antiparallel interactions between the gp41 N- and C-helices) brings the viral and cellular membranes together and membrane fusion takes place.

WO 02/072754

PCT/US02/06713

Use of Recombinant MVA Virus To Boost CD8+ Cell Immune Response

The present invention relates to generation of a CD8⁺ T cell immune response against an antigen and also eliciting an antibody response. More particularly, the present invention relates to "prime and boost" immunization regimes in which the immune response induced by administration of a priming composition is boosted by administration of a boosting composition. The present invention is based on inventors' experimental demonstration that effective boosting can be achieved using modified vaccinia Ankara (MVA) vectors, following priming with any of a variety of different types of priming compositions including recombinant MVA itself.

A major protective component of the immune response against a number of pathogens is mediated by T lymphocytes of the CD8⁺ type, also known as cytotoxic T lymphocytes (CTL). An important function of CD8⁺ cells is secretion of gamma interferon (IFN γ), and this provides a measure of CD8⁺ T cell immune response. A second component of the immune response is antibody directed to the proteins of the pathogen.

The present invention employs MVA which, as the experiments described below show, has been found to be an effective means for providing a boost to a CD8⁺ T cell immune response primed to antigen using any of a variety of different priming compositions and also eliciting an antibody response.

Remarkably, the experimental work described below demonstrates that use of embodiments of the present invention allows for recombinant MVA virus expressing an HIV antigen to boost a CD8⁺ T cell immune response primed by a DNA vaccine and also eliciting an antibody response. The MVA was found to induce a CD8⁺ T cell response after intradermal, intramuscular or mucosal immunization. Recombinant MVA has also been shown to prime an immune response that is boosted by one or more inoculations of recombinant MVA.

Non-human primates immunized with plasmid DNA and boosted with the MVA were effectively protected against intramucosal challenge with live virus. Advantageously, the inventors found that a vaccination regime used intradermal, intramuscular or mucosal immunization for both prime and boost can be employed, constituting a general immunization regime suitable for inducing CD8⁺ T cells and also eliciting an antibody response, e.g. in humans.

WO 02/072754

PCT/US02/06713

The present invention in various aspects and embodiments employs an MVA vector encoding an HIV antigen for boosting a CD8⁺ T cell immune response to the antigen primed by previous administration of nucleic acid encoding the antigen and also eliciting an antibody response.

A general aspect of the present invention provides for the use of an MVA vector for boosting a CD8⁺ T cell immune response to an HIV antigen and also eliciting an antibody response.

One aspect of the present invention provides a method of boosting a CD8⁺ T cell immune response to an HIV antigen in an individual, and also eliciting an antibody response, the method including provision in the individual of an MVA vector including nucleic acid encoding the antigen operably linked to regulatory sequences for production of antigen in the individual by expression from the nucleic acid, whereby a CD8⁺ T cell immune response to the antigen previously primed in the individual is boosted.

An immune response to an HIV antigen may be primed by immunization with plasmid DNA or by infection with an infectious agent.

A further aspect of the invention provides a method of inducing a CD8⁺ T cell immune response to an HIV antigen in an individual, and also eliciting an antibody response, the method comprising administering to the individual a priming composition comprising nucleic acid encoding the antigen and then administering a boosting composition which comprises an MVA vector including nucleic acid encoding the antigen operably linked to regulatory sequences for production of antigen in the individual by expression from the nucleic acid.

A further aspect provides for use of an MVA vector, as disclosed, in the manufacture of a medicament for administration to a mammal to boost a CD8⁺ T cell immune response to an HIV antigen, and also eliciting an antibody response. Such a medicament is generally for administration following prior administration of a priming composition comprising nucleic acid encoding the antigen.

The priming composition may comprise any viral vector, such as a vaccinia virus vector such as a replication-deficient strain such as modified vaccinia Ankara (MVA) or NYVAC (Tartaglia *et al.* 1992 *Virology* 118:217-232), an avipox vector such as fowlpox or canarypox, e.g. the strain known as ALVAC (Paoletti *et al.* 1994 *Dev Biol Stand* 82:65-69), or an adenovirus vector or a vesicular stomatitis virus vector or an alphavirus vector.

WO 02/072754

PCT/US02/06713

The priming composition may comprise DNA encoding the antigen, such DNA preferably being in the form of a circular plasmid that is not capable of replicating in mammalian cells. Any selectable marker should not be resistance to an antibiotic used clinically, so for example Kanamycin resistance is preferred to Ampicillin resistance. Antigen expression should be driven by a promoter which is active in mammalian cells, for instance the cytomegalovirus immediate early (CMV IE) promoter.

In particular embodiments of the various aspects of the present invention, administration of a priming composition is followed by boosting with a boosting composition, or first and second boosting compositions, the first and second boosting compositions being the same or different from one another. Still further boosting compositions may be employed without departing from the present invention. In one embodiment, a triple immunization regime employs DNA, then adenovirus as a first boosting composition, then MVA as a second boosting composition, optionally followed by a further (third) boosting composition or subsequent boosting administration of one or other or both of the same or different vectors. Another option is DNA then MVA then adenovirus, optionally followed by subsequent boosting administration of one or other or both of the same or different vectors.

The antigen to be encoded in respective priming and boosting compositions (however many boosting compositions are employed) need not be identical, but should share at least one CD8⁺ T cell epitope. The antigen may correspond to a complete antigen, or a fragment thereof. Peptide epitopes or artificial strings of epitopes may be employed, more efficiently cutting out unnecessary protein sequence in the antigen and encoding sequence in the vector or vectors. One or more additional epitopes may be included, for instance epitopes which are recognized by T helper cells, especially epitopes recognized in individuals of different HLA types.

An HIV antigen of the invention to be encoded by a recombinant MVA virus includes polypeptides having immunogenic activity elicited by an amino acid sequence of an HIV Env, Gag, Pol, Vif, Vpr, Tat, Rev, Vpu, or Nef amino acid sequence as at least one CD8⁺ T cell epitope. This amino acid sequence substantially corresponds to at least one 10-900 amino acid fragment and/or consensus sequence of a known HIV Env or Pol; or at least one 10-450 amino acid fragment and/or consensus sequence of a known HIV Gag; or at

WO 02/072734

PCT/US02/06713

least one 10-100 amino acid fragment and/or consensus sequence of a known HIV Vif, Vpr, Tat, Rev, Vpu, or Nef.

Although a full length Env precursor sequence is presented for use in the present invention, Env is optionally deleted of subsequences. For example, regions of the gp120 surface and gp41 transmembrane cleavage products can be deleted.

Although a full length Gag precursor sequence is presented for use in the present invention, Gag is optionally deleted of subsequences. For example, regions of the matrix protein (p17), regions of the capsid protein (p24), regions of the nucleocapsid protein (p7), and regions of p6 (the C-terminal peptide of the Gag polyprotein) can be deleted.

Although a full length Pol precursor sequence is presented for use in the present invention, Pol is optionally deleted of subsequences. For example, regions of the protease protein (p10), regions of the reverse transcriptase protein (p66/p51), and regions of the integrase protein (p32) can be deleted.

Such an HIV Env, Gag, or Pol can have overall identity of at least 50% to a known Env, Gag, or Pol protein amino acid sequence, such as 50-99% identity, or any range or value therein, while eliciting an immunogenic response against at least one strain of an HIV.

Percent identity can be determined, for example, by comparing sequence information using the GAP computer program, version 6.0, available from the University of Wisconsin Genetics Computer Group (UWGCG). The GAP program utilizes the alignment method of Needleman and Wunsch (*J Mol Biol* 1970 48:443), as revised by Smith and Waterman (*Adv Appl Math* 1981 2:482). Briefly, the GAP program defines identity as the number of aligned symbols (i.e., nucleotides or amino acids) which are identical, divided by the total number of symbols in the shorter of the two sequences. The preferred default parameters for the GAP program include: (1) a unitary comparison matrix (containing a value of 1 for identities and 0 for non-identities) and the weighted comparison matrix of Gribskov and Burgess (*Nucl Acids Res* 1986 14:6745), as described by Schwartz and Dayhoff (eds., *Atlas of Protein Sequence and Structure*, National Biomedical Research Foundation, Washington, D.C. 1979, pp. 353-358); (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap; and (3) no penalty for end gaps.

In a preferred embodiment, an Env of the present invention is a variant form of at least one HIV envelope protein. Preferably, the Env is composed of gp120 and the

WO 02/072754

PCT/US02/06713

membrane-spanning and ectodomain of gp41 but lacks part or all of the cytoplasmic domain of gp41.

Known HIV sequences are readily available from commercial and institutional HIV sequence databases, such as GENBANK, or as published compilations, such as Myers *et al.* eds., *Human Retroviruses and AIDS, A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences*, Vol. I and II, Theoretical Biology and Biophysics, Los Alamos, N. Mex. (1993), or <http://hiv-web.lanl.gov/>.

Substitutions or insertions of an HIV Env, Gag, or Pol to obtain an additional HIV Env, Gag, or Pol, encoded by a nucleic acid for use in a recombinant MVA virus of the present invention, can include substitutions or insertions of at least one amino acid residue (e.g., 1-25 amino acids). Alternatively, at least one amino acid (e.g., 1-25 amino acids) can be deleted from an HIV Env, Gag, or Pol sequence. Preferably, such substitutions, insertions or deletions are identified based on safety features, expression levels, immunogenicity and compatibility with high replication rates of MVA.

Amino acid sequence variations in an HIV Env, Gag, or Pol of the present invention can be prepared e.g., by mutations in the DNA. Such HIV Env, Gag, or Pol include, for example, deletions, insertions or substitutions of nucleotides coding for different amino acid residues within the amino acid sequence. Obviously, mutations that will be made in nucleic acid encoding an HIV Env, Gag, or Pol must not place the sequence out of reading frame and preferably will not create complementary domains that could produce secondary mRNA structures.

HIV Env, Gag, or Pol-encoding nucleic acid of the present invention can also be prepared by amplification or site-directed mutagenesis of nucleotides in DNA or RNA encoding an HIV Env, Gag, or Pol and thereafter synthesizing or reverse transcribing the encoding DNA to produce DNA or RNA encoding an HIV Env, Gag, or Pol, based on the teaching and guidance presented herein.

Recombinant MVA viruses expressing HIV Env, Gag, or Pol of the present invention, include a finite set of HIV Env, Gag, or Pol-encoding sequences as substitution nucleotides that can be routinely obtained by one of ordinary skill in the art, without undue experimentation, based on the teachings and guidance presented herein. For a detailed description of protein chemistry and structure, see Schulz, G.E. *et al.*, 1978 *Principles of Protein Structure*, Springer-Verlag, New York, N.Y., and Creighton, T.E., 1983 *Proteins:*

WO 02/072754

PCT/US02/06713

Structure and Molecular Properties, W. H. Freeman & Co., San Francisco, CA. For a presentation of nucleotide sequence substitutions, such as codon preferences, see Ausubel et al. eds. *Current Protocols in Molecular Biology*, Greene Publishing Assoc., New York, N.Y. 1994 at §§ A.1.1-A.1.24, and Sambrook, J. et al. 1989 *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. at Appendices C and D.

Thus, one of ordinary skill in the art, given the teachings and guidance presented herein, will know how to substitute other amino acid residues in other positions of an HIV env, gag, or pol DNA or RNA to obtain alternative HIV Env, Gag, or Pol, including substitutional, deletional or insertional variants.

Within the MVA vector, regulatory sequences for expression of the encoded antigen will include a natural, modified or synthetic poxvirus promoter. By "promoter" is meant a sequence of nucleotides from which transcription may be initiated of DNA operably linked downstream (i.e. in the 3' direction on the sense strand of double-stranded DNA). "Operably linked" means joined as part of the same nucleic acid molecule, suitably positioned and oriented for transcription to be initiated from the promoter. DNA operably linked to a promoter is "under transcriptional initiation regulation" of the promoter. Other regulatory sequences including terminator fragments, polyadenylation sequences, marker genes and other sequences may be included as appropriate, in accordance with the knowledge and practice of the ordinary person skilled in the art; see, for example, Moss, B. (2001). Poxviridae: the viruses and their replication. In *Fields Virology*, D.M. Knipe, and P.M. Howley, eds. (Philadelphia, Lippincott Williams & Wilkins), pp. 2849-2883. Many known techniques and protocols for manipulation of nucleic acid, for example in preparation of nucleic acid constructs, mutagenesis, sequencing, introduction of DNA into cells and gene expression, and analysis of proteins, are described in detail in *Current Protocols in Molecular Biology*, 1998 Ausubel et al. eds., John Wiley & Sons.

Promoters for use in aspects and embodiments of the present invention must be compatible with poxvirus expression systems and include natural, modified and synthetic sequences.

Either or both of the priming and boosting compositions may include an adjuvant, such as granulocyte macrophage-colony stimulating factor (GM-CSF) or encoding nucleic acid therefor.

WO 07/077754

PCT/US02/06713

Administration of the boosting composition is generally about 1 to 6 months after administration of the priming composition, preferably about 1 to 3 months.

Preferably, administration of priming composition, boosting composition, or both priming and boosting compositions, is intradermal, intramuscular or mucosal immunization.

Administration of MVA vaccines may be achieved by using a needle to inject a suspension of the virus. An alternative is the use of a needleless injection device to administer a virus suspension (using, e.g., Biojector™ needleless injector) or a resuspended freeze-dried powder containing the vaccine, providing for manufacturing individually prepared doses that do not need cold storage. This would be a great advantage for a vaccine that is needed in rural areas of Africa.

MVA is a virus with an excellent safety record in human immunizations. The generation of recombinant viruses can be accomplished simply, and they can be manufactured reproducibly in large quantities. Intradermal, intramuscular or mucosal administration of recombinant MVA virus is therefore highly suitable for prophylactic or therapeutic vaccination of humans against AIDS which can be controlled by a CD8⁺ T cell response.

The individual may have AIDS such that delivery of the antigen and generation of a CD8⁺ T cell immune response to the antigen is of benefit or has a therapeutically beneficial effect.

Most likely, administration will have prophylactic aim to generate an immune response against HIV or AIDS before infection or development of symptoms.

Components to be administered in accordance with the present invention may be formulated in pharmaceutical compositions. These compositions may comprise a pharmaceutically acceptable excipient, carrier, buffer, stabilizer or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material may depend on the route of administration, e.g. intravenous, cutaneous or subcutaneous, nasal, intramuscular, intraperitoneal routes.

As noted, administration is preferably intradermal, intramuscular or mucosal.

Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included.

WO 02/072754

PCT/US02/06713

For intravenous, cutaneous, subcutaneous, intramuscular or mucosal injection, or injection at the site of affliction, the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection. Preservatives, stabilizers, buffers, antioxidants and/or other additives may be included as required.

A slow-release formulation may be employed.

Following production of MVA particles and optional formulation of such particles into compositions, the particles may be administered to an individual, particularly human or other primate. Administration may be to another mammal, e.g. rodent such as mouse, rat or hamster, guinea pig, rabbit, sheep, goat, pig, horse, cow, donkey, dog or cat.

Administration is preferably in a "prophylactically effective amount" or a "therapeutically effective amount" (as the case may be, although prophylaxis may be considered therapy), this being sufficient to show benefit to the individual. The actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g. decisions on dosage, etc, is within the responsibility of general practitioners and other medical doctors, or in a veterinary context a veterinarian, and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners. Examples of the techniques and protocols mentioned above can be found in *Remington's Pharmaceutical Sciences*, 16th edition, 1980, Osol, A. (ed.).

In one preferred regimen, DNA is administered at a dose of 250 µg to 2.5 mg/injection, followed by MVA at a dose of 10⁹ to 10⁹ infectious virus particles/injection.

A composition may be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated.

Delivery to a non-human mammal need not be for a therapeutic purpose, but may be for use in an experimental context, for instance in investigation of mechanisms of immune responses to an antigen of interest, e.g. protection against HIV or AIDS.

Further aspects and embodiments of the present invention will be apparent to those of ordinary skill in the art, in view of the above disclosure and following experimental

WO 02/072754

PCT/US02/06713

exemplification, included by way of illustration and not limitation, and with reference to the attached figures.

EXAMPLE 1

Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine

Here we tested DNA priming and poxvirus boosting for the ability to protect against a highly pathogenic mucosal challenge. The 89.6 chimera of simian and human immunodeficiency viruses (SHIV-89.6) was used for the construction of immunogens and its highly pathogenic derivative, SHIV-89.6P, for challenge (G.B. Karlsson *et al.* 1997 *J Virol* 71:4218). SHIV-89.6 and SHIV-89.6P do not generate cross-neutralizing antibody (D.C... Montefiori *et al.* 1998 *J Virol* 72:3427) and allowed us to address the ability of vaccine-raised T cells and non-neutralizing antibodies to control an immunodeficiency virus challenge. Modified vaccinia Ankara (MVA) was used for the construction of the recombinant poxvirus. MVA has been highly effective at boosting DNA-primed CD8 T cells and enjoys the safety feature of not replicating efficiently in human or monkey cells (H.L. Robinson *et al.* 2000 *AIDS Reviews* 2:105).

To ensure a broad immune response both the DNA and recombinant MVA (rMVA) components of the vaccine expressed multiple immunodeficiency virus proteins. The DNA prime (DNA/89.6) expressed simian immunodeficiency virus (SIV) Gag, Pol, Vif, Vpx, and Vpr and human immunodeficiency virus-1 (HIV-1) Env, Tat, and Rev from a single transcript (R.J. Gorelick *et al.* 1999 *Virology* 253:259; M.M. Sauter *et al.* 1996 *J Cell Biol* 132:795).

Molecularly cloned SHIV-89.6 sequences were cloned into the vector pGA2 using *Cla*I and *Rsr*II sites. This cloning deleted both long terminal repeats (LTRs) and *nef*. The SHIV-89.6 sequences also were internally mutated for a 12-base pair region encoding the first four amino acids of the second zinc finger in nucleocapsid. This mutation renders SHIV viruses noninfectious (R.J. Gorelick *et al.* 1999 *Virology* 253:259). A mutation in gp41 converted the tyrosine at position 710 to cysteine to achieve better expression of Env on the plasma membrane of DNA-expressing cells (M.M. Sauter *et al.* 1996 *J Cell Biol* 132:795). pGA2 uses the CMV immediate early promoter without intron A and the bovine growth hormone polyadenylation sequence to express vaccine inserts. Vaccine DNA was

WO 02/072754

PCT/US02/06713

produced by Althea (San Diego, CA). In transient transfections of 293T cells, DNA/89.6 produced about 300 ng of Gag and 85 ng of Env per 1×10^6 cells.

The rMVA booster (MVA/89.6) expressed SIV Gag, Pol, and HIV-1 Env under the control of vaccinia virus early/late promoters.

The MVA double recombinant virus expressed both the HIV 89.6 Env and the SIV 239 Gag-Pol, which were inserted into deletion II and deletion III of MVA, respectively.

The 89.6 Env protein was truncated for the COOH-terminal 115 amino acids of gp41. The modified H5 promoter controlled the expression of both foreign genes.

Vaccination was accomplished by priming with DNA at 0 and 8 weeks and boosting with rMVA at 24 weeks (Fig. 1A).

I.d. and i.m. DNA immunizations were delivered in phosphate-buffered saline (PBS) with a needleless jet injector (Bioject, Portland, OR) to deliver five i.d. 100- μ l injections to each outer thigh for the 2.5-mg dose of DNA or one i.d. 100- μ l injection to the right outer thigh for the 250- μ g dose of plasmid. I.m. deliveries of DNA were done with one 0.5-ml injection of DNA in PBS to each outer thigh for the 2.5-mg dose and one 100- μ l injection to the right outer thigh for the 250- μ g dose. 1×10^6 pfu of MVA/89.6 was administered both i.d. and i.m. with a needle. One 100- μ l dose was delivered to each outer thigh for the i.d. dose and one 500- μ l dose to each outer thigh for the i.m. dose. Control animals received 2.5 mg of the pGA2 vector without vaccine insert with the Bioject device to deliver five 100- μ l doses i.d. to each outer thigh. The control MVA booster immunization consisted of 2×10^6 pfu of MVA without an insert delivered i.d. and i.m. as described for MVA/89.6.

Four groups of six rhesus macaques each were primed with either 2.5 mg (high-dose) or 250 μ g (low-dose) of DNA by intradermal (i.d.) or intramuscular (i.m.) routes using a needleless jet injection device (Bioject, Portland, OR) (T.M. Allen *et al.* 2000 *J Immunol* 164:4965).

Young adult rhesus macaques from the Yerkes breeding colony were cared for under guidelines established by the Animal Welfare Act and the NIH "Guide for the Care and Use of Laboratory Animals" with protocols approved by the Emory University Institutional Animal Care and Use Committee. Macaques were typed for the Mamu-A*01 allele with polymerase chain reaction (PCR) analyses (M.A. Egan *et al.* 2000 *J Virol* 74:7485; I. Ourmanov *et al.* 2000 *J Virol* 74:2740). Two or more animals containing at

WO 02/072754

PCT/US02/06713

least one *Mamu-A*01* allele were assigned to each group. Animal numbers are as follows: 1, RBr-5*; 2, RIm-5*; 3, RQf-5*; 4, RZe-5; 5, ROm-5; 6, RDm-5; 7, RAj-5*; 8, RJI-5*; 9, RAI-5*; 10, RDe-5*; 11, RAI-5; 12, RPr-5; 13, RKw-4*; 14, RW2-5*; 15, RGo-5; 16, RLp-4; 17, RWd-6; 18, RAt-5; 19, RPb-5*; 20, RJI-5*; 21, Rjq-5; 22, RSp-4; 23, RSn-5; 24, RGd-6; 25, RMb-5*; 26, RGy-5*; 27, RUa-4; and 28, RPM-5. Animals with the *A*01* allele are indicated with asterisks.

Gene gun deliveries of DNA were not used because these had primed non-protective immune responses in a 1996 - 98 trial (H.L. Robinson *et al.* 1999 *Nat Med* 5:526). The rMVA/89.6 booster immunization (2×10^8 plaque-forming units, pfu) was injected with a needle both i.d. and i.m. A control group included two mock immunized animals and two naive animals. The challenge was given at 7 months after the rMVA booster to test for the generation of long-term immunity. Because most HIV-1 infections are transmitted across mucosal surfaces, an intrarectal challenge was administered.

DNA priming followed by rMVA boosting generated high frequencies of virus-specific T cells that peaked at one week following the rMVA booster (Fig. 1). The frequencies of T cells recognizing the Gag-CM9 epitope were assessed by means of *Mamu-A*01* tetramers, and the frequencies of T cells recognizing epitopes throughout Gag were assessed with pools of overlapping peptides and an enzyme-linked immunospot (ELISPOT) assay (C.A. Power *et al.* 1999 *J Immunol Methods* 227:99).

For tetramer analyses, about 1×10^6 peripheral blood mononuclear cells (PBMC) were surface-stained with antibodies to CD3 conjugated to fluorescein isothiocyanate (FITC) (FN-18; Biosource International, Camarillo, CA), CD8 conjugated to peridinin chlorophyll protein (PerCP) (SK1; Becton Dickinson, San Jose, CA), and Gag-CM9 (CTPYDINQM)-*Mamu-A*01* tetramer (SEQ ID NO: 6) conjugated to allophycocyanin (APC), in a volume of 100 μ l at 8° to 10°C for 30 min. Cells were washed twice with cold PBS containing 2% fetal bovine serum (FBS), fixed with 1% paraformaldehyde in PBS, and analyzed within 24 hrs on a FACScaliber (Becton Dickinson, San Jose, CA). Cells were initially gated on lymphocyte populations with forward scatter and side scatter and then on CD3 cells. The CD3 cells were then analyzed for CD8 and tetramer-binding cells. About 150,000 lymphocytes were acquired for each sample. Data were analyzed using FloJo software (Tree Star, San Carlos, CA).

WO 02/072754

PCT/US02/06713

For interferon- γ (IFN- γ) ELISPOTs, MULTISCREEN 96 well filtration plates (Millipore Inc. Bedford, MA) were coated overnight with antibody to human IFN- γ (Clone B27, Pharmingen, San Diego, CA) at a concentration of 2 μ g/ml in sodium bicarbonate buffer (pH 9.6) at 8° to 10°C. Plates were washed two times with RPMI medium and then blocked for 1 hour with complete medium (RPMI containing 10% FBS) at 37°C. Plates were washed five more times with plain RPMI medium, and cells were seeded in duplicate in 100 μ l complete medium at numbers ranging from 2x10⁴ to 5x10⁴ cells per well. Peptide pools were added to each well to a final concentration of 2 μ g/ml of each peptide in a volume of 100 μ l in complete medium. Cells were cultured at 37°C for about 36 hrs under 5% CO₂. Plates were washed six times with wash buffer (PBS with 0.05% Tween-20) and then incubated with 1 μ g of biotinylated antibody to human IFN- γ per milliliter (clone 7-86-1; Diapharma Group, West Chester, OH) diluted in wash buffer containing 2% FBS. Plates were incubated for 2 hrs at 37°C and washed six times with wash buffer. Avidin-horseradish peroxidase (Vector Laboratories, Burlingame, CA) was added to each well and incubated for 30 to 60 min at 37°C. Plates were washed six times with wash buffer and spots were developed using stable DAB as substrate (Research Genetics, Huntsville, AL). Spots were counted with a stereo dissecting microscope. An ovalbumin peptide (SIINFEKL) (SEQ ID NO: 7) was included as a control in each analysis. Background spots for the ovalbumin peptide were generally <5 for 5x10⁴ PBMCs. This background when normalized for 1x10⁶ PBMC was <10. Only ELISPOT counts of twice the background (\geq 20) were considered significant. The frequencies of ELISPOTs are approximate because different dilutions of cells have different efficiencies of spot formation in the absence of feeder cells (C.A. Power *et al.* 1999 *J Immunol Methods* 227: 99). The same dilution of cells was used for all animals at a given time point, but different dilutions were used to detect memory and acute responses.

Gag-CM9 tetramer analyses were restricted to macaques that expressed the *Mamu-A*01* histocompatibility type, whereas ELISPOT responses did not depend on a specific histocompatibility type. As expected, the DNA immunizations raised low levels of memory cells that expanded to high frequencies within 1 week of the rMVA booster (Fig. 1 and 6). In *Mamu-A*01* macaques, CD8 cells specific to the Gag-CM9 epitope expanded to frequencies as high as 19% of total CD8 T cells (Fig. 6). This peak of specific cells underwent a 10- to 100-fold contraction into the DNA/MVA memory pool (Fig. 1A and 6).

WO 02/072754

PCT/US02/06713

ELISPOTs for three pools of Gag peptides also underwent a major expansion (frequencies up to 4000 spots for 1×10^6 PBMC) before contracting from 5- to 20-fold into the DNA/MVA memory response (Fig. 1B). The frequencies of ELISPOTs were the same in macaques with and without the A^*01 histocompatibility type ($P>0.2$).

Simple linear regression was used to estimate correlations between postbooster and postchallenge ELISPOT responses, between memory and postchallenge ELISPOT responses, and between logarithmically transformed viral loads and ELISPOT frequencies. Comparisons between vaccine and control groups and A^*01 and non A^*01 macaques were performed by means of two-sample *t* tests with logarithmically transformed viral load and ELISPOT responses. Two-way analyses of variance were used to examine the effects of dose and route of administration on peak DNA/MVA ELISPOTs, on memory DNA/MVA ELISPOTs, and on logarithmically transformed Gag antibody data.

At both peak and memory phases of the vaccine response, the rank order for the height of the ELISPOTs in the vaccine groups was 2.5 mg i.d. > 2.5 mg i.m. > 250 μ g i.d. > 250 μ g i.m. (Fig. 1B). The IFN- γ ELISPOTs included both CD4 and CD8 cells. Gag-CM9-specific CD8 cells had good lytic activity after restimulation with peptide.

The highly pathogenic SHIV-89.6P challenge was administered intrarectally at 7 months after the rMVA booster, when vaccine-raised T cells were in memory (Fig. 1).

The challenge stock (5.7×10^9 copies of viral RNA per milliliter) was produced by one intravenous followed by one intrarectal passage in rhesus macaques of the original SHIV-89.6P stock (G.B. Karlsson *et al.* 1997 *J Virol* 71:4218). Lymphoid cells were harvested from the intrarectally infected animal at peak viremia, CD8-depleted, and mitogen-stimulated for stock production. Before intrarectal challenge, fasted animals were anesthetized (ketamine, 10 mg/kg) and placed on their stomach with the pelvic region slightly elevated. A feeding tube (8Fr (2.7 mm) x 16 inches (41 cm); Sherwood Medical, St. Louis, MO) was inserted into the rectum for a distance of 15 to 20 cm. Following insertion of the feeding tube, a syringe containing 20 intrarectal infectious doses in 2 ml of RPMI-1640 plus 10% FBS was attached to the tube and the inoculum was slowly injected into the rectum. After delivery of the inoculum, the feeding tube was flushed with 3.0 ml of RPMI without FBS and then slowly withdrawn. Animals were left in place, with pelvic regions slightly elevated, for a period of ten minutes after the challenge.

WO 02/072754

PCT/US02/06713

The challenge infected all of the vaccinated and control animals (Fig. 2). However, by 2 weeks after challenge, titers of plasma viral RNA were at least 10-fold lower in the vaccine groups (geometric means of 1×10^7 to 5×10^7) than in the control animals (geometric mean of 4×10^8) (Fig. 2A) (S. Staprana *et al.* in: *Viral Genome Methods* K. Adolph, ed. CRC Press, Boca Raton, FL, 1996 pp. 167-184; R. Hofmann-Lehmann *et al.* 2000 *AIDS Res Hum Retroviruses* 16:1247).

For the determination of SHIV copy number, viral RNA from 150 μ l of ACD anticoagulated plasma was directly extracted with the QIAamp Viral RNA kit (Qiagen), eluted in 60 μ l of AVE buffer, and frozen at -80°C until SHIV RNA quantitation was performed. Five microliters of purified plasma RNA was reverse-transcribed in a final 20- μ l volume containing 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 4 mM MgCl₂, 1 mM each deoxynucleotide triphosphate (dNTP), 2.5 μ M random hexamers, 20 units MultiScribe RT, and 8 units ribonuclease inhibitor. Reactions were incubated at 25°C for 10 min, followed by incubation at 42°C for 20 min, and inactivation of reverse transcriptase at 99°C for 5 min. The reaction mix was adjusted to a final volume of 50 μ l containing 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 4 mM MgCl₂, 0.4 mM each dNTP, 0.2 μ M forward primer, 0.2 μ M reverse primer, 0.1 μ M probe, and 5 units AmpliTaq Gold DNA polymerase (all reagents from PerkinElmer Applied Biosystems, Foster City, CA). The primer sequences within a conserved portion of the SIV gag gene are the same as those described previously (S. Staprana *et al.* in: *Viral Genome Methods* K. Adolph, ed. CRC Press, Boca Raton, FL, 1996 pp. 167-184). A PerkinElmer Applied Biosystems 7700 Sequence Detection System was used with the PCR profile: 95°C for 10 min, followed by 40 cycles at 93°C for 30 s, and 59.5°C for 1 min. PCR product accumulation was monitored with the 7700 sequence detector and a probe to an internal conserved gag gene sequence: 6FAM-CTGTCTGCGTCATTGGTGC-Tamra (SEQ ID NO: 8), where FAM and Tamra denote the reporter and quencher dyes. SHIV RNA copy number was determined by comparison with an external standard curve consisting of virion-derived SIVmac239 RNA quantified by the SIV bDNA method (Bayer Diagnostics, Emeryville, CA). All specimens were extracted and amplified in duplicate, with the mean result reported. With a 0.15-ml plasma input, the assay has a sensitivity of 10³ RNA copies per milliliter of plasma and a linear dynamic range of 10³ to 10⁸ RNA copies ($R^2 = 0.995$). The intraassay coefficient of variation was <20% for samples containing >10⁶ SHIV RNA copies per milliliter, and

WO 02/072734

PCT/US02/06713

<25% for samples containing 10^3 to 10^4 SHIV RNA copies per milliliter. To more accurately quantitate low SHIV RNA copy number in vaccinated animals at weeks 16 and 20, we made the following modifications to increase the sensitivity of the SHIV RNA assay: (i) Virions from ≤ 1 ml of plasma were concentrated by centrifugation at 23,000g at 10°C for 150 min before viral RNA extraction, and (ii) a one-step reverse transcriptase PCR method was used (R. Hofmann-Lehmann *et al.* 2000 *AIDS Res Hum Retroviruses* 16:1247). These changes provided a reliable quantification limit of 300 SHIV RNA copies per milliliter, and gave SHIV RNA values that were highly correlated to those obtained by the first method used ($r = 0.91$, $P < 0.0001$).

By 8 weeks after challenge, both high-dose DNA-primed groups and the low-dose i.m. DNA-primed group had reduced their geometric mean loads to about 1000 copies of viral RNA per milliliter. At this time, the low-dose i.m. DNA-primed group had a geometric mean of 6×10^3 copies of viral RNA and the nonvaccinated controls had a geometric mean of 2×10^4 . By 20 weeks after challenge, even the low-dose i.m. group had reduced its geometric mean copies of viral RNA to 1000. Among the 24 vaccinated animals, only one animal, animal number 22 in the low-dose i.m. group, had intermittent viral loads above 1×10^4 copies per milliliter (Fig 2D).

By 5 weeks after challenge, all of the nonvaccinated controls had undergone a profound depletion of CD4 cells (Fig 2B). All of the vaccinated animals maintained their CD4 cells, with the exception of animal 22 in the low dose i.m. group (see above), which underwent a slow CD4 decline (Fig. 2B). By 23 weeks after challenge, three of the four control animals had succumbed to AIDS (Fig. 2C). These animals had variable degrees of enterocolitis with diarrhea, cryptosporidiosis, colitis, enteric campylobacter infection, splenomegaly, lymphadenopathy, and SIV-associated giant cell pneumonia. In contrast, all 24 vaccinated animals maintained their health.

Containment of the viral challenge was associated with a burst of antiviral T cells (Fig. 1 and 3A). At one week after challenge, the frequency of tetramer⁺ cells in the peripheral blood had decreased, potentially reflecting the recruitment of specific T cells to the site of infection (Fig. 3A). However, by two weeks after challenge, tetramer⁺ cells in the peripheral blood had expanded to frequencies as high as, or higher than, after the rMVA booster (Fig. 1 and 3A). The majority of the tetramer⁺ cells produced IFN- γ in response to a 6-hour peptide stimulation (Fig. 3B) (S.L. Waldrop *et al.* 1997 *J Clin Invest* 99:1739) and

WO 02/072754

PCT/US02/06713

did not have the "stunned" IFN- γ negative phenotype sometimes observed in viral infections (F. Lechner *et al.* 2000 *J Exp Med* 191:1499).

For intracellular cytokine assays, about 1×10^6 PBMC were stimulated for 1 hour at 37°C in 5 ml polypropylene tubes with 100 μ g of Gag-CM9 peptide (CTPYDINQM) (SEQ ID NO: 6) per milliliter in a volume of 100 μ l RPMI containing 0.1% bovine serum albumin (BSA) and 1 μ g of antibody to human CD28 and 1 μ g of antibody to human CD49d (Pharmingen, San Diego, CA) per milliliter. Then, 900 μ l of RPMI containing 10% FBS and monensin (10 μ g/ml) was added, and the cells were cultured for an additional 5 hrs at 37°C at an angle of 5° under 5% CO₂. Cells were surface stained with antibodies to CD8 conjugated to PerCP (clone SK1, Becton Dickinson) at 8° to 10°C for 30 min, washed twice with cold PBS containing 2% FBS, and fixed and permeabilized with Cytofix/Cytoperm solution (Pharmingen). Cells were then incubated with antibodies to human CD3 (clone FN-18; Biosource International, Camarillo, CA) and IFN- γ (Clone B27; Pharmingen) conjugated to FITC and phycoerythrin, respectively, in Perm wash solution (Pharmingen) for 30 min at 4°C. Cells were washed twice with Perm wash, once with plain PBS, and resuspended in 1% paraformaldehyde in PBS. About 150,000 lymphocytes were acquired on the FACScaliber and analyzed with FloJo software.

The postchallenge burst of T cells contracted concomitant with the decline of the viral load. By 12 weeks after challenge, virus-specific T cells were present at about one-tenth of their peak height (Figs. 1A and 3A). In contrast to the vigorous secondary response in the vaccinated animals, the naive animals mounted a modest primary response (Fig. 1B and 3A). Tetramer⁺ cells peaked at less than 1% of total CD8 cells (Fig. 3A), and IFN- γ -producing ELISPOTs were present at a mean frequency of about 300 as opposed to the much higher frequencies of 1000 to 6000 in the vaccine groups (Fig. 1B) ($P < 0.05$).

The tetramer⁺ cells in the control group, like those in the vaccine group, produced IFN- γ after peptide stimulation (Fig. 3B). By 12 weeks after challenge, three of the four controls had undetectable levels of IFN- γ -producing ELISPOTs. This rapid loss of antiviral T cells in the presence of high viral loads may reflect the lack of CD4 help.

T cell proliferative responses demonstrated that virus-specific CD4 cells had survived the challenge and were available to support the antiviral immune response (Fig. 3C).

WO 02/072754

PCT/US02/06713

About 0.2 million PBMC were stimulated in triplicate for 5 days with the indicated antigen in 200 μ l of RPMI at 37°C under 5% CO₂. Supernatants from 293T cells transfected with DNA expressing either SHIV-89.6 Gag and Pol or SHIV-89.6 Gag, Pol and Env were used directly as antigens (final concentration of ~0.5 μ g of p27 Gag per milliliter). Supernatants from mock DNA (vector alone)-transfected cells served as negative controls. On day six, cells were pulsed with 1 μ Ci of tritiated thymidine per well for 16 to 20 hours. Cells were harvested with an automated cell harvester (TOMTEC, Harvester 96, Model 1010, Hamden, CT) and counted with a Wallac 1450 MICROBETA Scintillation counter (Gaithersburg, MD). Stimulation indices are the counts of tritiated thymidine incorporated in PBMC stimulated with 89.6 antigens divided by the counts of tritiated thymidine incorporated by the same PBMC stimulated with mock antigen.

At 12 weeks after challenge, mean stimulation indices for Gag-Pol-Env or Gag-Pol proteins ranged from 35 to 14 in the vaccine groups but were undetectable in the control group. Consistent with the proliferation assays, intracellular cytokine assays demonstrated the presence of virus-specific CD4 cells in vaccinated but not control animals. The overall rank order of the vaccine groups for the magnitude of the proliferative response was 2.5 mg i.d. > 2.5 mg i.m. > 250 μ g i.d. > 250 μ g i.m.

At 12 weeks after challenge, lymph nodes from the vaccinated animals were morphologically intact and responding to the infection, whereas those from the infected controls had been functionally destroyed (Fig. 4). Nodes from vaccinated animals contained large numbers of reactive secondary follicles with expanded germinal centers and discrete dark and light zones (Fig. 4A). By contrast, lymph nodes from the non-vaccinated control animals showed follicular and paracortical depletion (Fig. 4B), while those from unvaccinated and unchallenged animals displayed normal numbers of minimally reactive germinal centers (Fig. 4C). Germinal centers occupied < 0.05% of total lymph node area in the infected controls, 2% of the lymph node area in the uninfected controls, and up to 18% of the lymph node area in the vaccinated groups (Fig. 4D). More vigorous immune reactivity in the low-dose than the high-dose DNA-primed animals was suggested by more extensive germinal centers in the low dose group (Fig. 4D). At 12 weeks after challenge, *in situ* hybridization for viral RNA revealed rare virus-expressing cells in lymph nodes from 3 of the 24 vaccinated macaques, whereas virus-expressing cells were readily detected in lymph nodes from each of the infected control animals. In the controls, which had

WO 02/072754

PCT/US02/06713

undergone a profound depletion in CD4 T cells, the cytomorphology of infected lymph node cells was consistent with a macrophage phenotype.

The prime/boost strategy raised low levels of antibody to Gag and undetectable levels of antibody to Env (Fig. 5). Postchallenge, antibodies to both Env and Gag underwent anamnestic responses with total Gag antibody reaching heights approaching 1 mg/ml and total Env antibody reaching heights of up to 100 µg/ml.

Enzyme-linked immunosorbent assays (ELISAs) for total antibody to Gag used bacterially produced SIV gag p27 to coat wells (2 µg per milliliter in bicarbonate buffer). ELISAs for antibody to Env antibody used 89.6 Env produced in transiently transfected 293T cells and captured with sheep antibody against Env (catalog number 6205; International Enzymes, Fairbrook CA). Standard curves for Gag and Env ELISAs were produced with serum from a SHIV-89.6-infected macaque with known amounts of immunoglobulin G (IgG) specific for Gag or Env. Bound antibody was detected with peroxidase-conjugated goat antibody to macaque IgG (catalog # YNGMOIGGFCP; Accurate Chemical, Westbury, NY) and TMB substrate (Catalog # T3405; Sigma, St. Louis, MO). Sera were assayed at threefold dilutions in duplicate wells. Dilutions of test sera were performed in whey buffer (4% whey and 0.1% tween 20 in 1X PBS). Blocking buffer consisted of whey buffer plus 0.5% nonfat dry milk. Reactions were stopped with 2M H₂SO₄ and the optical density read at 450 nm. Standard curves were fitted and sample concentrations were interpolated as µg of antibody per ml of serum using SOFTmax 2.3 software (Molecular Devices, Sunnyvale, CA).

By 2 weeks after challenge, neutralizing antibodies for the 89.6 immunogen, but not the SHIV-89.6P challenge, were present in the high-dose DNA-primed groups (geometric mean titers of 352 in the i.d. and 303 in the i.m. groups) (Fig. 5C) (D.C. Montefiori *et al.* 1988 *J Clin Microbiol* 26:231). By 5 weeks after challenge, neutralizing antibody to 89.6P had been generated (geometric mean titers of 200 in the high-dose i.d. and 126 in the high-dose i.m. group) (Fig. 5D) and neutralizing antibody to 89.6 had started to decline. By 16 to 20 weeks after challenge, antibodies to Gag and Env had fallen in most animals.

Our results demonstrate that a multiprotein DNA/MVA vaccine can raise a memory immune response capable of controlling a highly virulent mucosal immunodeficiency virus challenge. Our levels of viral control were more favorable than have been achieved using only DNA (M.A. Egan *et al.* 2000 *J Virol* 74:7483) or rMVA vaccines (I. Ourmanov *et al.*

WO 02/072754

PCT/US02/06713

2000 *J Virol* 74:2740) and were comparable to those obtained for DNA immunizations adjuvanted with interleukin-2 (D.H. Barouch *et al.* 2000 *Science* 290:486). All of these previous studies have used more than three vaccine inoculations, none have used mucosal challenges, and most have challenged at peak effector responses and not allowed a prolonged post vaccination period to test for "long term" efficacy.

The dose of DNA had statistically significant effects on both cellular and humoral responses ($P<0.05$), whereas the route of DNA administration affected only humoral responses. Intradermal DNA delivery was about 10 times more effective than i.m. inoculations for generating antibody to Gag ($P = 0.02$). Neither route nor dose of DNA appeared to have a significant effect on protection. At 20 weeks after challenge, the high-dose DNA-primed animals had slightly lower geometric mean levels of viral RNA (7×10^2 and 5×10^2) than the low-dose DNA-primed animals (9×10^2 and 1×10^3).

The DNA/MVA vaccine controlled the infection, rapidly reducing viral loads to near or below 1000 copies of viral RNA per milliliter of blood. Containment, rather than prevention of infection, affords the opportunity to establish a chronic infection (H.L. Robinson *et al.* 1999 *Nat Med* 5:526). By rapidly reducing viral loads, a multiprotein DNA/MVA vaccine will extend the prospect for long-term non-progression and limit HIV transmission. (J.W. Mellors *et al.* 1996 *Science* 272:1167; T.C. Quinn *et al.* 2000 *N Engl J Med* 342:921).

EXAMPLE 2

MVA Expressing Modified HIV Env, Gag, and Pol Genes

This disclosure describes the construction of a modified vaccinia Ankara (MVA) recombinant virus, MVA/HIV clade B recombinant virus expressing the HIV strain ADA env and the HXB2 gag pol (MVA/HIV ADA env + HXB2 gag pol). For amplification, the lab name of MVA/HIV 48 will be used, which denotes the plasmid from which the construct comes.

The HIV *gag-pol* genes were derived from the Clade B infectious HXB2 virus. The *gag-pol* gene was truncated so that most of the integrase coding sequences were removed and amino acids 185, 266, and 478 were mutated to inactivate reverse transcriptase, inhibit strand transfer activity, and inhibit the RNaseH activity, respectively. The Clade B CCR5 tropic envelope gene was derived from the primary ADA isolate; TTTTTNT sequences were mutated without changing coding capacity to prevent premature transcription

WO 02/072754

PCT/US02/06713

termination and the cytoplasmic tail was truncated in order to improve surface expression, immunogenicity, and stability of the MVA vector. The HIV genes were inserted into a plasmid transfer vector so that *gag-pol* gene was regulated by the modified mHS early/late vaccinia virus promoter and the *env* gene was regulated by the newly designed early/late Psyn II promoter to provide similar high levels of expression. A self-deleting GUS reporter gene was included to allow detection and isolation of the recombinant virus. The HIV genes were flanked by MVA sequences to allow homologous recombination into the deletion 3 site so that the recombinant MVA would remain TK positive for stability and high expression in resting cells. The recombinant MVA was isolated and shown to express abundant amounts of *gag-pol-env* and to process *gag*. Production of HIV-like particles was demonstrated by centrifugation and by electron microscopy. The presence of *env* in the HIV-like particles was demonstrated by immunoelectron microscopy.

Table of Sequences

Description	SEQ ID NO	FIG. NO
pLW-48	1	A
pLW-48	1	B
Psyn II promoter	2	B
ADA envelope truncated	3	B
PmHS promoter	4	B
HXB2 <i>gag pol</i>	5	B

Plasmid Transfer Vector

The plasmid transfer vector used to make the MVA recombinant virus, pLW-48, (Figure C) by homologous recombination was constructed as follows:

1. From the commercially obtained plasmid, pGem-4Z (Promega), flanking areas on either side of deletion III, designated flank 1 and flank 2, containing 926 and 520 base pairs respectively, were amplified by PCR from the MVA strains of vaccinia virus. Within these flanks, a promoter, the mHS, which had been modified from the originally published sequence by changing two bases that had been shown by previously published work to increase the expression of the cloned gene, was added.

WO 02/072754

PCT/US02/06713

2. A clade B gag pol (Figure D) was truncated so that the integrase was removed and was cloned into the plasmid so that it was controlled by the mHS promoter. This gene contained the complete HXB2 sequence of the gag. The pol gene has reverse transcriptase safety mutations in amino acid 185 within the active site of RT, in amino acid 266 which inhibits strand transfer activity, and at amino acid 478 which inhibits the RNaseH activity. In addition, the integrase gene was deleted past EcoRI site.

3. A direct repeat of 280 basepairs, corresponding to the last 280 base pairs of MVA flank 1, was added after flank 1.

4. The p11 promoter and GUS reporter gene were added between the two direct repeats of flank 1 so that this screening marker could initially be used for obtaining the recombinant virus, yet deleted out in the final recombinant virus (Scheiflinger, F. *et al.* 1998 *Arch Virol* 143:467-474; Carroll, M.W. and B. Moss 1995 *Biotechniques* 19:352-355).

5. A new promoter, Psyn II, was designed to allow for increased expression of the ADA env. The sequence of this new early/late promoter is given in Figure E.

6. A truncated version of the ADA envelope with a silent 5TNT mutation was obtained by PCR and inserted in the plasmid under the control of the Psyn II promoter. The envelope was truncated in the cytoplasmic tail of the gp41 gene, deleting 115 amino acids of the cytoplasmic tail. This truncation was shown to increase the amount of envelope protein on the surface of infected cells and enhance immunogenicity of the envelope protein in mice, and stability of the recombinant virus in tissue culture.

Recombinant MVA Construction

1. MVA virus, which may be obtained from ATCC Number VR-1508, was plaque purified three times by terminal dilutions in chicken embryo fibroblasts (CEF), which were made from 9 day old SPF Premium SPAFAS fertile chicken eggs, distributed by B and B Eggs, Stevens, PA.

2. Secondary CEF cells were infected at an MOI of 0.05 of MVA and transfected with 2 µg of pLW-48, the plasmid described above. Following a two day incubation at 37°C, the virus was harvested, frozen and thawed 3x, and plated out on CEF plates.

3. At 4 days, those foci of infection that stained blue after addition of X-gluc substrate, indicating that recombination had occurred between the plasmid and the infecting

WO 02/072754

PCT/US02/06713

virus, were picked and inoculated on CEF plates. Again, those foci that stained blue were picked.

4. These GUS containing foci were plated out in triplicate and analyzed for GUS staining (which we wanted to now delete) and ADA envelope expression. Individual foci were picked from the 3rd replicate plates of those samples that had about equal numbers of mixed populations of GUS staining and nonstaining foci as well as mostly envelope staining foci.

5. These foci were again plated out in triplicate, and analyzed the same way. After 5 passages, a virus was derived which expressed the envelope protein but which had deleted the GUS gene because of the double repeat. By immunostaining, this virus also expressed the gag pol protein.

Characterization of MVA Recombinant Virus, MVA/HIV 48

1. Aliquots of MVA/HIV 48 infected cell lysates were analyzed by radioimmunoprecipitation and immunostaining with monoclonal antibodies for expression of both the envelope and gag pol protein. In both of these tests, each of these proteins was detected.

2. The recombinant virus was shown to produce gag particles in the supernatant of infected cells by pelleting the ³⁵S-labeled particles on a 20% sucrose cushion.

3. Gag particles were also visualized both outside and budding from cells as well as within vacuoles of cells in the electron microscope in thin sections. These gag particles had envelope protein on their surface.

Unless otherwise indicated, all nucleotide sequences determined by sequencing a DNA molecule herein were determined using an automated DNA sequencer, and all amino acid sequences of polypeptides encoded by DNA molecules determined herein were predicted by translation of a DNA sequence determined as above. Therefore, as is known in the art for any DNA sequence determined by this automated approach, any nucleotide sequence determined herein may contain some errors. Nucleotide sequences determined by automation are typically at least about 90% identical, more typically at least about 95% to at least about 99.9% identical to the actual nucleotide sequence of the sequenced DNA molecule. The actual sequence can be more precisely determined by other approaches including manual DNA sequencing methods well known in the art. As is also known in the art, a single insertion or deletion in a determined nucleotide sequence compared to the

WO 02/072734

PCT/US02/06713

actual sequence will cause a frame shift in translation of the nucleotide sequence such that the predicted amino acid sequence encoded by a determined nucleotide sequence will be completely different from the amino acid sequence actually encoded by the sequenced DNA molecule, beginning at the point of such an insertion or deletion.

Summary

In summary, we have made a recombinant MVA virus, MVA/HIV 48, which has high expression of the ADA truncated envelope and the HXB2 gag pol. The MVA recombinant virus is made using a transiently expressed GUS marker that is deleted in the final virus. High expression of the ADA envelope is possible because of a new hybrid early/late promoter, Psyn II. In addition, the envelope has been truncated because we have shown truncation of the envelope enhances the amount of protein on the surface of the infected cells, and hence enhances immunogenicity; stability of the recombinant is also enhanced. The MVA recombinant makes gag particles which has been shown by pelleting the particles through sucrose and analyzing by PAGE. Gag particles with envelope protein on the surface have also been visualized in the electron microscope.

EXAMPLE 3

Additional Modified or Synthetic Promoters Designed for Gene Expression in MVA Or Other Poxviruses

Additional modified or synthetic promoters were designed for gene expression in MVA or other poxviruses. Promoters were modified to allow expression at early and late times after infection and to reduce possibility of homologous recombination between identical sequences when multiple promoters are used in same MVA vector. Promoters are placed upstream of protein coding sequence.

m7.3 promoter (SEQ ID NO:10):

CGCTTTTATAGTAAGTTTTCACCCATAAAATAATAATACAATAATTAAATTCT
CGTAAAAATTGAAAAACTATTCTAATTTATGCACGGT

Psyn II promoter (SEQ ID NO:2):

TAAAAAAATGAAAAAAATATTCTAATTTATAGGACCGTTGATTTCTTTTCT
ATGCTATAAAATAATAATA

WO 02/072754

PCT/US02/06713

Psyn III promoter (SEQ ID NO:11):

TAAAAAATTGAAAAAAATATTCTAATTATAGGACGGTTTGATTTCCTTTTCT
ATACTATAAATAATAAATA

Psyn IV promoter (SEQ ID NO:12):

TAAAAAATTGAAAAAACTATTCTAATTATAGGACGGTTTGATTTCCTTTTCT
ATACTATAAATAATAAATA

PsynV promoter (SEQ ID NO:13):

AAAAAAATGATAAAAGTAGGTTCAAGTTTATTGCTGGTTAAAATCACGCTTCGA
GTAAAAACTACGAATATAAAT

EXAMPLE 4

Tables A-F

Table A: MVA/48 immunization - guinea pigs.

Groups of guinea pigs were immunized at days 0 and 30 with 1×10^6 infectious units of MVA/48 by either the intramuscular (IM) or intradermal (ID) route. As a control another group was immunized IM with the same dose of non-recombinant MVA. Sera taken before as well as after each immunization was analyzed for neutralizing activity against HIV-1-MN. Titers are the reciprocal serum dilution at which 50% of MT-2 cells were protected from virus-induced killing. Significant neutralizing activity was observed in all animals after the second immunization with MVA/48 (day 49).

Table B: Frequencies of HIV-1 gag-specific T cells following immunization of mice with MVA/48.

Groups of BalbC mice were immunized at days 0 and 21 with 1×10^7 infectious units of MVA/48 by one of three routes: intraperitoneal (IP), intradermal (ID), or intramuscular (IM). A control group was immunized with non-recombinant MVA. At 5 weeks after the last immunization, splenocytes were prepared and stimulated *in vitro* with an immunodominant peptide from HIV-1 p24 for 7 days. The cells were then mixed either with peptide-pulsed P815 cells or with soluble peptide. Gamma interferon-producing cells were enumerated in an ELISPOT assay. A value of >500 was assigned to wells containing too many spots to count. Strong T cell responses have been reported in mice immunized IP

WO 02/072754

PCT/US02/06713

with other viruses. In this experiment, IP immunization of mice with MVA/48 elicited very strong HIV-1 gag-specific T cell responses.

Table C: DNA prime and MVA/48 boost - total ELISPOTS per animal.

Ten rhesus macaques were primed (weeks 0 and 8) with a DNA vaccine expressing HIV-1 antigens including Ada envelope and HXB2 gagpol. At week 24 the animals were boosted intramuscularly with 1×10^8 infectious units of MVA/48. Fresh peripheral blood mononuclear cells (PBMC) were analyzed for production of gamma interferon in an ELISPOT assay as follows: PBMC were incubated for 30-36 hours in the presence of pools of overlapping peptides corresponding to the individual HIV-1 antigens in the vaccines. The total number of gamma interferon-producing cells from each animal is shown in the table. T cell responses to DNA vaccination were limited (weeks 2-20). However, boosting with MVA/48 resulted in very strong HIV-1-specific T cell responses in all animals (week 25).

Table D: Antibody response following immunization of macaques with MVA/SIV KB9.

Groups of rhesus macaques were immunized with 2×10^8 infectious units of MVA/SIV-KB9 at weeks 0 and 4 by one of several routes: Tonsilar, intradermal (ID), or intramuscular (IM). Another group was immunized with non-recombinant MVA using the same routes. Serum samples from 2 weeks after the second immunization were analyzed for binding to KB9 envelope protein by ELISA and for neutralization of SIV-89.6P and SIV-89.6. In the ELISA assay, soluble KB9 envelope protein was captured in 96 well plates using an antibody to the C-terminus of gp120. Serial dilutions of sera were analyzed and used to determine the endpoint titers. Neutralization of SIV-89.6P and SIV-89.6 was determined in an MT-2 cell assay. Titers are the reciprocal serum dilution at which 50% of the cells were protected from virus-induced killing. In *in vitro* neutralization assays, SIV-89.6P and SIV-89.6 are heterologous, i.e. sera from animals infected with one of the viruses does not neutralize the other virus. Thus, two immunizations with MVA/SIV-KB9 elicited good ELISA binding antibodies in all animals and neutralizing antibodies to the homologous virus (SIV-89.6P) in some animals. In addition, heterologous neutralizing antibodies were observed in a subset of animals.

Table E: Frequencies of gag CM-9-specific CD3/CD8 T cells following immunization of macaques with MVA/SIV-KB9.

WO 07/072734

PCT/US02/06713

Groups of MamuA*01 positive rhesus macaques were immunized with 2×10^4 infectious units of MVA/SIV-KB9 at weeks 0 and 4 by one of several routes: tonsilar, intradermal (ID), or intramuscular (IM). Another group was immunized with non-recombinant MVA. The frequencies of CD3+/CD8+ T cells that bound tetrameric complex containing the SIV gag-specific peptide CM9 were determined by flow cytometry at various times after each immunization. Time intervals were as follows: 1a, 1b, and 1d were one, two, and four weeks after the first immunization, respectively; 2a, 2b, 2c, and 2d were one, two, three, and twelve weeks after the second immunization, respectively. Values above background are shown in bold face. Strong SIV gag-specific responses were observed after a single immunization with MVA/SIV-KB9 in all immunized animals. Boosting was observed in most animals following the second immunization. In addition, measurable tetramer binding was still found twelve weeks after the second immunization.

Table F: Frequencies of specific T cells following immunization of macaques with MVA/SIV KB9.

Groups of macaques were immunized with MVA/SIV-KB9 as described above. MVA/SIV-KB9 expresses 5 genes from the chimeric virus, SIV-89.6P: envelope, gag, polymerase, tat, and nef. Thus, the frequencies of T cells specific for each of the 5 antigens was analyzed using pools of peptides corresponding to each individual protein. Fresh PBMC were stimulated with pools of peptides for 30-36 hours in vitro. Gamma interferon-producing cells were enumerated in an ELISPOT assay. The total number of cells specific for each antigen is given as "total # spots". In addition, the number of responding animals and average # of spots per group is shown. PBMC were analyzed at one week after the first immunization (1a) and one week after the second immunization (2a). Another group of 7 animals was immunized with non-recombinant MVA. In these animals, no spots above background levels were detected. Thus, a single immunization with MVA/SIV-KB9 elicited strong SIV-specific T cell responses in all animals. Gag and envelope responses were the strongest; most animals had responses to gag, all animals had responses to envelope. The Elispot responses were also observed after the second immunization with MVA/SIV-KB9, albeit at lower levels. At both times, the rank order of responses was: tonsilar > ID > IM. We show good immune response to nef and some immune response to tat.

WO 01/072754

PCT/US02/06713

TABLE A

MVA/48 immunization - guinea pigs
HIV-MN neutralizing antibody - reciprocal titer

Animal #	Group	Route	day 0	Day 4 MVA #1	day 30	day 33 MVA #2	day 49
885	MVA	I.M.	<20	I.M.	31	I.M.	24
891	"	"	<20	"	85	"	<20
882	MVA/48	I.M.	<20	I.M.	<20	I.M.	5,524
883	"	"	<20	"	68	"	691
886	"	"	<20	"	<20	"	4,249
890	"	"	<20	"	180	"	89
879	MVA/48	I.D.	<20	I.D.	<20	I.D.	817
881	"	"	<20	"	<20	"	234
888	"	"	<20	"	24	"	112
889	"	"	<20	"	22	"	376

TABLE B

**Frequencies of HIV-gag-specific T cells following immunization of mice
with MVA/48**

Group	P815 cells + gag peptide	gag peptide	no stimulation
MVA control	0	2	1
MVA/48 (IP)	>500	>500	8
MVA/48 (ID)	12	5	4
MVA/48 (IM)	22	18	12

WO 02/072734

PCT/US02/06713

TABLE C

DNA prime and MVA/48 boost
Total ELISPOTS per Animal

Animal #	WEEKS						
	0	2	6	10 ¹	14 ²	20 ³	28 ³
RLw	4	731*	<	47	43	50	3905
RVI	5	997*	<	<	<	8	205
Rca	<	<	1	<	<	<	245
RHc	<	<	<	<	<	<	533
Ryl	<	<	<	<	<	<	4130
RQk	<	46	<	<	<	<	630
RDr	<	<	<	14	<	<	1965
RZc	<	5	<	58	<	<	925
RRf	<	118	<	<	<	20	5370
R2a	<	69	<	<	<	<	1435
Total	9	1966	1	119	43	78	19545
Geo Mean	4.5	105.3	1.0	33.7	43.0	20.0	1147.7

DNA primes were at 0 and 8 weeks and MVA/48 boost was at 24 weeks

¹< - Background (2x the number of ELISPOTS in the unstimulated control + 10)

²Costimulatory antibodies were added to the ELISPOT incubations

* Animals from this bleed date exhibited higher than usual ELISPOTS.

WO 02/072754

PCT/US02/06713

TABLE D

Antibody response following immunization of macaques with MVA/SIV KB9

Animal #	Route	KB9 env ELISA titer	KB9 env elisa		SHIV-89.6 Nab titer	SHIV- 89.6P Nab titer	SHIV-89.6 # pos animals	SHIV- 89.6P # pos animals
			average	std dev.				
598	tonsil	25,600	31,086	20,383	<20	<20	3	2
601	"	51,200			<20	<20		
606	"	25,600			<20	<20		
642	"	51,200			75	31		
646	"	51,200			61	48		
613	"	6,400			<20	<20		
654	"	6,400			22	<20		
602	i.d.	25,600	18,800	15,341	38	<20	2	4
604	"	12,800			<20	262		
608	"	3,200			20	66		
637	"	12,800			<20	35		
618	"	51,200			<20	<20		
645	"	25,600			<20	<20		
647	"	12,800			32	162		
650	"	6,400			<20	<20		
599	i.m.	6,400	17,000	16,516	<20	<20	0	3
600	"	6,400			<20	29		
609	"	6,400			<20	<20		
639	"	51,200			<20	85		
640	"	12,800			<20	<20		
641	"	25,600			<20	41		
649	"	1,600			<20	<20		
651	"	25,600			20	<20		
603	Control	<100	<100		<20	<20	0	0
605	"	<100			<20	<20		
607	"	<100			<20	<20		
643	"	<100			<20	<20		
644	"	<100			<20	<20		
648	"	<100			<20	<20		
652	"	<100			<20	<20		

WO 02/072754

PCT/US02/06713

TABLE E

Frequencies of gag CM9-specific CD3/CD8 T cells following immunization of macaques with
MVA/SIV KB9

Animal #	Route	Virus	pre-bleed	1a	1b	1c	2a	2b	2c	2d
598	Tonsil	MVA/K B9	0.018	0.41	0.79	0.25	2.64	1.13	0.51	0.21
601	"	"	0.071	0.34	0.38	0.27	0.83	0.7	0.36	0.039
646	"	"	0.022	0.61	0.76	0.43	1.12	0.91	0.31	0.15
653	"	"	0.041	0.69	0.85	0.53	0.68	0.49	0.47	0.3
648	"	MVA		0.033	0.039		0.022	0.058	0.033	0.013
602	Id.	MVA/K B9	0.019	0.17	0.92	0.5	0.93	0.59	0.5	0.2
604	"	"	0.013	0.11	0.38	0.32	0.44	0.38	0.19	0.35
630	"	"	0.095	0.17	0.6	0.23	2.87	1.12	0.9	0.16
647	"	"	0.032	0.22	0.38	0.14	0.84	0.91	0.34	0.17
652	"	MVA		0.041	0.038	0.059	0.025	0.022	0.026	0.055
599	I.m.	MVA/K B9		0.081	0.31	0.082		0.12	0.054	0.11
600	"	"	0.034	0.15	0.41	0.17	0.29	0.27	0.16	0.049
649	"	"	0.00486	0.35	1.34	0.56	2.42	0.77	0.69	0.22
651	"	"	0.049	0.12	0.69	0.25	1.01	0.32	0.24	0.22
603	"	MVA		0.024	0.087	0.073		0.082	0.027	0.17

WO 02/072754

PCT/US02/06713

TABLE F
Frequencies of specific T cells following immunization of macaques with MV A/J/HTV K99

Study groups	Gag specific			Tat specific			Nef specific			Env specific			Total
	# responding animals	Total # spots	average # spots	# responding animals	Total # spots	average # spots	# responding animals	Total # spots	average # spots	# responding animals	Total # spots	average # spots	
Const. 1a	4/6	1325	221	0/6	0	0	3/6	195	33	6/6	8760	1460	6/6
Const. 2a	5/6	1405	234	0/6	0	0	1/6	560	93	6/6	4485	748	6/6
i.d. 1a	2/7	1335	191	0/7	0	0	2/7	215	31	7/7	7320	1046	7/7
i.d. 2a	4/7	755	108	0/7	0	0	1/7	55	8	7/7	2700	386	7/7
i.m. 1a	7/7	925	132	1/7	60	9	3/7	160	26	7/7	5490	784	7/7
i.m. 2a	4/7	250	36	0/7	0	0	0/7	0	0	6/7	2205	315	6/7

-45-

WO 02/072734

PCT/US02/06713

While the present invention has been described in some detail for purposes of clarity and understanding, one skilled in the art will appreciate that various changes in form and detail can be made without departing from the true scope of the invention. All patents, patent applications and publications referred to above are hereby incorporated by reference.

WO 02/072754

PCT/US02/06713

WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising a recombinant MVA virus expressing an HIV *env*, *gag*, and *pol* gene or modified gene thereof for production of an HIV Env, Gag, and Pol antigen by expression from said recombinant MVA virus, wherein said HIV *env* gene is modified to encode an HIV Env protein composed of gp120 and the membrane-spanning and ectodomain of gp41 but lacking part or all of the cytoplasmic domain of gp41, and a pharmaceutically acceptable carrier.
2. The pharmaceutical composition of claim 1, wherein said HIV *pol* gene or modified gene thereof is modified to inactivate reverse transcriptase and integrase.
3. The pharmaceutical composition of claim 1, wherein said HIV *env*, *gag*, or *pol* gene or modified gene thereof is taken from clade A.
4. The pharmaceutical composition of claim 1, wherein said HIV *env*, *gag*, or *pol* gene or modified gene thereof is taken from clade B.
5. The pharmaceutical composition of claim 1, wherein said HIV *env*, *gag*, or *pol* gene or modified gene thereof is taken from clade C.
6. The pharmaceutical composition of claim 1, wherein said HIV *env*, *gag*, or *pol* gene or modified gene thereof is taken from clade D.
7. The pharmaceutical composition of claim 1, wherein said HIV *env*, *gag*, or *pol* gene or modified gene thereof is taken from clade E.
8. The pharmaceutical composition of claim 1, wherein said HIV *env*, *gag*, or *pol* gene or modified gene thereof is taken from clade F.
9. The pharmaceutical composition of claim 1, wherein said HIV *env*, *gag*, or *pol* gene or modified gene thereof is taken from clade G.
10. The pharmaceutical composition of claim 1, wherein said HIV *env*, *gag*, or *pol* gene or modified gene thereof is taken from clade H.
11. The pharmaceutical composition of claim 1, wherein said HIV *env*, *gag*, or *pol* gene or modified gene thereof is taken from clade I.
12. The pharmaceutical composition of claim 1 wherein said HIV *env*, *gag*, or *pol* gene or modified gene thereof is inserted at the site of deletion III within the MVA genome.

WO 02/072754

PCT/US02/06713

13. The pharmaceutical composition of claim 1 wherein said HIV *env*, *gag*, or *pol* gene or modified gene thereof is under transcriptional initiation regulation of a HS-like early/late vaccinia virus promoter.

14. The pharmaceutical composition of claim 1 wherein recombinant MVA virus additionally expresses an additional HIV gene or modified gene thereof for production of an HIV antigen by expression from said recombinant MVA virus, wherein said additional HIV gene is a member selected from the group consisting of *vif*, *vpr*, *tar*, *rev*, *vpu*, and *nef*.

15. MVA/HIV48 comprising SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5.

16. pLW-48 having SEQ ID NO:1.

17. A plasmid transfer vector having the sequence of pLW-48 (SEQ ID NO:1) excluding the HIV *env*, *gag*, and *pol* genes.

18. pLW-48 (SEQ ID NO:1) wherein the HIV *env*, *gag*, and *pol* genes have a sequence taken from another clade.

19. A poxvirus comprising a promoter selected from the group consisting of m7.5 promoter having SEQ ID NO:10, Psyn II promoter having SEQ ID NO:2, Psyn III promoter having SEQ ID NO:11, Psyn IV promoter having SEQ ID NO:12, and Psyn V promoter having SEQ ID NO:13.

20. A method of boosting a CD8⁺ T cell immune response to an HIV Env, Gag, or Pol antigen in a primate, the method comprising provision in the primate of a composition of any of claims 1-15, whereby a CD8⁺ T cell immune response to the antigen previously primed in the primate is boosted.

21. A method of inducing a CD8⁺ T cell immune response to an HIV Env, Gag, or Pol antigen in a primate, the method comprising provision in the primate of a composition of any of claims 1-15, whereby a CD8⁺ T cell immune response to the antigen in the primate is induced.

22. A method of inducing a CD8⁺ T cell immune response to an HIV Env, Gag, or Pol antigen in a primate, the method comprising provision in the primate of a priming composition comprising nucleic acid encoding said antigen and then provision in the primate of a boosting composition which comprises any of claims 1-15, whereby a CD8⁺ T cell immune response to the antigen is induced.

PCT/US02/06713

WO 02/072754

23. The method of any of Claims 20-22, wherein the primate is a human.
24. The method of any of Claims 20-22, wherein administration of the recombinant MVA virus is by needleless injection.
25. The method of Claim 22, wherein the priming composition comprises plasmid DNA encoding said antigen.
26. A method of making a composition of any of claims 1-15 comprising preparing a plasmid transfer vector encoding an HIV *env*, *gag*, and *pol* gene or modified gene thereof, wherein said HIV *env* gene is modified to encode an HIV Env protein composed of gp120 and the membrane-spanning and ectodomain of gp41 but lacking part or all of the cytoplasmic domain of gp41, and recombining said plasmid transfer vector with a MVA virus to produce a composition of any of claims 1-15.

WO 02/072754

1/94

PCT/US02/06713




Figure 7

WO 02/072754

PCT/US02/06713

2/54




Figure II

WO 02/072754

3/54

PCT/US02/06713

Chemokine coreceptor used	PBM _C replication	Macrophage replication	T-Cell-Line replication	Replicative phenotype	Syncytium-inducing phenotype
X4	+	-	+	Rapid/high	++
R5	+	+	-	Slow/low	-
R5/X4	+	+	+	Rapid/high	+

Figure III

WO 02/072754

PCT/US02/06713

4/54




Figure IV

WO 02/072754

PCT/US02/06713

5/54




Figure 7

WO 02/072754

PCT/US02/06713

6/54




Figure VI

WD 02/072754

PCT/US02/06713

7/54




Figure 1

WO 02/072754

PCT/US02/06713

8/54




FIGURE 2

WO 02/072754

PCT/US02/06713

9/54




Figure 3

WO 02/072754

10/54

PCT/US02/06713




Figure 4

WO 02/072744

PCT/US02/06713

11/54




Figure 5

WO 02/072754

PCT/US02/06713

12/54




Figure 6

WO 02/072754

13/54

PCT/US02/06713




FIG. A,

WO 02/072754

PCT/US02/06713

14/54

1 GAAITCGTTG- GGGTCCCA TCGATGCTGT TATTCTATAC TGTCTAAACC CGTTAGTAAA ACATGGCCAG
CTTAACCAAC CACCAAGGGT ACTAACATAC ATAACATAC ACAGATTTEC GCAATCATTT TGTAACCGCTC

71 GAAATAATC ATATTAATAA TGATTTCATG ATTAAACCAT GTCCTGAAAA ACTCAAC-AAC CTTCACATTC
CTTATTAG TATATTTT ACTAAACTAC TAATTGGTA CAACACTTT TCAGTTCTC CAACTGTAAC

141 CCCCACAACT TAAACCAT ACAGTCATTG CAGATTGCC ATATAAGGAT AATGCCCTAT
CCCCTGTTAG ATTGTTGTTA TGTCACTAAC CTCTAAAGG TATATACETA TTACGCCATA GGCTACATAC

211 CAACTCACTG TATAAAAGA AAGCTATCAG AATATCCAGA TTTCGCTAATT TGATTAAGAT AGATGAGGAT
GTTAACTGAC ATATTTTCT TACATAGTC AACCGATTAA ACTATTCTA TCTACTGCTA

281 GACAAGCACTC CTACTCGGT ATATAATTAT TTTAAACCTA AACATGCCAT TECTGTTATT ATATCCATAG
CCTTCTGAG GATGACCACA TATATAATA AATTGGAT TTCTAACCGTA AGGACAATAA TATAGGTATC

351 GAAAGCATACTCTTGT GAACTTAA TCTCATCTGA TAAACCGCTT CCGCTATAG ACTTAAATTCTT
CTTCTCTATC TCTAACAACTTCTGATAATT AGACTAGACTTCCACACGTTATTAAAG

FIG. A2

WO 02/072754

PCT/US02/06713

15/54

421 ATATAAGTA CCCATTCTTC CCATGGATCT TCCCTTTT ACCAAGGAA ATGCATCATT GATTAATTC
GATTTCTAT CGCTAAGAAG GGTACCTACA AGCAAAAGA TGGTTTCTT TACGTAGAA CTAATAAGAG

491 CTTTTGATT TCTCTATCGA TCCGGCACCT CTCTTAAGAA CTGTAACCGA TAATAATCTT ATTATATCTA
GACAAACTAA AGAGATAGCT ACGGCGCTGA GAGAATTCTT CACATTCGCT ATTATTACAA TAATATAGAT

561 GACCCAGG TCTACATGAC GAGCTTCCGA GTTCCATTGCTT CTCAAGGTT TACATAACTA TAAGCTCCGA
CTCTGGCC AGATGACTC CTCCAGGCC CAAGGTTAAC CAAGTTCAAA ATGTTCAAT ATTTCAGGCT

631 CTATTTCTT ATATTTATA TGGTTCTGA TGGATCTCTG ATGCCATCAA TAGCTGATAA TAGAACTTAC
GATAACAAGA TATAATATACCTAAACACT ACCTAGACAC TAGGTACCTT ATGGACTATT ATCTGAAATG

701 GCAAAATTA GCAAAATAT ATTACACAAT ACTACAAAT ACCATGAGTC TAGATGCTT TATTTGAAAC
CGTTTATAAT CGTTTATAAT TATCTGTTA TCACTCTAAT TCTTACTCAC ATCTACACAA ATAAAGACTG

FIG. A₂ cont.

WO 02/072754

PCT/US02/06713

16/54

771 CACAGATTAG CATTCTTGAT AGAGATGAGA TGCTCAATCC ATCATCTCTT GATATGACA GACATGAT
GTGCTAAC CTAACTAACTA TCTCTACTCT ACCAGGTTACC TGAATGACA CTATACCTCTT CTGTAACTAA

841 TATGATGAAT TTACCTGATC TAGGCCAATT TGGCAJCTAGT ATCTTGCGGA ATATATCAACC TGACATCATT
ATACATACCA ATATGGCACTAC ATCCGGCTAA ACCTACATCA TACAACCCCT TTATACTTGG ACTGTACTAA

911 AGGATTTGCTC TTTCGGCGCC TGGGTACCGG GCGCGCGCTT CATTTTGTTT TTTCCTATGCC TATAAAATGGT
TTCTAACCGAG AAACCCACCG ACCCATGGTC CCGGGGAAAG GTAAACAAA AAAGATACG ATATTTACCA

981 ACCCTCCCTTA GAAACCCCAA CCCCTGAAAT CAAAAAACCTC GAGGGCCTGT GGGCATTCAG TCTGGATGCC
TGGAGGACAT CTTCGGCTT GGGCACTTAA GTTTTTGAC CTGGGGGACA CCGGGTAACTC AGACCTGGC

1051 CAAACTCTCA GAACTCTCA GCGTCTCTCC GAAACCCATT TACAAGAAAG COGCCAATT CCTCTCCAG
CTTTCACAC CTTCAGCT ACCACCCCA ATTCCTTCCTC GGGCCCTTAA GCAACCGTC

FIG. A₂ cont.

WO 02/072754

PCT/US02/06713

17/54

1121 GCACTTTAA CGATCACTTC CGCGATCCAG ATATTCGAT TATGGGCC AACGTCGGT ATCAAGCCAA
CGTCAAATT CCTACTCAAC CGCCTACCTC TATAGCATT ATAGCGCC TTEGAGCCA TACTCCCT

1191 AGCTTATA CGAAAGCTT CCCAGCCA ECGTATCGT CTGCCTTCG ATCGGTCAC TCATTACGGC
TCAGAAATTCGCTTCAA CCCGTCGGT CGCAATGCC GACCAAACG TACGCCACTG AGTAATGCC

1261 AAAGCTCGG TCATAATCA CGAAGTGTAGC GACCATCAGG ECGCTATAC CCCATTTGAA ECGGATGCA
TTTACACCC AGTTATTAGT CCTRACTAC CTCGATCTC CGCGATATG CGCTAAACTT CGCTACAGT

1331 CGCTTACTT TATGGCGG AAAGCTGTAC GATCACTGT TTTACATC CATACTGCA AACACACTTC TTGCTTACT
GGGGCATACA ATAAACGCC

1401 TATCCGGCG CGATCGTA TTACCGGA AAACGGACG AAAAGGACT TTACTTCCA TGATTTCTT
ATACCCGGC CCTTACACT AAAGCTCTT TTGCGCTTC TAACTGAGT ACTAAACAA

1471 AACTATGCCG GAATCCATCG CAGCGTATC CTCTACACCA CGCCGAACAC CTGGCTGGAC GATATACCC
TTGATACGGC CTTAGCTAC GAGATGTGT CGCCGACCTG CTATAGTCCC

FIG. A₂ cont.

WO 02/072754

PCT/US02/06713

18/54

1541	TGGTCACTCA TGTGCCGCAA GACTTAACG AGCCCTCTCT TCACTCCAC GTCGTGCCA ATGCTGATCT ACCACTGGT ACAGGGCTT CTGACATTCG TCCGACACA ACAGACCTC CACCACTCT TACCACTACA
1611	CAGCCTTCA CTCGCTGATC CGCATCAAGA GTCCTTCAAC ACTGCCAACG CCACCTASCC GACTTCCAA CTCGCAACTT GACCGACTAC GGCTAGTTG CCACTTACCT TCACTTACG CTCGACCTT
1681	GTGCTGAATC CGCACCTCTG GCAACCGGGT GAAGGTATAC TCTATGAACT GTCGCTCAACG CCCAAAGCC CACCACTTAG CGCTGCAACG CCTTCGGCCA CTTCCAAATAG AGAACTGAA CTCGCACTGT CGGTGTTACGG
1751	ACACAGAGTC TGTATCTAC CGCGCTCGCC TCGGCTCCG GTCGCTCCG GTCGCTCCG AACGCTCT TCGTCTCAC ACTATAGTC GCGCAAGCCG AGCCCTAGCC CAGTCACCGT CAGCTCCCG TTTCGAAGA
1821	GATTAACCAAC AACCGTTCT ACITTAATCG CTTTGTCTCT CTCGAAGATC CGCACTTCC TCCAAAGCA CTAATTCGG TTCGCAAGA TCAATTCG CAAACCCCA GTCATTCAC CGCTCAACCC AGCCGTTCTCT
1891	TTCCATACC TCTCTAGT CCACGACAC GCAATTATCG ACTGCAATTCG CGCAACTCC TACCCGACTCT AAGCTTATCC ACCAGTACCA CGTGCTCTG CGTAATTCG CGCTTACG ATGCGATCA

FIG. A₂ cont.

WO 02/072754

19/54

PCT/US02/06713

1981 CCCATTACCC TTACCTCAA GAGATGCTCG ACTGGCCAGA TGAACATGGC ATTCGCGCA TGCATGAAAC
CCCTTAATGGC ATTCGGCACTT CTCAGCGCC TAGTGTACCC TAGCAGCTA AACTACTTTC

2031 TGCTTCTTC GCCTTAAAC TCTCTTACG CATTGGTTTC GAAAGGGCA ACAAGCCAA AGAACTCTAC
ACCCGACAG CCGAAATGGC AGAGAAATCC GAAACCAAC CTTGGCCCT TCTTGACATC

2101 ACCGAAAGGG CAGTCACCG GGAACACTCAG CAACCCACT TACAGCCAT TAAACAGCTC ATAGCCGCTG
TGGCTTCTCC GTCAAGTCGC CCTTTCAGTC GTTCGGCTGA ATTCGCGCTA ATTTCCTGAC TATCCGGCAC

2171 ACATAAACCA CCCAAAGGCTG CTGATGCTGA STATTCCCAA CGAACCCGAT ACCCTCCGC AAGGTCCAGG
TGTTTTGGT GGGTTCGAC CACTACACCT CATAACGCT TCTGGCCCTA TGGGCAGCCG TGGCACCC

2241 GGAATATTTC GCGCCACTCG CGGAACCCAGC EGGTAACCTC GCGCCATTACG CTGGCTCAAT
CCCTTAAGC CGGGTGAAC CGCTTCCTTC GCGATTTGAG CTGGGCTCC CAGGCTAGTG CACGGCACTA

2311 CTATGTCTT GGGACGGCTCA CACCGATACC ATCAGCCATTC TCTTGTATGT GCTGGCCCTC AACCGTTATT
CAATACAAGA CGCTGGCACT GTGGCTATGG TACTGGCTAG AGAAACTACA CGACACGGAC TTGGCAATAA

FIG. A₂ cont.

WO 02/072754

PCT/US02/06713

20/54

2381 ACGGATGCTA TETCCMAEC GGCGATTGGG AACCGGAGA GAAAGCTACTG GAAAACAAAC TTCTGGCCCTG
TCCCTAACCC CCGCTAACCC TTTCCTCTT CTTCATGAC CTTCATGAC AAGACGGAC

2451 CCACCGAAA CTGCGATCAGC CGATTATCAT CACCGATAAC CGCGCGATA CGTTAGCGG CCTGCACTCA
CGTCCTTT GACGTAGTCG CCTAATAGTA GCGCTTATG CGCGACCATAT CGAATCGGCC CGACCTGACT

2521 ATCTACACCG ACATGTCGAG TCAAGACTAT CACTTGCAAT CCTCTGGATAT CTATCACCCG GTCFTGATC
TACATETGCC TETACACCTC ACTTCCTATA GTCACACATA CGACCTATA CATACTGCC CACAAACTAC

2591 CGCTTAGCCC CGTCCTGGT GAACAGCTAT CGAAATTCCC CGATTTCCG ACCTCGCAAG CGATATTCCG
CGCAGTCGG CGAGCAGCCA CTGTCGATA CCTTAACCC OCTAAACCC TGGACCGTC CGTATKACCC

2661 CGTTCGGGT AACAGAAAG CGATCTTCAC TCGCGACCC AACCCGAAT CGGGGGTTT TCTCTGCCAA
GCAACGGCA TTCCTCTTC CCTACAACTG AGCGCTTCA TTGGCTTCA GCGCCAAA AGACCGCTT

2731 AACGGCTGGAA CTGGCATGAA CTTCGGTCAA AACCGGAGC AGGGAGGCAA ACAATGAGAG CTGGCTTGT
TTGGGACCT GACCGTACTT GAAGCCACTT TCCCTCCGTT TCTTACTCTC GAGCCAAACAA

FIG. A₂ cont.

WO 02/072754

21/54

PCT/US02/06713

2801 GATGCGATCG TCAAGGATCC AATAGAAGCTT ACCGAAATAT TACGAAATT ATATTACACA
CTACCTAGAC ACTACCTAAC TTATCGACTA TTATCTGAA TCGGTITATA ATCGTTTTA TATAAFTCTGT

2871 ATACTACAT TAACCAAGAC TCTAGATGCTT GTTATTTGA ACCACAGATT AGCATTCTTC ATAGAGATGA
TATCGATGTA ATTCCTACTC ACACCTACCA CAACTACCA CAACTAACCT TTCTCTACAC TATCTCTACT

2941 . CATECTCAAT CCATCATCGT GTGATATGAA CACACATTTGT ATTATGATGA ATTACACCTGA TGTAGCCGAA
CTACCGATTA CCTACTAGCA CACATATACTT GTCTGTAACTA TAATACTACT TAATTCGACT ACATCCGCTT

3011 TTGGGAACTA GIAFGTTGGG GAAATATGAA CCTCACATGA TTAACTATTGC TCTTCGGGCT GCTGGGGCT
AAACCTAGAT CATAAACCC CTTTATACTT TTATAAGAT TAATATCCCT GCACTGIACT AATTCTAACG AGAAACCCAC CGACCCCG

3081 CGCTGCACTA AAAAATGAAA AAAATCTCA ATTATAGGA CGCTTTGAT TTTCTTTTT TCTATCTAT
GGAGGCTAT TTCTTACTTT TTATAAGAT TAATATCCCT GCAAAACTA AATTCTAACG AGAAACCCAC CGACCCCG

3151 AAAATAATAAA TAGGGGGGG ACCATGAAAG TGAACGGAT CACGAAGAT TATCAGCACT TCTGGAAATG
TTATTTATTT ATCCCGGGCG TGGTACTTC ACTTCCTCA GTCCTCTTA ATAGTCGTGA ACACCTTAC

FIG. A₂ cont.

WO 02/072754

22/54

PCT/US02/06713

3221 GGGCATCAG CTCCCTGAA TGTGTATGAT CCGTACTGCT GTAGAAATT TGTGTGTGTCAC AGTTTATTAT
CCCGTACTAC CACCAACCT ACAACTACTA CACATCAAGA CATCTTTAA ACACCAGTG TCAAATAATA

3291 CGGCTACCTC TGTGAAAGA ACCAACCAAC ACTCTATTCT GTGCCATCACA TGCTAAAGCA TAGCATACAG
CCCCATGCCAC ACACCTTCTC TCGTTCCTC TGACATAAAC CACCTAAAC AGCATTCTC ATACTATGTC

3361 ACCTACATAA TGTGTTGGCCC ACACATGCCCT GTGTACCCAC AGACCCCCAAC CCACAGAAAG TAGTATTGGA.
TCCATGTATT ACAAAACCCCG TGNTACGGA CACATGGTC TCTGGGTTTC GGTGTTCTC ATCATTAACCT

3431 AAATGTCACA GAAATTTTA ACATGTCAGA AAATTAACATC GTAGAACAGA TCCATGAGGA TATAATCAGT
TTTACACTT CTTTAAAT TGTACACCTT TTATTTGTCAC CATCTGTCT ACGTACTCTT ATATTAGTCAA

3501 TTATGGCAGT AAACCTTAA GCCTATGTA AAATTAACCC CACTCTCTT TACCTTAAT TGCACCTATT
AAATACCTTAA TTTCGGATTG TTGTACACAT TTAAATGGC GTGAGACACA ATGAATTTA ACCTCACTAA

3571 TTAGGAATGT TACTAAATAC AATAATACTA CTGAGGAAAT CAGAGGAGAA ATAAAAGACT GCTCTTCACAA
ACTCCTTACA ATGATTATAG TTATTAATCAT CACTCCCTTA CTCTCTCTT TATTTTGTCA CGAGAAAGTT

FIG. A₂ cont.

WO 02/072754

PCT/US02/06713

23/54

3641 TATCACCACCA ACCGATAAGAG ATAAGCTGAA GAAACACTAT GCACTTTCCT ATAGACTTCA ATAGACTTCA TGTTAGTACCA
ATAGCTGCTG TCGTATTCCT TATTCACCT CTTCCTGATA CGTCAAAAGA TATCTGAACT ACATCATGGT

3711 ATAGATAAAC ATAATTACTACG CTATAGCTTC ATAATTGTA ATACCTCAAC CATTACACAG CGCTGTGCCAA
TATCTTAC TATTTATGTC GATACTCAAC TATTCACAT TATGGACTG TAAATGTC CGGACAGGGT

3781 ACGTATCCCTT TCAACCAATT CCCATACATT ATTCTACCC CGCTCGTTT ECGATTCTAA ACTCTAAAGA
TCATAGAA ACTCGTTAA CGGTATGAA TAACATGCG CCGACCAAA CGCTAAAGTT TCACATTTCT

3851 CAGAAGTC ATTCGAAACG CGGCGATCTAA AAATCTCAGC ACAGTACAAT GTACACATGG AAATTAGGCCA
GTCTCTCAAG TTACCTTCCTC CGGCGTACATT TTTACAGTCG TCTCATTTTA CAGTGCTACC TTAAATCCGGT

3921 GTAGCTCAA CTCAACCTCTT GTTAAATGCC ACTCTAGCAG AAGAAAGGTT ACTAATTAGA TCTAGTAATT
CATTCACATT GAGTTGACCA CAACTTACCG TCAAGTCTGC TTCTCTCCA TCAATTACCT AGATCATTTAA

3981 TCAAGACAA TCCAAAAAC ATAATAGTAC AGTCTGAGA ATCTGTTAGAA ATTAATTGTA CAAGACCCAA
AGTGTCTGTT ACCTTTCCTC TATTTATGTC TCAACTTCT TAGACATCTT TAATTACAT GTTCTGGGT

FIG. A₂ cont.

WO 07/072754

74/51

PCT/US02/06713

4061 CAAACAATACA AGGAAAGTA TACATATAGG ACCAGGAACA GAAATTATAA CAACAGGAGA AATAATAGGA
GTTGTTATGT TCCTTTCAT ATGTATATCC TGGTCCTCT CGTAAATAAT GTGTGCTCT TTTTTATCTT

4131 GATAAACAC AGGACATTC CAACATTACT AGAACAAAT GGAATAACAC TTTAAATCAA ATACCTACAA
CTATATTCTG TTCTGTAAAC GTTGTAAATCA TCTCTTTA CCTTAACTG AAATTAGTT TATGATGTT

4201 AATTAAGA ACAATTGGC AATAATAAA CAATAGTCCT TAATCAATCC TCAAGGAGGG ACCCAGAAAT
TTAATTCTCT TGTAAACCC TTATTATTT GTTATCGA ATTACCTAGG AGTCCTCTCCC TGGCTCTTA

4271 TCTAATCAC AGTTTAAATT GTGGACGGGA ATTCCTCTAC TGTAAATTCAA CACAACCTGT TAATAGTACT
ACATTACCTG TCAAATTTAA CACCTCCCT TAGGAGATG ACATTAAGT GTGTTEACAA ATTATCAAGA

4341 TCGGATTAA ATGCTACTTG GAAATTACA CAATGAAATG GTACTGAAAGG AATAACACT ATCACACTCC
ACCTAAAT TACCATGAAAC CTTAAATTGT GTAACTTAC CTCACCTCC TTTACTCTCA TAGTGTGAGG

4411 CAGTAGAAAT AAAACAAAT ATAAATATGT GCCAGGAAGT AGGAAAGCA ATGTAIGCCC CTGCCATCAG
GTACATCTTA TTTTCTTAA TATTATAGA CGCTCTCTCA TCCTTTCTGT TACATACCC GAGGGTAACTC

FIG. A₂ cont.

WO 02/072754

PCT/US02/06713

25/54

4481 AGGACAAATT AGATGCTCAT CAATATTAAC AGGGCTTAATA TTAACAAAGAG ATGGTCCAAC TAACACTAGT
TCCCTGTTAA TCTACAGTA GTTTATAATG TCCCGATATC ATTTGTTCTC TACCACTTG ATTCATCA

4551 CGCTCCGAGA TCTTCAGACC TCGGGCACCA CATACTACGG ACAATTGAG AACTGAAATA TATAAATAATA
CDCAGGCTCT AGAACCTCTC AGCCCTCTC CTATACCTCTC ATGTTAAGCTC TTCACTTATC ATATTTATAT

4621 AACCTACTAA ATTGAACCA TTAGGACTAG CACCCACCAA GCGAAAGAG AGAGCTGGCC AGAGAGAAAGA
TTCACTATT TAACTCTCT AATCCTCATC GTGGGTGGTT CGGTTTCTCTC TCTCACCAAG TCTCTCTTT

4691 AACCCAGTG CGAACCTAAC GAGCTATTT CCTTGCGTC TCTGGACAG CAGGAAGCAC TATGGCGGCA
TTCTGTCAC CCTTCCTCATC CTGGATACAA GGAACCCAG AACCCCTCTC GTCCCTTCCTC ATACCCGGCT

4761 CGCTCAAATAC CGCTGACCT ACAGGCCAGA CTATTAATTCT CGGTATAGT GCAACACCCAG AACMATTTCG
CGCAGTTATT CGGACTGCCA TGTCCGGCTCT GATAATAACA GACCATATCA CGTGTCTCTC TTGTAAACCC

4831 TGAAGCTAT TGAAGCCAA CACCATCTGT TCCAACTCAC AGTCTGGGCC ATCAAGGCAAC TCCAGGCCAG
ACTCCGGATA ACTCCGGCTT CTCCTAGACA ACCTTGACTG TCAGACCCCG TACTTCGTGG AGGTCCGGTTC

FIG. A₂ cont.

WO 02/072754

26/54

PCT/US02/06713

4901 ACTGCTTCT ACCAACAT TCAACACCTC CTAGGGATTG CGCGTTCCTC TGGAAACTC
 TCAGGACCCA [ACCTTCTA TGGATTCCCT AGTTGTCAG GATCCCTAA CCCCAAGGAG ACCTTTCAG

4971 ATCTGCACCA CTGCTCTGCC TGGCAACTCT AGTGGCACTA ATAAACCTCT GGATATGATT TGGGATAACA
 TAGACCTCTCT GACCGACACCC ACCCTTACCA TCAACCTCAT TATTGAGA CCTATACAA ACCCTATCT

5041 TCACCTGGAT GGAGTGGAA AGACAAATCG ARAATTACAC AGCGTTATA TACACCTTAAT TGGAGAAC
 ACTGCACCTA CCTCACCCCT TCTCTTACG TTTTAATGTC TCCGAATTAT ATGCGGAAIT AACCTCTTAC

5111 GCAAGACCA CAAGAACAGA ATGAAACAGA CTTATAGCA TTAGATAACT GGGCAAGTCT GGGCAATTGG
 CCTCTTCCCT GTTCTTCTCT TACITCTCT CAATAATCT ATCTATCTA CCCTTCAAAC CACCTTAACC

5181 TTTGACATAT CAAATTGGCT GTGGCTTTTA AAAATCTCA TAAATGAACT AGGAAGCTTC ATACCTTTAA
 AACATGTTAA GTTAAACCA CACCA[ACTT ITTTAGAACT ATTACTATCA TCTCTCCAAAC TATCCAAAT

5251 GAAIAGTTT TACTGTACTT TCTATACTAA ATAGAGTTAG GCACGGATAC TCACCATTTT CATTTCAGAC
 CTTATCAAAC ATGACATCAA ACATATCATT TATCTCAATC CTCCTCTTAC AGTGGTAAAC GAAAGTCTG

FIG. A₂ cont.

WO 02/072754

PCT/US02/06713

27/54

5321 CCACCTCCA CCCCGAGG CACCCACAG CCCGGAGGA ATCGAAGAAG AAGTGGACA CAGACACTAA
GGTGGGGCT CGGGGCTCCC CTGGGCTGTC CGGGCTTCTCT TAGCTTCTTC TTCCACCTCT GTCTCTGATT5381 TTTTATGCC CCCCGCTGTA OCCAACCTAA AAATGAAATA TAAATAACAA CGTTCAGC CGTTCAGTAA
AAAATACGC CGGGGACCAT CGGTGGATT TTAACTTTT ATTATGTTT CCAGAACTC OCACACAT5461 ATTTGAAAGC GAGAAATAAT CATAATAAAC CCCCGGATC CTCCTAGACTC GACACCAGG GTGCCAGAGC
TTAACCTTCG CTCCTTATTA CTATTTATTC GGGCCCTAG GACATCTAG CTGTGTACG CACCGCTCTCC5531 GTCAGTATA ACCGGGGCAC ATTAGATCG ATGGGAAAA ATTGGTTAA GGCAGGGG AAGAAAAAA
CAGTCATAT TCGCCCGCTC TTAAATCTGG TACCCATT TAACCCATT CGGGTCCCGC TTTCCTTTTT5601 TATAAATTAA AACATATACT ATGGGCAAGC AGGGAGCTAC AACGATTCC ACTAAATCCG GGCCTCTTAC
ATATTAATT TGTATATCA TACCGGTCG TCCCTGATC TGGTAAGG TCAATTAGGA CGGACAAAC5671 AAACATCACA AGGCTCTACA CAAATACTGC GACACCTACA ACCATCCCTT CAGACAGCAT CAGACAGACT
TTTCCTACTCT TCCGACATCT GTTATACCC CTGTGTATGT TGTTAGGCA GTCTGTCCAA GTCTCTCTCA*FIG. A₂ cont.*

WO 02/072754

PCT/US02/06713

2R/54

5741 TAGATCATTA TATAATACG TACCAACCCCT CTTATGTTG CATTAAAGGA TAGAGATAAA AGACACCCAG
ATCTAATGTC ATATATGTC ATCGTTGGGA GATAACACAC GTACTTCTT ATCTCTTATT TCTGTGCTTC

5811 GAA GCT TTA G AC AAG A T A G G A A G G C A A A C A A A A G G C A A C A G C A A G G C T G A C A
CT:CGAAATC TCTCTATC TTGTCTTCAT CCTTCCTTCC TCTTTTTCG TCTGTTCG TCTCTGCTCT

5881 CAGGACACAG CAAATCAGGTC ACCCTAAATT ACCCTTAAGT CCAGAACATC CAGGGGAAA TGGTACATCA
GTCCCTCTGTC CTTACTCCAC TCCGTTTAAC TGGCTATCA CGTCTCTGTC ACCATGTTT ACCATGTAAT

5954 CCCATATCA CCTAGACCT TAATGCATG CCTAAAGTA GTAGAACGA AGGCTTCTG CCCAGAAGC
CGGCTAAGCT GGTCTTGAATTACCTAC CCATTCTCT CATCTTCAAT CCCAAAGTC CGCTCTCAC

6021 ATACCCATGT TTTCAGCATT ATTCAGAAGGA CCCACCCAC AAGATTAAA CACCATGCTA AACACACTGC
TATTEGGTACA AAGTCGTTAA TAGTCCTCGT CGGTCTTCCT TGTCAATT GTGGTACGAT TTGTGTCAAC

6091 CGGACATCA AGCACCATG CAAATGGTAA AAGAGACCAT CAAATGGAA GCTGCAGAT GGGATAGCT
CCCCTGACT CGTCCGTAC GTTACMATT TTCTCTGGTA CTTACICCTA CCACGTCTA CCCTATCTCA

FIG. A² cont.

WO 02/072754

29/54

PCT/US02/06713

6161 **GCATTCAGTC ATGGCAGCC CTATTCACCC AGGCCAGATG AGAGAACCAA CGCGAAGTGA CATAAGGGA**
CTTAACTCAC GTACGGTCCC GATAACGTCG TCGGGTCTAC TCTCTTGTCTT CCCCTTCAT CTATCGTCTT

6231 **ACTACTAGTA CCCTTCAGCA ACAAAATACCA TCGATGACAA ATAATCCACC TATCCAGTA CGACAAATT**
TCATGATCAT CGCGAACTCTT TCTTTATCCT ACCTACTCTT TATTAGCTGC ATAGGCTCAT CCTCTTAA

6301 **ATAAAAGATG GATAAATCCTG CGATTAAATAA AAATAGTAAC AATCTATAGC CCTACCGCA TTCTCGACAT**
TATTTTCTAC CTATTAGCAC CCTAAATTAT TTTATCCTT TACATATCG GGATGGTCTT AAGACCTGTA

6371 **AAGACAAAGGA CCAAAAGAAC **CC**TTTACAGA CTATGAGAC CGGTCTATA AAACTCTAAAG AGGCCACAA**
TTCTCTTCCT GTTTTCTTC CGAAATCTCT GATACTCTG CCCAACATAT TTGAGCTTC TCGGCTCGTT

6441 **GGTTACACGG AGCTTAAATAA TTGGATGACA CAAACCTCTT TGGTCTCAAAT TCGGAACCCA GATGTGAAGA**
CGAACTCTCC TCCATTTT AACCTACTCTT CTTTGCAACCA ACCAGGTTT ACCGCTT ACCGCTT CTAAACATTCT

6511 **CTATTTAAAGGCAATGGGA CCAGGGCTA CACTAGAACAA AATGATCACA CCATGTCAAGG CAGTAGGAGG**
CAJAAATTTC TCGTAAACCTT CGTCGGCGAT GTGATCTCTT TACTACTGT CGTACAGTCC CTCATCCTCC

FIG. A₂ cont.

WO 02/072754

30/54

PCT/US02/06713

6581	ACCCGCCAT ACCAACAG TTTGCCCTCA ACCAATACG CAACTAACAA ATTCCTAC CATAATGATC TGGGCCGTA TGCCTCTCTC AACACGACI TCTTACCC CTCATGTT TAGTGCCAT GATGACTAC	
6651	CACAGGCCA ATTAGCA ACCAACAG ATTCCTAC TAAATCCCTT CGAGTAAAC ACCGTTTCTT CCGTGTCTC	
6721	CCAGAACAT CTTAGCA ACCAACAG CTCCTTCC CTCCTTCC CTCCTTCC TTTACCTTCTC CTTCAGCTC CTCCTTCC CTCCTTCC CTCCTTCC CTCCTTCC CTCCTTCC CTCCTTCC	
6791	TTCCTACAG AGACAGCTTA ATTATTCG CAACTCTCC CTCCTCCAGTCA AGGAAAGCC AGGAAATT ACACAGCTC TCTCTCCAT TAAATCC CTCCTACCC GAAAGGATC TCCCTTCGG TCCCTTAAA	
6861	CTTCAGCA ACCAACAG CTCCTCCAGTCA AGGAAAGCC CTCCTCCAGTCA AGGAAATT CACGTCCT CTCCTCCAGTCA AGGAAAGCC CTCCTCCAGTCA AGGAAATT	
6931	CCCTTACAG CCAGAACCCG ATAGACAGG AACCTATCC TTTAACTTCC CTCACATCAC TCTTGGAA GGGAGCTT CTCCTCCAGTCA TATCTCTTCC TTTCACATAG AAATTGAGG GAGCTGAGC AGAACCGTT	

FIG. A₂ cont.

WO 02/072754

31/54

PCT/US02/06713

7001 CGACCCCTCG TCACAAATAAA GATAGGGGG CAACTAAGG ACCCTCTT AGATACAGGA CCAGATGATA
GTCGGGACCC ACTGTTTCTT CTATCCCCC GTTCATTCC TTCCGATAA TCTAIGCTCC CGTCCTACTAT

7071 CACATTAGA AGCAATGACI TTGCGACCAA GATCGAAACC AAAATCATA CGGGAAATTG GACGTTTTAA
GTCATTAATCTT TCTTACTCA AACGGTCTT CTACCTTTCG TTTCCTACTAT CGCCCTTAAC CTCACAAATA

7141 CAAAGTAAGA CAGTATGATC AGATACTCAT AGAAATCTGT CGACATAAAC CTATAGGTAC AGTATTAGTA
CTTCATTTCTT CTCAATCTAG TCTTATGACTA TCTTATGACTA CCTCTATTTC GATATCCATG TCATAATCAT

7211 CCACCTAACAT ATTCGGAAAGA AATCTGTGTA CTCAGATIGG TTTCACCTTA AATTTTCCTCA
CCTGGATGTG GACAGGTGTA TTAACCTTCT TTACACAACT CAGTCIAACC AACCTGAAT TTAAAAGGGT

7281 TTACCCCTAT TCACTACTGTA CCACTAAAT TAAGCCAGG ATTCGATGCC CCAAAGTTA ACCAATGCC
AATCCGGATA ACTCTGACAT CCTCATTTA ATTCGGTCTC TTACCTACCG CCTTTCAAT TTGTTACCG

7351 ATTCACAGAA CAAAAATAA AAGCATTAGT AGAAATTTGT AGAGAAATGG AAAGGAAGG GAAAATTCA
TAACCTGTCTT CTTTTTATT TTGCTTAAACA TCTTAAACA TGTCTTACCC TTTCCTTCC CTTTAAGCT

FIG. A₂ cont.

WO 02/072754

32/54

PCT/US02/06713

7421 AAAATTGGCC CTCGAGAATCC ATACAAATACT CCACATTTG CCAAAAGAAA AAAGACAGT ACTAAATGGA
TTTAAACCCG GACCTTACCC TATCTTATGA GCTCATAAC CCTTCTGTCA TGATTTACCT

7491 GGAATTAATG AGATTTACCA GAACTTAAATA AGGAGAACTCA AGACTTCTGG GAACTTCAT TAGGAATACC
CTTAAATCA TCTAAACTCT CTCGAATAT TCTCTTCACT TCTCTTCACT CTCGAACCC CTTCAACTTA ATCCCTTATGG

7561 ACATCCCGCA GCGTTAAGAA AGCAAAATC AGTAAACAGIA CGGGATGTTG GTCATCCATA TTTTCAGTT
TGTAGGGCT CCCAAATTCTT TCTTCTTAC TCTATGTCAT GACCTACACC CACTACCTAT AAAAAGCTCAA

7631 CCTTACAGC AGACTTCAG GAACTTACCT GCAATTAACCA TNCCTAAGT AACAAATGAG ACACCAAGGA
GGGAATCTAC TTCTGAAGTC CTCATATGA CCTAAATGCT ATGGATCATTA TTGTCTACTC TTGTCTCCCT

7701 TTAGATAATCA GTACAAATGTC CTTCACAGG GATCCAAAGG ATCACCAACCA ATATTCAAA GTCAGATGAC
AATCTTACCT CAGCTTACAC GAACTCTTCG CTCACCTTCC TAGTCCTCTCT TATAACCTT CTCCTACTG

7771 AAAAATCTTA GAGCCTTTA AAAAACAAAAA TCCAGACATA GTATCTATC AATACATCA CGATTCTAT
TTTTAGAAAT CTCGGAAAT TTTTCTTTT AGGTCTGTAT CATAAGATAG TTATGACTT GCTAAACATA

FIG. A₂ cont.

WO 02/072754

PCT/US02/06713

33/54

7841 CTAGGATCTG ACTTAGAAAT AGGGCAGCAT AGAACAAAAA TAGAGGACCT CAGGAAACAT CCGTCAGGT
CAICCTAGAC TGAATCTTA TCCCTCTGTA TCTTGTGTTT ATCTCCTCGA CTCTCTGTA GACAACTCCA

7911 CCCGACTTAC CACACCAGAC AAAAAGATC AGAAGAAAC TCGATTCCTT TCGATTCCTT ATCAACTCCA
OCCCTCAATG GTCCTCTG TTTTGTAG TCTTCTCTG AGCTAACGAA ACCAACCAA TACTTGAGGT

7961 TCCCTGATAA TCGACAGTAC ACCCTATAGT CCTGCCACAA AAAGACAGCT GGACTTCAA TGACATACAG
ACGACTTACCTT ACCTGTCTAG TCGGATATCA CGACGCTCTT TTCTCTGTCGA CCTCACAGTT ACTGTAATCTC

8051 AGCTTACTGCC GCAATATGAA TACCCGAAGT CACATTACCC CAGGATTAA ACTAAGGCAA TTAATGTAAC
TCAATCACC CCTTAACTT ATGCCGTTCAGCTCA GCTAAATGG GTCCTTAAATT TCAATTGCTT AATACATTTC

8121 TCCCTGAGG AACCAAGCA CTAACAGAAG TAATAACCACT AACACAAAGAA CCAGAGCTAG AACTGCCAGA
ACGAATCTCC TTGGCTTCGTTGTTCTC ATTATGGTC ATTCTCTCTT CCCTCTGATC TTGACCGTCT

8191 AACACAGAC ATTCTAAAG AACCAAGTACA TCGAGTGTAT TATGACCAAT CAAAGACTT AATAAGCAGAA
TTTGCTCTC TAAGATTTTC TTGGCTATGT ACCTCACATA ATACTGGTA GTTTCTGAA TTATCTGCTT

FIG. A₂ cont.

WO 02/072754

PCT/US02/06713

34/54

8261 ATACAGAACG CCAATGGACA TATCAAATTG ATCAAAGACCC ATTAAAKAT CIGAAACAG
TATGTCCTCG GTCGGTTCG ATAGTTAA TAGTCTCGG TAAATTGTTA GACTTTCGTC

8331 GAAATATCC AACAAATGAGC GGTCGCCACA CTAATGATGT AAAACAATTAA ACAGAGGCCAG TCCAAATAAT
CTTTTATAGC TTCTTACTCC CCACGGCTGT GATTACTACA TTTCCTTATAT TCTCTCCGTC ACGGTTTTA

8401 AACCAAGAA ACCATACTAA TATGGGAAA CACTCCTAAA TTAAACTAC CCATACAAA GCAAACATGC
TTEGTTCTT TCCTATCATT ATACCCCTT CTGAGGATTI AATTGATG CGTATCTTT CCTTGTAC

8471 GAAACATGGT CCACACACTA TTGGCAAGCC ACCGGGATC CTCAGCTGGAA GTTGTGTTAT ACCCCTCTT
CTTGTACCA CCTGCTCTCA ACCCCTTCG TGGACCTAAG GACTCACTT CAACAAATTAA TGGGAGGAA

8541 TAGTGAATT ATGGTACCCAG TTAGAGAAC AACCCATAGT ACCGGGAGA ACCTTCTATC TACATGGCCC
ATCACTTAA TACCATTCCTC AATCTCTTC TTGGCTTATCA TCCTCGCTT TCGAAAGATTC ATCTACCCG

8611 AGCTAACAGG GAGACTAAAT TACCAAAAGC ACCATAATGTT ACTAACAAAG GAAGACAAA CGTTCCTCCC
TCGATTCGTC CTCGATTIA ATDCTTTGC TCCTATACAA TGATTCCTTC CTCTCTTIT CCAACAGGGG

FIG. A₂ cont.

WO 02/072754

PCT/US02/06713

35/54

8681 CTAACAAACA CAAACAACTCA GAAACACTCAG TTACAAGCAA TTATATCTAGC TTTCAGGAT TCAGCATTAG
GATGGATCTG CTGTTTACTC MATGTTCTT AAATAGATCG AAACCTCTTA AGCTCTTAATC

8751 AAGTAACAT AGTAACAGAC TCACAAATAC CATTAGGAAT CATTCAAGCA CAAACAGATA AAAGTGAATC
TTCAATTCTA TCATTCTCTC ACTCTTATAC GTAAATCCCTA GTAAAGTCTAT TTTCACCTAC

8821 AGACTTACTC AATCAAAATAA TACAGCACTT AATAAAAAAC CAAAAGCTCT ATCTGGCATE GGCACCCAGCA
TCTCAATCAG TTACTTTAAT ATCTCTCAA TTATTTTCCTT CTTTCCAGA TAGACCGTAC CCATGGCTCT

8891 CACAAAGCAA TTGGAGCAA TGAACAGATA CATAAAATTAG TCAGTGCTGC AATCAAGAA ATACIAATT
CTCTTCCCT AACCTCCCTT ACTCTCTCAT CTATTTAATC ACTCACGCC TTAGTCCTT TATGATAAAA

8961 TAGATTCGAAT ACATAAGGCC CAAGATCAAC ATTAGTTTT ATGTCGACCT GCAGGAAAG TTTTATAGCT
ATCTACCTTA TCTTAATTCCG GTCTACTTC TAATCAAAA TACACCTGGA CGTCCCTTC AATATATCCA

9031 AGTTGATAGA ACAAATACA TAATTTCGTA AAATAAAATC ACTTTTATAA CTAATATCAC ACCATTACCA
TCAACTATCT TGTTTTATGT ATAAACAT TTTTATTTAG TGAAAATAAT CATTATACTC TCCATAATGGT

FIG. A₂ cont.

WO 02/072754

PCT/US02/06713

36/54

8101 ATACTTTGT TACTAATAC ATTAGTATAAC GCTACACCTT TTCTCAGAC ATCTAAAGAA ATAGGTGATG
TATGAAACA ATGATTATAG TAATCATATG CGATCTGAA AGGAGTGTG TAGATTTT TATCCACTAC

8171 ATGCAACTTT ATCATGTAAT CGAAATAA CAAATGACTA CGTGTGTTAC AGTCCTGGCT ATAGGAGCC
TAGGTGAA TAGTACATTA GCTTACTGAT GAAACAATAC TCACGAACCA TATTCCTGGG

9241 CAATTCCATT ATTCCTTTAG CTGGCTAACG CGACGCTTTC TATTTGATA ATTATACAA GGATAAATA
GTTAAGCTAA TAAGAATAC GACGATTTTC GCTGCACAC ATAAACATAT TAATATGTTT CCTATTTAT

9311 TCTTACCACT CTCCAAACCGA TCAATCAGTT ACAACIATCA CAAATAATC ATTCACCTCT AGACATGCC
AGAAATGCTGA GAGGTATGCT ACTAGATCAA TGTGTGATAGT GTTAAATTTAG TAATCTAACGA TCTCTACGGC

9381 CTACCTAATG ATCTGCAATC TTATGACAT CCCCTACAAA TGACACTGAT AAAGTAGATT ATCAAGAAATA
CATGAAATACA TACAGCTAAG AAACTCTGA GCGGATGTTT ACTGTGACTA TTTCATCAA TACTCTTAT

9451 CTCCACACG TTCAATGCACT ATACAGATAG TCAATGCACT ATAGACATAA TACTATCTGC ATCTACACAT
GAGGTCTTC AACATGCAATT TATCTCTATC ACTTAGCTGA TATCTGATT ATGATAGACC TAGATGTTA

FIG. A₂ cont.

WO 02/072754

PCT/US02/06713

J7/54

9521 TCACCAAAA CTTCTTAACC TTGTCTCCCT ATACTCTGC GATTAGAGC TTGGCGTAAT CAGGGCTATA
ACTGGTCTT CATCAATTCC ACAGAGGGAA TATCACTCG CATAATCTGG AACGGCATTA CTACCAAGTAT

9591 CCTGTTCCT CTCTAAATT GTTATCDECT CACATTCGA CACAACTAC GACCCGAAGG CATAAAGTGT
CGACAAAGGA CACACTTAA CAATAGCCCA GTCATTAAGGT GTCTCTATG CTGGCCCTC GIAATTCAAC

9661 AAAGCCTGGG CTCCTTAATG ACTGAGCTAA CTCACATAA TTGGCTTGCC CTCACTGCC GCTTTCGAGT
TTTCCGACCC CACCAATTAC TCACTGATT GTCGTAAATT AACCCAAAGC SACTGACGGC CGAAGGCTCA

9731 CCCGAAACCT GTCGTCGGCAG CTGGCATTAAT CAATCGGCCA ACCGCCGGG AGAGCCGGTT TGGTATTGC
GCCCTTTGGA CAGCCTCCCT GACCTTAATTA CTTAACCCGT TCCGCCCGC TCTCCGCCAA ACCAAIAAC

9801 CCCTCTCTCC GCTTCCTGC TCACTACTC GTCCTCCCTC CTCTTCCTCC TGGGGGCC GCTTCACCT
CGGGGAGACGG CGAACGGGCC AGTCACTAG CGACGGCCAG CAGCAAGCC ACCCCCCCTGG CCATAGTCC

9871 CACTCAAGG CCCTAAATCC GTTATCCACA GAATCAGGGG ATAACCCAGG AAAGAACATC TGACCAAGG
CTCACTTTCG CCCATTAACC CAACTCTGT CTACTCCCC TATTGGTCC TTTCCTGAC ACTCTTTTC

9941 CCCACCAAAA CGCAGGAAAC CGTAAAAAGG CGCGCTTGCT GCCTTTTC CATACTCTCC CGCCCGCTGA
GGCTCTTTCG CGCTCTCCCTGC CCATTTTTCG GGCGCAAGGA CGGCAAAAGG CTATCGAGG CGGGGGACT

FIG. A₂ cont.

WO 02/072754

PCT/US02/06713

38/54

10011 CCAGCATCAC AAAATCGAC GCTCAACTCA GACCTGGCGA AACCCGAGAG CACTATAAG ATACCAGGGC
GCCTCTAGTC TTCTTACCTC CGAGTTAGT CTTCACCGCT TTGGCCCTTCGCT CTGATATTTC TATGGCGGC

10081 TTTCGGCGCTC GAACCTCCCTT CCTGGCTCTT CCTGTCGCGA CCTGGCGCTT TCCGGATAC CTGTCGGGCT
AAACGGGAC CTTGAGGGA GCACGGAGA GAGACAGGGT GGCACGGGA ATGGCGTAC GACAGGGCA

10151 TTCTCCCTTC GCGAACCGTG GCGCTTCTC ATAGCTCACG CTGTCGGTAT CTCACTTCGG TTGAGTCCT
AAAGGGGAG CCCTTCGGCAC CGCGAAAGAG TATCGACTGC GACATCCATA GAGTCAGCC ACATCCAGCA

10221 TCGCTCCAG CTGGCTCTC TGCACGGAAC CCCGCTTCAG CCCGACCGCT CGCCCTTATC CGCTAACTAT
ACCGAGGGTC GACCGAACAC ACCTGGCTTC CGGGGAGTC CGGGTGGGA CGGGAAATAG CGGATTGATA

10291 CCTCTTGACT CCAACCGGT AAGACCGAC TTATGGCAC TTGGCGACC CACTGGTAC AGGATTAGCA
GCACAACTCA GTTGGGGCA TTCTCTCTC AATAGGGTG AGAACTTCAC ACCGGTCTC GTGACCATTC TCCTAATCT

10361 GAGGGAGGAA TCTAGGGGT GCTACAGCT TCTTGAAGTC GTGGCCTAAC TACGGCTACA CTAGAACGAC
CTGGCTCCAT ACATCCCA CGATGCTCA AGAACTTCAC AGGGGGATTG ATGGGATGT GATGTTCCCTG

10431 ACTATTTGGT ATCTGGCTC TCTCTAAAGCC ACTTACCTTC GGAAGAGAG TTGGCTAGCTC TTGATCCGGC
TCATTAACCA TCTGGCGAG ACCACCTTCG ACCATGGAG CCTTTTTCG ATGGGATGT GACTAGGGCG

FIG. A₂ cont.

WO 01/072754

PCT/US02/06713

39/54

10501 AAACAAACCA CGCGCGGTAG CGGTGGTTT TTTCCTTCA ACCAGCAGT TACCCGAGA AAAAAGGAT
TTTCCTTGT GCGCAACCTC GCGACCAAAGA AACAAACCTG TTGTCCTCA ATGCGGCTCT TTTCCTCA

10571 CTCAGAAAGA TCCTTTCATC TTTCCTACGG CGTCACCC TCAGTGGAAC CAAACTCAC CTTAAGGGAT
GACTCTCT AGGAAACTAG AAAGATGCC CGAGACTGGG ATGCACTTG CTITTCAGTG CAATTCCTCA

10641 TTTCGTCATG AGATTATCAA AAAGGATCTT CACCTAGATC CTTTAATATC AAMATGAG TTTCATAATCA
AAACCAAGAC TCTTAATACTT TTTCCTCAAA GCGGATCAG CAAATTTAA TTTCATCTC AAATTTACT

10711 ATCTAAACTA TATATGACTA AACTGGCTC GACAGTTCAC ATATCTTAAT CAGTCAGGCA CCTATCTCA
TAGATTTCAT ATATACTCAT TTGAACAGA CTCATATCC TTACCAATTA GCACTCGT GGATAGACTC

10781 CGATCTGTCT ATTTCCTCA TCCATAGTC CCTCTCTTC CCTCTCTTC AATACCTACCA TACCCGACCC
GCTAGACAGA TAAAGCAAGT AGCTATCACG GGAATGAGGG CGAGCACATC TATTGATGCT ATTCCTCC

10851 CTTAACATCT CGCCCACTC CTCAATCAT ACCCGAGAC CCACCTCAC CGCTCCAGA TTTCATCAGA
GATTCCTCA CGCTCTCA GACCTACTA TCCCTCTTC GCTCCGAGT GCGAGGTCT AAATAGTCGT

10921 ATAAACCCAG CAGCCGAAG GCCCCAGCC AGAACTGGTC CTCACACTT ATCCGCCTCC ATCCAGCTTA
TATTCGGTCC GTCGGCTTC CGCGCTCGTC TCTTCACCCAG GACCTGCAA TAGCCGGAGG TAGCTCAGAT

FIG. A₂ cont.

WO 02/072754

PCT/US02/06713

40/54

10991 TTAATTCGG CGGGAAACCT AGAGTAAAGTA GTTCGCCCACT TAATACCTTG CGCAACGTTG TGGCATTTGC
ATTAAACACG GGGCCTTCGA TCTCATTCAT CAAGCGGTCA ATTATCAAC CGCTTCCAAAC AACCGTAACC

11061 TACAGGCCATC GTCCTCTCAC GCTCTCTCTT TGGTATGGCT TCAATTCACTT CGCGTTCCCCA ACGATCAAGG
ATGTCCTTAS CACCAAGTG CGAACCTCAA ACCATACCGA AGTAAGCTCA AGCCAGGGT TCTTACGTTTC

11131 CGAGTACAT GATGCCCAT GTGTGCAAA AAAGCGGTTA CCTCCTTCGG TCCTCCGATC GTCCTCACAA
CCTCAATCTA CTAGCCGCTA CAACACGTT TTTCCCTAAT CGAGGAAGCC AGGAGGCTAG CAACAGTCTT

11201 GTAAGTGGC CGGAGTGTAA TCACTCTGG TTATGGAGC ACTGGATTAAT TCTCTTACCT TCATGCCATC
CATTCACCG GCGTCACAAAT AGTCACTAAC ATATCCGTCG TCAAGTATTA AGAGAATGAC AGTACGGTAG

11271 CCTAAGATGC TTTCCTGTGA CTGGTCACTA CTCAACCAAG TCATTCGAG AATAGTGTAT GGGCGAACCG
CCATTCTACG AATAGACACT GACCTCTCAT GACTTCCTTC ACTAACACTC TTATCACATA CGCCCTTGCAC

11341 AGTTCTTCTT GCGGGCGTC AATACGGAT AATACGGCC CACATAGCAG AACTTAAAGA GTCCTCATCA
TCAACGGAGA CGGGCGGAG TTATCCCTA TTATGGGGCC GTCGTATCTC TTGAAATTTC CACCACTAGT

FIG. A₂ cont.

WO 02/072754

41/54

PCT/US02/06713

11441 TTGGAAACC TTCCTCCGG CGAAACTCTT CAAGGATCTT ACCCTCTTC ACATCCAGTT CGAIGTAACC
AACCTTTGCC AACAAACCCCT GCTTTCAGA GTTCCTACAA TGGCGACAA TCTACACTG

11481 CACTCTCCA CCCAACCTCAT CTTCAGGATC TTTAACCTTC ACCACCCCTT CTTCCTCAGG AAAACACAGGA
GTGAGCACGT GGTTGACTA CAAGCTCTAG AAAATGAAAC TGGTGGCAA GAACTCACTG TTTCCTCTCT

11551 AGGAAAAATG CCGCAAAAAA CGGAATTAAGG CGGACACCGGA AAGCTTAAT ACTCATACTC TTCTCTTTTC
TCCCTTTTAC GGGCTTTTCC CCCCTTATTCC CECTGCTCT TTACAACTTA TEACTATGAG AAGGAAAG

11621 AATATTTTC AACCAATTAT CAGGCTTATT CTCTCATGAG CGGATACATA TTGAAATGTA TTGAAAAA
TTATAAAC TTGCTAAATA CTCCTAAAC CAGACTACTC CCCTATCTAT AACCTACAT AAATCTTTT

11691 TAACAAATA CGGCTTCGG CCACATTCC CGAAAAACTG CCACCTGAG CCTAACAAAC CATTATTTC
ATTTGTTAT CCCAAAGGGG CGCTGAAAGG CGCTTTCAC GCTGGACTGC AGATTCCTG GAAATATAG

11761 ATCACATTAA CCTAAAAA TAGGGTATC ACCAGGCTTCTT TCTCTCTCTG GCTGTTCTG GATGACCTG
TACTGAAATT CGATATTCTT ATCCGGATAG TCTCTGGCA AAGCAGAGCC CCCAAAGCCA CTACTGCCAC

FIG. A₂ cont.

WO 02/072754

PCT/US03/06713

42/54

11831 AAAACCTCTG ACACATCCAG CTCCCCGAGA CGCTCACAGC TTGTCTGAA CGCGATGCCG GSACAGAGACA
TTTTCACAC TCTGTAAC TCTGCTCT GAGGGCTCTT GCGAGTGTG AAGAGACATT CGCTTAACCC CCTCGCTCTGT

118901 ACCCGCTCAE GCGCCCTCAC CGCGCTCTGC CGCGTGCCTG GCGCGCTTAA ACTATGCCG ATCACAGGAG
TCCGGCACTC CGCCACACC GCCCCACAGC GCGCACACCC CGCAACCCAT TCATACCCG TACITCTGTC

11971 ATTGTACTGA GAGTCACCA TATCCCTT CAATACCCCG ACAGATCGT AAGGAGAAA TACCCCATCA
TAACATGACT CTCACCTGGT ATACGCCACA CTTATGGG GAGCTTACCA TCTCTTTT ATGGCTGAGT

12041 CCCGCCATTC GCGATTCAGG CTGGCCAACT GTTGGAAAGC CGGATCCGTC CGCCGCCTCTT CGCTTAACTC
CCGGCTTAAC CGGTAACTCC GAGGCGTTGA CAACCCCTCC CGCTAGCCAC GCGGGAGAA GGCGATAATGC

12111 CCACCTCGGG AAAGCCCCAT GTCTCTCAG CGGATTAAGT TGGCTAACCG CAGGGTTTC CCACTTACGA
GGTCGACCCG TTTCCTCTA CACGGCTTC CGCTTAATCA ACCATTCG GTCGAAAG GGTCACTCT

12181 CCTTCATAAA CGACCCCCAG TGAATTGGAT TTAGGGTACA CTATA
GCAACATTCTT CCTGGGGTC ACTTAACCTA AATCCACCTT GATA

FIG. A₂ cont.

WO 02/072754

PCT/US02/06713

43/54

Text File of pLW-48 and the Included Individual HIV Genes and Their Promoters

Entire pLW-48 plasmid sequence:

GAATTCGGTGGTCGCCATGGATGGTATTGTATACTGTCTAACGCG
TTAGAAACATGCCAGGAAATAATCATATAAAAAATGATTATGATTAA
ACCATGTTGTGAAAAGTCAAGAACGTTACATGGCGGACAATCTAAAAC
AATACAGTGATTGCAGATTGCCATATGGATAATGCGGTATCCGATGTAT
GCAATTCACTGTATAAAAGAATGTATCAAGAATATCCAGATTGCTAATTG
ATAAAGATAGATGACGATGACAAGACTCTACTGGTGTATATAATTAA
ACCTAAAGATGCCATTCTGTATTATATCCATAGGAAAGGATAGAGATGTTT
GTGAACATTAAATCTCATCTGATAAAGCGTGTGCGTGTATAGAGTTAAATCA
TATAAAGTAGCCATTCTCCCATTGGATGTTCTTTTACCAAAGGAAATGC
ATCATTGATTATTCTCCTGTTGATTCTCATCGATGCGGACCTCTCTTAA
GAAGTGTAAACCGATAATAATGTTATTATATCTAGACACCCAGCGTCTACATGA
CGAGCTTCCGAGTTCAATTGGTCAAGTTTACATAAGTATAAAGTCCGAC
TATTGTTCTATATTATATGGTTGATGGATCTGTGATGCATGCAATAGC
TGATAATAGAACTTACGCAAATTAGCAAAATATATTAGACAATACTACAA
TTAACGATGAGTGTAGATGCTGTTATTGAAACCACAGATTAGGATTCTTGAT
AGAGATGAGATGCTCAATTGGATCATCGTGTGATATGAACAGACATTGTATTA
TGATGAATTACCTGATGTTAGGCGAATTGGATCTAGTATGTTGGGAAATA
TGAACCTGACATGATTAAGATTGCTCTTCGGTGGCTGGTACCGAGCGCG
CTTTCTATTGTTCTATGCTATAAAATGGTACGTCTGTAGAAACCCC
AACCCGTGAAATCAAAACTCGACGGCTGTGGCATTCACTGGATCG
CGAAAATGTGGAATTGATCAGCGTGGTGGAAAGCGCGTTACAAGAAAG
CCGGGCAATTGCTGTGCCAGGCAGTTAACGATCAGTTGCCGATGCAGA
TATTGTAATTATGCCGGCAACGCTGGTATCAGCGGAAGTCTTATACCG
AAAGGTTGGCAGGCCAGCGTATCGTGCCTCGATGCCGTCACCG
TACGGCAAAGTGTGGGTCATAATCAGGAAGTGTGGAGCATCAGGGCGG
CTATACGCCATTGAAAGCCGATGTACGCCGTATGTTATTGCCGGAAAG
TGTACGTATCACCGTTGTGTAACAACGAACTGAACCTGGCAGACTATCC
GCCGGGAATGGTATTACCGACGAAAACGGCAAGAAAAAGCAGTCTTACTT
CCATGATTCTTAACTATGCCGGAAATCCATCGCAGCGTAATGCTCTACACC
ACGCCGAACACCTGGTGGACGATATCACCGTGGTACCGCATGTCGCGCA
AGACTGTAACCACCGCTCTGTTGACTGGCAGGTGGTGGCAATGGTGT
CAGCGTTGAACCGCGTATGCCGATCAACAGGTGGTGGCAACTGGACAAG
GCACTAGCGGGACTTGCAGTGCGTCAACAGCCAAAGCCAGACAGAGTGT
GAAGGTTATCTCATGAACTGTGCGTCACAGCCAAAGCCAGACAGAGTGT
GATATCTACCGCTTGGCAGTCCGGTCACTGGCAACTGGCTTGGTGT
ACAGTTCTGATTAACCACAAACCGTTCTACTTACTGGCTTGGTGT
GAAGATGCGGACTTGCCTGGCAAAGGATTCGATAACGTGCTGATGGTGCAC
GACCACGGATTATGGACTGGATTGGGCCACTCCTACCGTACCTCGCAT
TACCCCTACGCTGAABAGATGCTCGACTGGCAGATGAACATGGCATCGTG

Figure B₁

WO 02/077754

PCT/US02/06713

44/54

GTGATTGATGAAACTGCTGCTCGGCTTAACCTCTTTAGGCATTGGTT
TCGAAGCGGGCAACAAGCCAAAAGAACTGTACAGCGAAGAGGGCAGTCAC
GGGAAACTCAGCAAGCGCACTTACAGGCATTAAAGAGCTGATAGCGCGT
GACAAAAACCACCCAAGCGTGGTGTGAGTATTGCCAACGAAACCGGAT
ACCCGTCGCAAGGTGACGGGAATTTCGCGCCACTGGCGGAAGCAAC
GCGTAAACTCGACCCGACCGTCCGATCACCTGCGTCAATGTAATGTTCTG
CGACGCTCACACCGATAACCATCAGCGATCTCTTGATGTGCTGTGCCGAA
CCGTTATTACGGATGGTATGTCAGGAAACTGCGGCGATTGAAACGGAGAGAA
GGTACTGGAAAAAGAACTTCTGGCCTGGCAGGAGAAACTGCATCAGCCGAT
TATCATACCGAATACGGCGTGGATACGTTAGCCGGGCTGCACTCAATGTA
CACCGACATGTGGAGTGAAGAGTATCAGTGTGATGGCTGGATATGTATCA
CCCGCTTGTGCGTCACTCGCGTCAAGCGCCGTCGCGTGAACAGGTATGGAATT
CGCCGATTTGCGACCTCGCAAGGCAATTGCGCGTGGCGTAACMGA
AGGGATCTCACTCGCGACCGCAAACCGAAGTCGGCGGCTTTCTGCA
AAAACGCTGGACTGGCATGAACTCGGTAAAAACCGCAGCAGGGAGGCA
AACAAATGAGAGCTCGGTTGTGATGGATCTGTGATGCAATAGCTGATA
ATAGAACATACGCAAATATTAGAAAAATATATTAGACAATACTACAATTAAAC
GATGAGTGTAGATGCTGTTATTGAAACCACAGATTAGGATTCTGATAGAG
ATGAGATGCTCAATGGATCATCGTGTGATATGAAACAGACATTGTATTATGAT
GAATTACCTGATGTAGGCGAATTGGATCTAGTATGTTGGGAAATATGAA
CCTGACATGATTAAGATTGCTCTTCGGTGGCTGGCGGCCGCTCGAGTAA
AAAATGAAAAAATATTCTAATTAGGACGGTTTGATTTCTTTCTAT
GCTATAATAATAAGCGGCCGACCATGAAAGTGAAGGGGATCAGGAA
GAATTATCAGCACTGTGGAAATGGGCGATCATGCTCCTGGGATGTTGATG
ATCTGAGTGTGAGAAAATTGTTGGTCACAGTTATTATGGGGTACCTG
TGTGGAAAGCAACCACCACTCTATTGTCATCAGATGCTAAAGCATA
TGATACAGAGGTACATAATGTTGGGCCACACATGCTGTGACCCACAGA
CCCCAACCCACAAGAAGTAGTATTGGAAATGTGACAGAAAATTAAACATG
TGGAAAAATAACATGGTAGAACAGATGCACTGGGATATAATCAGTTATGGG
ATCAAAGCCTAAAGCCATGTGAAAATTAAACCCACTCTGTGTTACTTTAAAT
TGCACGTGTTGAGGAATGTTACTAATATCAATAATAGTAGTGAGGGAATGA
GAGGAGAAAATAAAACTGCTCTTCAATATCACACAGATAAAGAGATAA
GGTAGAAGAAAGACTATGCACTTTCTATAGACTTGA1GTAGTACCAATAGATA
ATGATAATAGCTATAGGTTGATAATTGTAATACCTCAACCATTACACAG
GCCTGTCCTAAAGGTATCTTCAAGCCATTTGAGCCATTCCCACATTGTAACCCGG
CTGGTTTGCGATTCTAAAGTGTAAAGACAAGAAGTTCAATGGAACAGGGCC
ATGTAATAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTG
TCAACTCAACTGCTGTTAAATGGCAGTCTAGCAGAAGAAGGGTAGTAATTA
GATCTAGTAATTTCACAGACAATGCAAAAAACATAATAGTACAGTTGAAAGAA
TCTGTAGAAATTAAATTG1ACAAGACCCAAACAATAACAAGGAAAGTATAAC
ATATAGGACCAAGGAAAGACATTGAAACAGGAGAAATAATAGGAGATAT
AAGACAAGCACATTGCAACATTAGTAGAACAAAATGGAATAACACTTTAAAT
CAAGTAGCTACAAAATTAAAAGAACAAATTGGAATAATAAAACAATAGTCTT
TAATCAATCCTCAGGAGGGGACCCAGAAATTGTAATGCACAGTTAAATTGT
GGAGGGGAATTCTCTACTGTAATTCAACACAACGTTAAATAGTACTTGGAA
ATTTAAATGGTACTTGGAAATTAAACACAATCGAATGGTACTGAAAGGAAATGA

Figure B₂

WO 02/072754

PCT/US02/06713

45/54

CACTATCACACTCCCATGTAGAATAAAACAAATTATAAAATATGTGGCAGGAA
GTAGGAAAAGCAATGTATGCCCTCCCATCAGAGGACAAATTAGATGCTCAT
CAAATATTACAGGGCTAATATTAAACAAGAGATGGAACTAACAGTAGTCC
GTCGAGATCTTCAGACCTGGGGAGGAGATATGAGGGACAATTGGAGAA
GTGAATTATATAAAATATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCC
ACCAAGGAAAAAGAAGAGTGGTAGCAGAGAGAAAAAGAGCAGTGGAAC
GATAAGGAGCTATGTCCTGGGTTGGGAGCAGCAGGAAGCAGTGGTATGG
CGCAGCGTCAATAACGCTGACGGTACAGGCCAGACTATATTGTCTGGTAT
AGTGCAACAGCAGAACATTGCTGAGGGTATTGAGGCGAACAGCATCT
GTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAGTGGT
CTGTGGAAAGATACTTAAGGGATCAACAGCTCTAGGGATTGGGTTGCT
CTGGAAAACCTCATCTGCACCACTGCTGTGCCTTGGAAATGCTAGTTGGAGTA
ATAAAACTCTGGATATGATTGGATAACATGACCTGGATGGAGTGGAAA
GAGAAATCGAAAATTACACAGGCTTAATATACACCTTAATTGAGGAATCGCA
GAACCAACAAGAAAAGAATGAACAAGACTTATTAGCATTAGATAAGTGGGCA
AGTTGTGGAATTGG1TGACATATCAAATTGGCTGTGGTATGTAATTCTT
CATATTGATAGTAGGGAGGCTTAGGTTAAGAATAGTTTTACTGTACTTT
CTATAGTAAATAGAGT1AGGCAGGGACTCACCATTGTCATTAGACACCCA
CTTCCCAGCCCCGAGGGGACCCGACAGGCCGAAGGAATCGAAGAAGAAG
GTGGAGACAGAGACTAATTATGCGGCCGCTGGTACCCAACCTAAAAATT
GAAAATAATTACAAAGGTTCTTGAGGGTTGTGTTAAATTGAAAGCGAGAAAAT
AATCATAAATAAGCCCCGGGATCCTCTAGAGTCGACACCATGGTGCGAGA
GCGTCAGTATTAAGCGGGGAGAATTAGATCGATGGAAAAAAATTGGTTA
AGGCCAGGGGAAAGAAAAAATTAAATTAAACATATAGTATGGGCAAGCA
GGGAGCTAGAAGCATTGCACTTAACTCTGGCTTTAGAACATCAGAAG
GCTGTAGACAAATACTGGGAGAGCTACAACCATCCCTCAGACAGGATCAG
AAGAACTTAGATCA1TATATAATACAGTAGCAACCCCTATTGTGTGCATCAA
AGGATAGAGATAAAAGACACCAAGGAGCTTAGACAAGAGATAGAGGAAGAG
CAAAACAAAAGTGAAGAAAAGCACAGCAAGCAGCAGCTGACACAGGACAC
AGCAATCAGGTCAAGCCAAAATTACCCATAGTGCAGAACATCCAGGGCAA
ATGGTACATCAGGCCATATCACCTAGAACCTTAAATGCATGGTAAAGTAG
TAGAAGAGAAGGCTTCAGCCCAGAAGATTAAACACCATGCTAAACACAGTGGGG
AGAAGGAGCCACCCCACAAGATTAAACACCATGCTAAACACAGTGGGG
ACATCAAGCAGCCATGCAAATGTTAAAGAGACCATCAATGAGGAAGCTGC
AGAATGGQATAGAGTGCATCCAGTGCATGCAGGGCTATTGCACCCAGGCCA
GATGAGAGAGCAAGGGAGTGCATAGCAGGAACATAGTACCTAGTACCCCTCA
GGAACAAATAGGATGGATGACATAATCCACCTATCCCAGTAGGAGAAATT
TATAAAAGATGGATAATCTGGGATTAAATAAAATAGTGAATGTATAAGCCC
TACCAAGCATTCTGGACATAAGACAAGGACAAAAGAACCTTAAAGAGACTAT
GTAGACCGGTTCTATAAAACTCTAAGAGCCGAGCAAGCTTCAAGGAGGTA
AAAAATTGGATGACAGAAACCTTGGGTTCCAAAATGCGAACCCAGATTGTA
AGACTATTAAAGCATGGGACCAGCAGCTACACTAGAAGAAATGATGAC
AGCATGTCAGGGAGTAGGAGGACCCGGGCATAAGGCAAGAGTTGGCTG
AAGCAATGAGCCAAGTACAAATTCACTACCATATAATGATGCAGAGAGGCA
ATTAGGAACCAAAGAAAGATTGTTAAGTGT1TCATTGTGGCAAAGAAGG
GCACACAGCCAGAAATTGCAGGGCCCTAGGAAAAAGGGCTGTTGGAAAT

Figure B;

WO 02/072754

PCT/US02/06713

46/54

GTGGAAAGGAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATT
TTTAGGGAAGATCTGGCC1TCCTACAAGGGAAGGCCAGGGATTCTTCA
GAGCAGACCAGAGCCAACAGCCCCACCAAGAAGAGAGCTTCAGGTCTGGGG
TAGAGACAACAACCTCCCCCTCAGAAGCAGGAGCCGATAGACAAGGAACGT
ATCCTTAACCTCCCTCAGATCACTCTTGCAACGACCCCTCGTCACAATA
AAGATAGGGGGGAACTAAAGGAAGCTCTATTAGATAACGGAGCAGATGAT
ACAGTATTAGAAGAAATGAATTGCCAGGAAGATGAAACCAAAATGATAG
GGGGAAATTGGAGGTTTATCAAAGTAAGACAGTATGATCAGATACTCATAGA
AATCTGTGGACATAAAAGCTATAGGTACAGTATTAGTAGGACCTACACCTGTC
AACTAAATTGGAAGAAATCTGTTGACTCAGATTGGTTGCACCTAAATTTCC
CATTAGCCCTATTGAGACTGTACAGTAAATTAAGCCAGGAATGGATGGC
CCAAAAGTTAAACAATGGCATTGACAGAAGAAAAAATAAAGCATTAGTAG
AAATTGTACAGAAATGGAAAAGGAAGGGAAATTCAAAAATTGGCCTGA
GAATCCATACAATACTCCAGTATTGCCATAAAAGAAAAAGACAGTACTAAAT
GGAGGAAATTAGTAGATTCAAGAGAACTTAATAAGAGAACTCAAGACTTCTG
CGAAGTTCAATTAGGAATACCACATCCCGCAGGGTAAAAAGAAAAATCA
GTAACAGTACTGGATGTGGGTGATGCATAATTTCAGTTCCCTAGATGAAG
ACTTCAGGAAGTATACTGCATTACCATACCTAGTATAAAACAATGAGACACC
AGGGATTAGATATCAGTACATGTGCTCCACAGGGATGGAAAGGATCACC
AGCAATATTCCAAAGTAGCATGACAAAAACTTAGAGCCATTAAAAAGAAA
ATCCAGACATAGTTATCTATCAATACATGAACGATTGTATGTAGGATCTGAC
TTAGAAATAGGGCAGCATAGAACAAAAATAGAGGAGCTGAGACAAACATCTG
TTGAGGTGGCAGCTTACACACCCAGAACAAAAACATCAGAAAGAACCTCCA
TTCCCTTGATGGTTATGAACTCCATCCTGATAAAATGGACAGTACAGCCTA
TAGTGCTGCCAGAAAAAGACAGCTGGACTGTCAATGACATACAGAAGTTAG
TGCGGAAATTGAATACCGCAAGTCAGATTACCCAGGGATTAAAGTAAGGC
AATTATGTAACCTCTAGAGGAACCAAGCACTAACAGAAGTAATACCACT
AACAGAAGAAGCAGAGCTAGAACTGGCAGAACACAGAGAGATTCTAAAAGA
ACCACTACATGGAGTGTATTATGACCCATCAAAGACTTAATAGCAGAAATA
CAGAAGCAGGGCAAGGCAATGGACATATCAAATTATCAAGAGCCATT
AAAAATCTGAAAACAGGAAATATGCAAGAATGAGGGGTGCCACACTAAT
GATGTAACAACTAAACAGAGGCAGTGCACAAATAACCACAGAAAGCATA
TAATATGGAAAAGACTCTAAATTAAACTACCCATACAAAGGAACATG
GGAAACATGGTGGACAGAGTATTGGCAAGCCACCTGGATTCTGAGTGGGA
GTTGTTAATACCCCTCCTTACTGAAATTATGGTACCAAGTAGAGAAAGAA
CCCATAGTAGGAGCAGAACCTCTATGTAGATGGGCAGCTAACAGGGAG
ACTAAATTAGGAAAGCAGGATATGTTACTAACAAAGGAAGACAAAAGGTTG
TCCCCCTAACTAACACAACAAATCAGAAACTCAGTTACAAGCAATTATCTA
GCTTGCAGGATTAGGATTAGAAGTAAACATAGTAACAGACTCACAAATATG
CATTAGGAATCATTCAAGCACAACCAGATAAAAGTGAATCAGAGTTAGTC
TCAAATAATAGAGCAGTTAATAAAAAGGAAAAGGTCTATCTGGCATGGTA
CCAGCACACAAAGGAATTGGAGGAAATGAAACAGTAGATAAATTAGTCAGT
GCTGGAATCAGGAAATACCTTTAGATGGAATAGATAAGGCCAAGATG
AACATTAGTTTATGTCGACCTGCAGGGAAAGTTTATAGGTAGTTGATAG
AACAAAATACATAATTGTAAAAATCACTTTATACTAATATGACACG
ATTACCAACTTTGTTACTAATATCATTAGTATACTACGCTACACCTTCTCA

Figure B₄

WO 02/072754

PCT/US02/06713

47/54

GACATCTAAAAAATAGGTGATGCAACTTATCATGTAATCGAAATAATA
CAAATGACTACGTTGTTATGAGTGCCTGGTATAAGGAGCCCAATTCCATTAT
TCTTTAGCTGCTAAAGCGACGCTTGATTTGATAATTATACCAAGGATA
AAATATCTTACGACTCTCCATACGATGATCTAGTTACAACATACACAATTAA
TCATTGACTGCTAGAGATGCCGGTACTTATGTATGTGCATTCTTATGACATC
GCCTACAAATGACACTGATAAAGTAGATTATGAAGAATACTCCACAGAGTTG
ATTGTAATACAGATACTGAATCGACTATAGACATAACTATCTGGATCTAC
ACATTCAACCAGAAACTAGTTAAGCTTGTCTCCCTATACTGAGTCGTATTAGA
GCTTGGCGTAATCATGGTCATAAGCTGTTCTGTGTGAAATTGTTATCCGCT
CACAATTCCACACAAACATA CGAGCCGGAAAGCATAAAAGTGTAAAGCCTGGGG
TGCCTAATGAGT GAGCTAACTCACATTAAATTGCGTTGCGCTCACTGCCGCT
TTCGAGTCGGGAAACCTGTCGIGCCAGCTGCATTAAATGAATCGGCCAACGC
GCCGGGGAGAGGGGGTTTGCATTTGGCGCTCTCCGCTCCTCGCTCAC
TGA CTCGCTGCGCTCGGTGTTGGCTGCGGCGAGCGGTATCAGCTCACT
CAAAGGCGGTAAATACGGTTATCCACAGAATCAGGGATAACGCAGGAAAGA
ACATGTGAGCAAAAGGCCAGC AAAAGGCCAGGAACCGTAAAAGGCCGCG
TTGCTGGCGTTTCGATAGGCTCCGCCCCCTGACGAGC ATCACAAAAAT
CGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAGATAACCAG
GCGTTTCCCCCTGGAAAGCTCCCTCGTGCCTCTCCTGTTCCGACCCCTGCCG
CTTACCGQATACCTGTCCGCCCTTCTCCCTCGGGAAAGCGTGGCGCTTCT
CATAGCTCACGCTGTAGGTATCTCAGTTGGTGTAGGTGTTGCTCCCAAG
CTGGGCTGTGCA CAGAACCCCCCGTTAGCCCCGACCGCTGCGCCTTATC
CGGTAACTATCGCTTGAGTCCAACCCGGTAAGACACGACTTATGCCACT
GGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCCGGTG
CTACAGAGTTCTGAAGTGGTGGCTAACTACGGCTACACTAGAAGGACAG
TATTTGGTATCTGCCTCTGCTGAAGCCAGTTACCTTGGAAAAAGAGTTGG
TAGCTCTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTGTT
TGCAAGCAGCAGATTACCGCGAGAAAAAAAGGATCTCAAGAAGATCCTTG
ATCTTTCTACGGGGCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGG
ATTTGGTCATGAGATTATCAAAGGATCTCACCTAGATCCTTTAAATTAA
AAAATGAAGTTTAAATCAATCTAAAGTATATGAGTAAACTGGTCTGACA
G11ACCAATGCTTAATCACTGAGGCACCTATCTCAGCGATCTGCTATTTGG
TTCATCCATAGTTGCCTGACTCCCCGTCGTAGATAACTACGATAACGGGAG
GGCTTACCATCTGGCCCCAGTGTGCAATGATAACCGCGAGACCCACGCTCA
CCGCTCCAGATTATCAGCAATAAACAGCCAGCCGGAAAGGGCCGAGCG
CAGAAGTGGTCTGCAACTTATCCGCTCCATCCAGTCTATTAAATTGTTGC
CGGGAAAGCTAGAGTAAGTAGTTGCCAGTTAATAGTTGCGCAACGTTGTT
GGCATTGCTACAGGCATCGTGGTGCACGCTCGTGTGGTATGGCTTCA
TTCAGCTCCGGTCCCAACGATCAAGGGAGTTACATGATCCCCCATGTTGT
GCAAAAAAGCGGGTAGCTCCTCGGTCTCCGATCGTTGTCAAGAAGTAAGT
TGGCCGAGTGTATCACTCATGGTTATGGCAGCACTGCATAATTCTTAC
TGTCTGCCATCCGTAAGAATGCTTCTGTGACTGGTAGACTCAACCAAG
TCATTCTGAGAATAGTGTATGCCGGACCCGAGTTGCTCTGCCGGGTCA
ATACGGGATAATACCGGCCACATAGCAGAACTTTAAAGTGCTCATCATTG
GAAACGTTCTCGGGCGAAAACCTCTCAAGGATCTTACCGCTGTTGAGAT
CCAGTTGATGTAACCCACTCGTGCACCCAACTGATCTTCAAGCATCTTAC

Figure B5

WO 02/072754

PCT/US02/06713

48/54

TTTCAACCAGCGTTCTGGGTGAGCAAAACAGGAAGGCAAAATGCCGCAA
 AAAGGGAATAAGGGCAGACACGGAAATGTTGAATACTCATACTCTTCCCTTT
 CAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATAACATATT
 TGAATGTTAGAAAAATAACAAATAGGGTTCCGGGACATTTCGGCGA
 AAAGTGCACCTGACGTCTAAGAAACCATTATTATCATGACATTAACCTATAA
 AAATAGGCGTATCAGGAGGCCCTTCGTCTCGCGCGTTTCQGTGATGACGG
 TGAAAACCTCTGACACATGCAGCTCCGGAGACGGTCACAGCTTGTCTGTA
 AGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGT
 GCGGGGTGTCCCCGCTGGCTTAACTATGCCGCATCAGAGCAGATTGTACT
 GAGAGTGCACCATATCGGGTGTGAAATACCCACAGATGCGTAAGGGAGAAA
 ATACCGCATCAGGCCATTGCCATTAGGCTGCGCACTGTTGGGAAGG
 GCGATCGGTGCGGGCCTCTCGCTATTACGCCAGCTGGCAAAGGGGGAT
 GTGCTGCAAGGCATTAAAGTGGTAACGCCAGGGTTTCCCAGTCACGAC
 GTTGTAAAACGACGCCAGTGAATTGGATTAGGTGACACTATA

New Psyn II Promoter which controls ADA envelope expression:

TAAAAAAATGAAAAAATTCTAATTAGGACGGTTTGATTTCCTTTTC
 TATGCTATAATAATAATA

ADA envelope truncated:

ATGAAAGTGAAGGGATCAGGAAGAATTATCAGCACTTGTGGAAATGGGGC
 ATCATGCTCCTGGGATGTTGATGATCTGTAGTGCTGTAGAAAATTGTGGG
 TCACAGTTATTATGGGTACCTGTGTGAAAGAACCAACCAACTCTATT
 TTGTGCATCAGATGCTAAAGCATATGATAACAGAGGTACATAATGTTGGCC
 ACACATGCCGTGTACCCACAGACCCACAAAGAAGTAGTATTGGAA
 AATGTGACAGAAAATTAAACATGTGGAAAATAACATGGTAGAACAGATGC
 ATGAGGATATAATCAGTTATGGGATCAAAGCCTAAAGCCATGTGTTAAATT
 AACCCCACCTGTGTACTTTAAATTGCACTGATTTGAGGAATGTTACTAATA
 TCAATAATAGTAGTGGAAATGAGAGGAGAAATAAAACTGCTCTTCAA
 TATCACCAAGCATAAGAGATAAGGTGAAGAAAGACTATGCACCTTCTAT
 AGACTTGATGTAGTACCAATAGATAATGATAACTAGCTATAGGTTGATAAA
 TTGTAATACCTCAACCATTACACAGGCCGTGCCAAAGGTATCCTTGAGCCA
 ATTCCCACATTATTGTACCCCGCTGGTTTGCATTCTAAAGTGTAAAG
 ACAAGAAGTCAATGGAACAGGGCATGTAAAAATGTCAGCACAGTACAAT
 GTACACATGGAATTAGGCCAGTAGTGTCAACTGCTGTAAATGGCAG
 TCTAGCAGAAGAAGAGGTAGTAATTAGATCTAGTAATTTCACAGACAATGCA
 AAAAACATAATAGTACAGTTGAAAGAATCTGTAGAAATTAAATTGTACAAGACC
 CAACAACAATACAAGGAAAGTATACTATAGGACCAGGAAGAGCATTAT
 ACAACAGGAGAAATAATAGGAGATAAGAACAGCACATTGCAACATTAGTA
 GAACAAAATGGAATAACACTTTAAATCAAATAGCTACAAATTAAAGAACAA
 TTTGGGAAATAAAACAATAGTCTTAATCAATCCTCAGGAAGGGGACCCAG
 AAATTGTAATGCACAGTTTAATTGTGGAGGGAAATTCTTCACTGTAATTCA
 ACACAACGTAAATAGTACTGGAAATTAAATGGTACTTGGAAATTAAACACA

Figure B6

WO 02/072754

PCT/US02/06713

49/54

ATCGAATGGTACTGAAGGAAATGACACTATCACACTCCCATGTAGAATAAAA
 CAAATTATAAAATATGTGCGAGGAAGTAGGAAAAGCAATGTAGCCCTCCCCA
 TCAGAGGACAAATTAGATGCTCATCAAATATTACAGGGCTAATATTAACAAQ
 AGATGGTGGAACTAACAGTAGTGGGTCCGAGATCTTCAGACCTGGGGAG
 GAGATATGAGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTAGTAAA
 AATTGAACCATTAGGAGTAGCACCCACCAAGGCAAAAGAAGAGTGGTGCA
 GAGAGAAAAAGAGCAGTGGGACGATAGGAGCTATGTTCCCTGGGTTCTT
 GGGAGCAGCAGGAAGCACTATGGCGCAGCGTCAATAACGCTGACGGTAC
 AGGCCAGACTATTATTGCTCTGGTATAGTGCAACAGCAGAACAAATTGCTGAG
 GGCTATTGAGGCGAACAGCATCTGTTGCAACTCACAGTCTGGGCACTCAA
 GCAGCTCCAGGCAAGAGTCCTGGCTGTGGAAGATACTTAAGGGATCAACA
 GCTCCTAGGGATTGGGTTGCTCTGGAAAACATCTGCACCAACTGCTGT
 GCCTTGGAAATGCTAGTTGGAGTAATAAAACTCTGGATATGATTGGATAAC
 ATGACCTGGATGGAGTGGAAAGAGAAATCGAAAATTACACAGGGCTTAATAT
 ACACCTTAATTGAGGAATCGCAGAACCAAGAAAGAATGAACAAGACTT
 ATTAGCATTAGATAAGTGGCAAGTTGTGGATTGGTTGACATATCAAATT
 GGCTGTGGTATGAAAAATCTCATAATGATAGTAGGAGGCTTAGGTT
 AAGAATAGTTTACTGTACTTCTATAGTAAATAGAGTTAGGCAAGGGATACT
 CACCATTGTCAATTCAAGACCCACCTCCAGCCCCAGGGGACCCGACAGG
 CCCGAAGGAATCGAAGAAGAAGGTGGAGACAGAGAC

PmH5 promoter (which controls HXB2 gag pol expression):

AAAAATTGAAAATAAATACAAAGGTTCTGAGGGTTGTTAAATTGAAAGC
 GAGAAATAATCATAAATA

HXB2 gag pol (with safety mutations, Δ Integrase):

ATGGGTGGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGATGGGA
 AAAAATTGGTTAAGGCCAGGGGGAAAGAAAAAAATATAAATTAAACATATA
 GTATGGCAAGCAGGGAGCTAGAACGATTGGCAGTTAACCTGGCCTGTTA
 GAAACATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCT
 CAGACAGGATCAGAAGAACCTAGATCATTATATAAACAGTAGCAACCCCT
 ATTGTGTGATCAAAGGATAGAGATAAAAGACACCAAGGAAGCTTAGACAA
 GATAGAGGAAGAGCAAAACAAAGTAAGAAAAAGCACAGCAAGCAGCAGC
 TGACACAGGACACAGCAATCAGGTCAGCCAAATTACCCATAGTGCAGAA
 CATCCAGGGCAAATGGTACATCAGGCCATATCACCTAGAACCTTAAATGCA
 TGGGIAAAAGTAGTAGAAGAGAAGGCTTCAGGCCAGAAGTGTACATCCATG
 TTTTCAGCATTATCAGAAGGAGCCACCCACAAGATTAAACACCATGCTAA
 ACACAGTGGGGGACATCAAGCAGCCATGCAAATGTTAAAGAGACCATCA
 ATGAGGAAGCTGAGAATGGATAGAGTGCATCCAGTGCATGCAGGGCCT
 ATTGCACCGGCCAGATGAGAGAACCAAGGGAGTGTACATAGCAGGAAC
 TACTAGTACCCCTCAGGAACAAATAGGATGGATGACAATAATCCACCTATC
 CCAGTAGGAG/ATTTATAAAAGATGGATAATCCTGGATTAAATAAAATAG
 TAAGAATGTATAGCCCTACCAAGCATTGGACATAAGACAAGGACCAAAAGA
 ACCCTTAGAGACTGTAGACCGGTTCTATAAAACTCTAAGAGCCGAGCAA

Figure B1

WO 02/072754

PCT/US02/06713

50/54

GCTTCACAGGAGGTAAAAATTGGATGACAGAACCTTGTGGTCCAAATG
CGAACCCAGATTGTAAGACTATTTAAAGCATTGGGACCAGCGGCTACACT
AGAAGAAATGATGACAGCATGTCAGGGAGTAGGGAGGACCCGGCATAAGG
CAAGAGTTTGGCTGAAGCAATGAGCCAGTAACAAATTGAGTACCCATAAT
GATGCAGAGAGGGCAATTAGGAACCAAGAAAGATTGTTAAGTGTTCAT
TGTGGCAAAGAAGGGCACACAGCCAGAAATTGAGGCCCCCTAGGAAAAA
GGGCTTGGAAATGTGAAAGGAAGGACACCAATGAGATTGTACTGA
GAGACAGGCTAATTAGGAAGATCTGGCCTCCTACAAAGGGAGGCC
AGGGAAATTCTCAGAGCAGACCAACAGCCCCACAGAAGAGAG
CTTCAGGTCTGGGGTAGAGACAAACACTCCCCCTCAGAAGCAGGAGGCCGAT
AGACAAGGAACTGTATCCCTTAACCTCCCTCAGATCACTCTTGGCAACGAC
CCCTCGTCACAATAAAGATAGGGGGCAACTAAAGGAAGCTCTATTAGATA
CAGGAGCAGATGATACAGTATTAGAAGAAATGAGTTGCCAGGAAGATGGA
AACCAAAATGATAGGGGGATTGGAGGTTTATCAAAGTAAGACAGTATGA
TCAGATACTCATAGAAATCTGTGGACATAAAGCTATAGGTACAGTATTAGTA
GGACCTACACCTGTCAACATAATTGGAAGAAATCTGTGACTCAGATTGGTT
GCACTTAAATTCCATTAGCCCTATTGAGACTGTACAGTAAATTAG
CCAGGAATGGATGGCCAAAAGTTAAACAATGCCATTGACAGAAAGAAAAA
ATAAAAGCATTAGTAGAAATTGTACAGAAATGGAAAAGGAAGGGAAAATT
CAAAAATTGGCCTGAGAATCCATACAATACTCCAGTATTGCCATAAAGAA
AAAAGACAGTACTAAATGGAGGAATTAGTAGATTTCAGAGAACTTAATAAG
AGAACTCAAGACTCTGGGAAGTTCAATTAGGAATTACACATCCCGCAGGG
TTAAAAAAGAAAAATCAGTAACAGTACTGGATGTGGGTGATGCATATTTC
AGTCCCTTAGATGAGACTTCAGGAAGTATACTGCATTACCATACCTAGT
ATAAACAAATGAGACACCAAGGGATTAGATATCAGTACAATGTGCTCCACAGG
GATGGAAAGGATCACCAGCAATTCCAAAGTAGTACATGACAAATCTTAGA
GCCCTTAAACAAATCCAGACATAGTTATCTATGAATACATGAACGATT
TGTATGTAGGACTCTGACTTAGAAATAGGGCAGCATAGAACAAAATAGAGGA
GCTGAGACAAACATCTGTTGAGGTGGGACTTACACACACAGAACAAAAA
TCAGAAGAACCTCATTCCATTGGATGGTTATGAACTCCATCCGTATAAA
TGGACAGTACAGCCTATAGTGCTGCCAGAAAAGACAGCTGGACTGTCAAT
GACATACAGAGTAGTGGGAAATTGAATACCGCAAGTCAGATTACCCCA
GGGATTAAAGTAAGGCAATTATGTAACCTTAGAGGAACCAAGCACTAA
CAGAAGTAATACCACTAACAGAAGAACAGAGCTAGAACACTGGCAGAAAACA
GAGAGATTCTAAAAGAACCAAGTACATGGAGTGTATTATGACCCATCAAAGA
CTTAATAGGAGAAATACAGAAGCAGGGCAAGGCCATGGACATATCAAAT
TTATCAAGAGCCATTAAAATCTGAAAACAGGAAAATATGCAAGAATGAGG
GGTGCACACTAATGATGAAAACAATTACAGAGGCAGTGCAAAAAATAA
CCACAGAAAGCATAGTAATATGGGAAAGACTCCCTAAATTAAACTACCCAT
ACAAAAGGAAACATGGGAAACATGGTGGACAGAGTATTGGCAAGCCACCTG
GATTCCGTAGTGGGAGTTGTTAATACCCCTCCTTAGTGAATTATGGTAC
CAGTTAGAGAAAGAACCCATAGTAGGGAGCAGAAACCTTCTATGTAGTGGG
GCAGCTAACGGGAGACTAAATTAGGAAAAGCAGGATATGTTACTAACAAA
GGAAGACAAAAGGTTGCCCCCTAACTAACACAAACAAATCAGAAAACAGT
TACAAGCAATTATCTAGCTTGCAGGATTCAAGGATTAGAAGTAAACATAGTA
ACAGACTCACAATATGCATTAGGAATCTCAAGCACAACCAGATAAAAGTG

Figure B₁

WO 02/072754

51/54

PCT/US02/06713

AATCAGAGTTAGTCAATCAAATAATAGAGCAGTTAATAAAAAGGAAAAGGT
CTATCTGGCATGGGTACCAAGCACACAAAGGAATTGGAGGAAATGAACAAQT
AGATAAAATTAGTCAGTGCTGGAATCAGGAAAATCTATTAGATGGAATA
GATAAGGCCAAGATGAACATTAG

02005MXGNH211A.001PRPLW-48 AND HIV GENES SEQ.DOC
022802

Figure B9

WO 02/072754

PCT/US02/06713

52/54



Plasmid pLW-48**Virus MVA/HIV 48**

Figure C

WO 02/072754

PCT/US02/06713

53/54




Figure 8

WO 02/072754

PCT/US02/06713

54/54

Sequence of new Psyn II promoter:**Early part of promoter**Critical region

Early start site

TAAAAAAATGAAAAAAATATTCTAATTATAAGGACGGT

Late part of promoter

TTTGATTTTCTTTTGTATGCTATAATAATAATA

Figure E

WO 02/072754

PCT/US02/06713

1/8

SEQUENCE LISTING

<110> THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE
SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Moss, Bernard
Nyatt, Linda
Earl, Patricia

<130> RNA EXPRESSION MODIFIED HIV ENVELOPE,
GAG, AND POL GENES

<130> NIH311.001PCT

<150> US 60/274,434
<151> 2001-03-08

<160> 13

<170> SeqCSEx for Windows Version 4.0

<210> 1
<211> 12225
<212> DNA
<213> Artificial Sequence

<220>

<223> Plasmid pLW-48

<400> 1
gaattccatq gtggtegcca tggatggcgt tattgtatac tggctaaacc cggcagtaaa 60
acatggugac qaataataat atataaaaaa tgaatccatg attaaaccat gttgtgaaaa 120
agtcagaaac gttcacatgg ggggacaaat taaaacatg acatgttttg cagatrrgccc 180
atatacggat aacqcggtat cegatgtatg caattccatg tataaaaaaa atgtatcaag 240
atataccaga ttcgcttaatt tggatccatg agatgacgtt gaaatggatc ctatgggtgt 300
atataattat tccaaaccta aatataccat tootgtatt atataccatg gaaaggatag 360
atataatgtt gaaatcttca tcttcatttca taatggatgtt gggatgtatg agttttatc 420
atataaagtat gccatttttc ccatggatgt ttccctttttt accaaaggaa atgcataatt 480
gatttttttc ctgttttgcatt tccccccacca tccggcacat ctcttaagaa gtgttacccaa 540
taataaagtat tttatataatca gacaccacgg tttatccatgac qaattcccgaa gttoccatgg 600
gttcaatgtt tttatataatca tttatgttca tttatataatca tttatataatca tggtttttga 660
tggatctgtt atgcattgttca tagctgtatca tttatgttca tttatataatca tttatataatca 720
atccggatccat tttatataatca aatgtgtatgtt tagatgtgtt tttatgttca cacaqatgg 780
ttttttttttt tttatataatca tttatataatca tttatataatca tttatataatca tttatataatca 840
ttttttttttt tttatataatca tttatataatca tttatataatca tttatataatca tttatataatca 900
ttttttttttt tttatataatca tttatataatca tttatataatca tttatataatca tttatataatca 960
ttttttttttt tttatataatca tttatataatca tttatataatca tttatataatca tttatataatca 1020
ttttttttttt tttatataatca tttatataatca tttatataatca tttatataatca tttatataatca 1080
gatggccctgtt gggcatccat tttatgttca tttatgttca tttatgttca tttatgttca tttatgttca 1140
gaaatggcgat tttatgttca tttatgttca tttatgttca tttatgttca tttatgttca tttatgttca 1200
cccgatgtcag tttatgttca tttatgttca tttatgttca tttatgttca tttatgttca tttatgttca 1260
ccggaaagggtt gggccaggccaa ggttgcgttgg tttatgttca tttatgttca tttatgttca tttatgttca 1320
aaatgtgtggg tttatgttca tttatgttca tttatgttca tttatgttca tttatgttca tttatgttca 1380
ggccgatgttca tttatgttca tttatgttca tttatgttca tttatgttca tttatgttca tttatgttca 1440
aaatgtgttca tttatgttca tttatgttca tttatgttca tttatgttca tttatgttca tttatgttca 1500
ttttatgttca tttatgttca tttatgttca tttatgttca tttatgttca tttatgttca tttatgttca 1560
ttttatgttca tttatgttca tttatgttca tttatgttca tttatgttca tttatgttca tttatgttca 1620
ttttatgttca tttatgttca tttatgttca tttatgttca tttatgttca tttatgttca tttatgttca 1680

WO 02/072754

PCT/US02/06713

28

WO 02/072754

PCT/US02/06713

34

WO 02/072754

PCT/US02/06713

4/8

WD 02/072754

PCT/US03/06713

5/8

<211> 74
<212> DNA
<213> Artificial Sequence

<220>
<221> Psyn II promoter

=400> 2
tcacaaatcg aaaaaatattc ttatttatag gacggtttcg atttctttt ttatatgt 60
ataaaacaaa acts 74

<210> 3
<211> 2314
<212> DNA
<213> artificial sequence

«220»

<210> 4

WO 02/072754

PCT/US02/06713

0/8

<211> 70
<212> DNA
<213> Artificial Sequence

220s
223s Promoter

24005 4
aaaaaattgaa aataaataca aaggtttcttg agggttcgcgt taaattgaaa gcgagaaata 60
atccatataa 70

<210> 5
<211> 3479
<212> DNA
<213> Artificial Sequence

<27.0>

<400> 5
atcggtgtcgaa gagcggtcagt atcgatcgaa aaaaatccgg 60
ttcaggcccg ggggaaagaa aaaaatcaaa ttaaaacata tagatcgccg aagcaggtag 120
ccagaacgat tggatgttca tccgtggcccg ttagaaacat cagaaggctg tagacaaat 180
cgggaaatgc tacaatccat ccttcagaca ggatcagaag aacttagate atcatataat 240
acatgtacaa cccatccatcg tggatataaa aggatcagaga taaaagacac ctagggatct 300
tttagaaatgc tagaggtaga gctttttttt aatggatggaa aatggatggaa agaaggatct 360
gacatcaggac acatgtatca ggtcagccaa aatccatccat tggatggaa aatggatggaa 420
caatggatcc atcaggccat atcacttaga atccatccatcg atgttttttcaq atgttttttcaq atgttttttcaq 480
tggatggctt tcaatccatcg aatggatggaa aatggatggaa aatggatggaa aatggatggaa 540
ccatcayatt tacaatccatcg aatggatggaa aatggatggaa aatggatggaa aatggatggaa 600
tttagaaatgc ccatcaatgc ttttttttttcaq aatggatggaa aatggatggaa aatggatggaa 660
gggcccattcg caccaggcca gacgagagaa ccaaggggaa qcqacatcg aqqaaccact 720
atcactccccc agggatcaat agggatcgatg acaaataatc caccatccc agttagggagaa 780
atcactccccc agggatcaat agggatcgatg acaaataatc caccatccc agttagggagaa 840
agcatccccc agggatcaat agggatcgatg acaaataatc caccatccc agttagggagaa 900
tataaaatcc taaagagccga gcaaggccca caggaggtaa aaaaatggat gacagaaacc 960
tggatggatcc aaaaatggat cccagatcg aagactatcc taaaagcatcg tggaccagcg 1020
gttacactcg aaaaatggat gacgatcg aatggatggatcc gaggacccgg ccataaggca 1080
agatgtttcggt ctggatcgat gatggatggatcc acaatccatcg atcactatcg tggatggatcc 1140
ggatccatcc tggatccatcg aatggatggatcc aatggatggatcc aatggatggatcc aatggatggatcc 1200
acatcactcg aatggatggatcc aatggatggatcc aatggatggatcc aatggatggatcc aatggatggatcc 1260
ccatcactcg aatggatggatcc tggatcgatcg gtcataatcc tggatggatcc atggatggatcc 1320
tacaaaggaa gggaaaggaa ttttttttca aatggatggatcc aatggatggatcc aatggatggatcc 1380
qatqatcgatcg ttttttttca aatggatggatcc aatggatggatcc aatggatggatcc aatggatggatcc 1440
aaatggatcc ttttttttca aatggatggatcc aatggatggatcc aatggatggatcc aatggatggatcc 1500
taatggatcc tggatggatcc aatggatggatcc aatggatggatcc aatggatggatcc aatggatggatcc 1560
tagaaagaaat gagcccgccca gggatggatcc aatggatggatcc aatggatggatcc aatggatggatcc 1620
ccatcactcg aatggatggatcc tggatggatcc aatggatggatcc aatggatggatcc aatggatggatcc 1680
gttacatcgatcc agttagggatcc acacatcgatcg aatggatggatcc aatggatggatcc aatggatggatcc 1740
tggatggatcc ttttttttca cccatcgatcg ttttttttca aatggatggatcc aatggatggatcc aatggatggatcc 1800
cggatggatcc tggatggatcc aatggatggatcc aatggatggatcc aatggatggatcc aatggatggatcc 1860
tagatggatcc ttttttttca aatggatggatcc aatggatggatcc aatggatggatcc aatggatggatcc 1920
atccatcgatcc ttttttttca aatggatggatcc aatggatggatcc aatggatggatcc aatggatggatcc 1980
tagatggatcc ttttttttca aatggatggatcc aatggatggatcc aatggatggatcc aatggatggatcc 2040
tggatggatcc aatggatggatcc aatggatggatcc aatggatggatcc aatggatggatcc aatggatggatcc 2100
catatccatcg aatggatggatcc aatggatggatcc aatggatggatcc aatggatggatcc aatggatggatcc 2160
gttacatcgatcc ttttttttca aatggatggatcc aatggatggatcc aatggatggatcc aatggatggatcc 2220
aaatggatcc aatggatggatcc aatggatggatcc aatggatggatcc aatggatggatcc aatggatggatcc 2280
gatggatcc aatggatggatcc aatggatggatcc aatggatggatcc aatggatggatcc aatggatggatcc 2340

WO 02/072754

PCT/US02/06713

8/8

<223> Xaa - Any Amino Acid

<400> 9
Tyr Xaa Xaa Leu
1<210> 10
<211> 93
<212> DNA
<213> Artificial Sequence<220>
<223> m7.5 promoter<400> 10
cgcttttat agtaatgtttt tccacccataa ataataaaca caataattaa ttctctctaa 60
aaatggaaa accatttataa ttatgtgtac ggt 93<210> 11
<211> 74
<212> DNA
<213> Artificial Sequence<220>
<223> Psyn III promoter<400> 11
taaaatgtga aaaaatattt caatctatag gacggttttt attttctttt ttctctatct 60
ataataataata aata 74<210> 12
<211> 74
<212> DNA
<213> Artificial Sequence<220>
<223> Psyn IV promoter<400> 12
taaaaatgtga aaaaatattt caatctatag gacggttttt attttctttt ttctctatct 60
ataataataata aata 74<210> 13
<211> 75
<212> DNA
<213> Artificial Sequence<220>
<223> Dsyn V promoter<400> 13
aaaaatgtat aaatgtatgtt cagttttttt gatggttttt aatcaatgtt tccatgtaaaa 60
accatgtatata taaat 75